Distribution Agreement

In presenting this thesis or dissertation as a partial fulfillment of the requirements for an advanced degree from Emory University, I hereby grant to Emory University and its agents the non-exclusive license to archive, make accessible, and display my thesis or dissertation in whole or in part in all forms of media, now or hereafter known, including display on the world wide web. I understand that I may select some access restrictions as part of the online submission of this thesis or dissertation. I retain all ownership rights to the copyright of the thesis or dissertation. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation.

Signature:

_____________________________   _____________
Christopher D. Makinson           Date
Role of the Voltage Gated Sodium Channel Scn8a in Epilepsy

By

Christopher D. Makinson
Doctor of Philosophy

Graduate Division of Biological and Biomedical Sciences
Neuroscience

Andrew P. Escayg, Ph.D
Advisor

Raymond Dingledine, Ph.D
Committee Member

Ellen Hess, Ph.D
Committee Member

Stephen Traynelis, Ph.D
Committee Member

David Weinshenker, Ph.D
Committee Member

Accepted:

Lisa A. Tedesco, Ph.D.
2013
Role of the Voltage Gated Sodium Channel Scn8a in Epilepsy

By

Christopher D. Makinson
B.S., Wake Forest University 2007

Advisor: Andrew P. Escayg, Ph.D

An abstract of
A dissertation submitted to the Faculty of the
James T. Laney School of Graduate Studies of Emory University
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
Graduate Division of Biological and Biomedical Sciences
Neuroscience
2013
Abstract
Role of the Voltage Gated Sodium Channel Scn8a in Epilepsy
By Christopher D. Makinson

Voltage gated sodium channels (VGSCs) are critical regulators of neuronal excitability and synchrony. Alterations in the function of the CNS VGSCs are associated with susceptibility to epilepsy, cognitive impairment, and emotional disturbances. Mice with mutations in the VGSC Scn8a exhibit increased resistance to induced seizures; however, interestingly, Scn8a mutant mice also experience frequent spontaneous absence seizures. Epilepsy-causing mutations in the human SCN8A gene were recently identified but little is currently known about the mechanisms by which altered SCN8A function leads to epilepsy, or perhaps can confer seizure protection.

Using genetic approaches we probed the developmental and brain-region dependence of Scn8a-mediated seizure protection in order to establish the feasibility of achieving seizure protection by selectively targeting Scn8a during adulthood. We assessed induced hippocampal bursting properties throughout postnatal development in Scn8a mutant mice. We also established that increased resistance to induced seizures is achieved when Scn8a is inactivated in the adult mouse and we further demonstrated that selective targeting of Scn8a in the hippocampus via either lentiviral-delivered Cre or adeno-associated viral-delivered Scn8a shRNA is sufficient to confer seizure resistance.

In order to provide a more complete understanding of the consequences of altering Scn8a function, we investigated the seizure, behavioral, and electrophysiological effects of a novel mutation in the Scn8a gene, R1627H. Analysis of Scn8a-R1627H channels in Xenopus oocytes revealed a depolarizing shift in the voltage dependence of activation, increased recovery from inactivation and increased persistent current. To establish the in vivo effects of this mutation, it was knocked into the mouse Scn8a gene. Interestingly, heterozygous Scn8aRH/+ mutants exhibited increased resistance to induced seizures, but this was not observed in homozygous Scn8aRH/RH mutants. Scn8aRH/RH mice were also susceptible to audiogenic seizures and displayed a recessive movement disorder.

Lastly, we propose a cellular mechanism to explain the paradoxical seizure outcomes that arise from loss of Scn8a activity. Scn8a conditional knockout mice were crossed to cell-type specific Cre transgenic lines to selectively delete a floxed Scn8a allele. Electrocorticogram (EEG) analysis and seizure thresholds were used to evaluate the contribution of Scn8a in different cell types to seizure phenotypes. We found that selective reduction of Scn8a expression in excitatory neurons results in increased seizure resistance without the generation of absence seizures. We
were also able to elevate seizure thresholds to normal levels in Scn1a mutant mice by reducing Scn8a expression in excitatory cells. In contrast, the deletion of Scn8a in interneurons leads to spontaneous absence seizures but does not influence seizure thresholds. Furthermore, Scn8a immunoreactivity and electrophysiological recordings raise the possibility that Scn8a expression in the thalamic reticular nucleus is important for the generation of absence seizures.

In conclusion this work 1) provides fundamental information about the development of Scn8a-related seizure phenotypes 2) expands upon the known seizure and behavioral phenotypes associated with altered Scn8a function, and 3) identifies critical cell-types mediating increased seizure resistance and absence seizure generation in Scn8a mutant animals.
Role of the Voltage Gated Sodium Channel Scn8a in Epilepsy

By

Christopher D. Makinson
B.S., Wake Forest University 2007

Advisor: Andrew P. Escayg, Ph.D

A dissertation submitted to the Faculty of the
James T. Laney School of Graduate Studies of Emory University
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
Graduate Division of Biological and Biomedical Sciences
Neuroscience
2013
Acknowledgements

Completing this dissertation has been an immensely challenging and rewarding endeavor. Without the support of my advisor, my committee members, and my friends and family, the work presented here would not have been possible.

I would especially like to thank my dissertation advisor Dr. Andrew Escayg for his steadfast support. Over the past several years Dr. Escayg has encouraged me to improve in all aspects of graduate studies. Dr. Escayg has pushed me when needed but also has provided the space and freedom necessary for me to develop independent ideas. He has been dedicated to my training and maturation as a scientist and also supportive of my interests outside of the laboratory.

I would like to thank the members of my thesis committee, Raymond Dingledine, Ellen Hess, Stephen Traynelis, and David Weinshenker, for their guidance and support throughout my graduate studies. I am also grateful to the students and faculty of the Neuroscience Graduate Program. It has been a privilege to study and work with such talented individuals.

Lastly, I would like to thank my friends and family for their unwavering support. In particular, I would like to thank my fiancé, Stefanie Ritter. She is one of the most thoughtful and inquisitive scientist and one of the most caring and decent people I have ever met. She has both made me a better scientist and a better person.
CHAPTER 1: Introduction and Background

1.1. Voltage Gated Sodium Channel Structure and Function ............................................. 2-5
   1.1.A. Overview ............................................................................................................ 2
   1.1.B. Molecular and Genomic Organization of VGSCs ............................................. 2-5
1.2. Genomic Organization of VGSCs ............................................................................. 6
1.3. Distribution of VGSCs ............................................................................................ 7-11
   1.3.A. Overview ............................................................................................................ 7
   1.3.B. Scn1a Distribution ............................................................................................. 7-8
   1.3.C. Scn8a Distribution ........................................................................................... 8-9
   1.3.D. Scn2a Distribution ........................................................................................... 9
   1.3.E. Scn3a Distribution ........................................................................................... 9
   1.3.F. Glial Expression of VGSCs ............................................................................... 9-10
1.4. Overview of Epilepsy .............................................................................................. 12-12
   1.4.A. What is Epilepsy .............................................................................................. 12
   1.4.B. Idiopathic Epilepsies ......................................................................................... 13
1.5. VGSC Epilepsy Mutations ....................................................................................... 14-16
   1.5.A. SCN1A Epilepsy Mutations ............................................................................ 14-15
   1.5.B. SCN2A Epilepsy Mutations ............................................................................ 15
   1.5.C. SCN3A, SCN8A, and SCN9A Epilepsy Mutations ........................................ 15-16
   1.5.D. Epilepsy Mutations in VGSC Beta Subunits ................................................... 16
1.6. VGSC and Epilepsy: Mechanisms ......................................................................... 16-21
   1.6.A. Mechanisms of SCN1A Epilepsies ................................................................. 17-18
   1.6.B. Mechanisms of SCN8A Epilepsies ................................................................. 19-20
   1.6.C. Mechanisms of SCN2A and SCN3A Epilepsies ............................................ 20-21
1.7. VGSC Dysfunction in Cognition and Behavior ........................................... 21-23
  1.7.A. SCN1A in Cognition and Behavior .................................................... 21-22
  1.7.B. SCN8A in Cognition and Behavior ................................................... 22-23
  1.7.C. SCN2A and SCN3A in Cognition and Behavior ................................. 23
1.8. VGSCs as Antiepileptic Drug Targets .................................................... 23-24

CHAPTER 2: Partial Knockdown of Na,1.6 (Scn8a) Sodium Channels in the hippocampus Confers Seizure Protection
2.1. Summary ................................................................................................ 26
2.2. Introduction ............................................................................................ 27-28
2.3. Results ..................................................................................................... 28-50
2.4. Discussion ............................................................................................... 51-55
2.5. Materials and Methods ........................................................................... 55-64
2.6. Acknowledgments ................................................................................... 65

CHAPTER 3: Effects of an Epilepsy Mutation in the Voltage Sensor of Scn8a on Seizure Susceptibility and Behavior
3.1. Summary ................................................................................................ 67
3.2. Introduction ............................................................................................ 68-69
3.3. Results ..................................................................................................... 69-90
3.4. Discussion ............................................................................................... 91-93
3.5. Materials and Methods ........................................................................... 93-103
3.6. Acknowledgments ................................................................................... 104

CHAPTER 4: Contrasting Effects on Seizure Susceptibility of Conditional Cell-Type Specific Inactivation of the Scn8a Gene
4.1. Summary ................................................................................................ 106
4.2. Introduction ............................................................................................ 107-108
4.3. Results...................................................................................................................................... 108-128
4.4. Discussion................................................................................................................................ 129-131
4.5. Materials and Methods........................................................................................................... 132-135
4.6. Acknowledgments..................................................................................................................... 135

CHAPTER 5: Overall Discussion and Conclusions

5.1. Overview................................................................................................................................... 137-138
5.2. Reconciliation of Seizure Outcomes Associated with Scn8a Mutations ................................. 138-141
5.3. A Circuit Model of SCN1A-Epilepsy and Genetic Modification by SCN8A Mutations 142-143
5.4. Persistent Sodium Current: Unifying VGSC Epilepsy Mechanisms? ................................. 144
5.5. A Circuit Model of Scn8a-Absence Epilepsy ........................................................................ 144-147
5.6. Therapies for VGSC-Derived Epilepsies ............................................................................... 149-150
5.7. Concluding Remarks.............................................................................................................. 150-151

REFERENCES................................................................................................................................... 152-181

Figure Index

Figure 1.1. Schematic representation of α and β subunits of a voltage gated sodium channel....... 5
Figure 1.2. Schematic representation of VGSC subcellular Localization................................. 11
Figure 1.3. Loss of inhibition model of Scn1a dysfunction leading to epilepsy......................... 18
Figure 2.1. Spontaneous seizure-like burst discharges in CA3 pyramidal cell layer induced by elevated potassium in hippocampal slices from Scn8a\textsuperscript{med/+} mutant and WT mice........ 31-32
Figure 2.2. Analysis of burst characteristics between Scn8a\textsuperscript{med/+} and WT mice............... 33
Figure 2.3. Developmental expression of VGSCs in the hippocampus of Scn8a\textsuperscript{med/+} mutant and WT mice .................................................................................................................. 36-37
Figure 2.4. Tamoxifen-induced global deletion of the Scn8a gene............................................. 39-40
Figure 2.5. Inducible deletion of the Scn8a gene in the adult mouse is sufficient to increase the latency to flurothyl- and KA-induced seizures and to protect against electrically induced 6-Hz psychomotor seizures ................................................................. 42-43

Figure 2.6. Lentiviral Cre-mediated knockdown of Scn8a in the hippocampus reduces seizure activity following PT administration ...................................................................... 46-47

Figure 2.7. Efficient adeno-assocoated viral shRNA-mediated knockdown of the Scn8a gene in the hippocampus of Scn1a+/− and WT mice .............................................................. 48-49

Figure 2.8. Adeno-associated viral shRNA-mediated knockdown of the Scn8a gene in the hippocampus increases flurothyl-induced seizure thresholds in Scn1a+/− and WT mice ....... 50

Figure 3.1. Characterization of the biophysical properties of Scn8a-R1627H channels .......... 70

Figure 3.2. Generation of the R1627H mutant mouse line ......................................................... 72-73

Figure 3.3. Homozygous Scn8a-R1627H mutants have reduced weight ..................................... 75

Figure 3.4. Recessive motor impairment in R1627H mice ......................................................... 76

Figure 3.5. Effects of the R1627H mutation on flurothyl- and 6 Hz-induced seizure susceptibility and hippocampal bursting ................................................................. 81-82

Figure 3.6. The Scn8a-R1627H mutation increases lifespan and seizure resistance in a mouse model of GEFS+ (Scn1a-R1648H) ........................................................................ 83

Figure 3.7. Scn8aRH/RH mice are susceptible to audiogenic seizures ....................................... 86-87

Figure 3.8. Scn8aRH/RH mice have reduced auditory brainstem nuclei responses (ABRs) .......... 88

Figure 3.9. Flurothyl seizure thresholds and response to acoustic stimuli in mice carrying the Scn8a-medjo mutation ....................................................................................... 90

Figure 4.1. The floxed Scn8a allele does not alter Na,1.6 (Scn8a) protein levels or flurothyl-induced seizure thresholds in the absence of Cre but is efficiently recombined in expected brain regions by the Emx1- and Dlx5/6-Cre drivers ........................................... 110

Figure 4.2. Seizure thresholds are increased by loss of Scn8a from excitatory but not inhibitory neurons .................................................................................................................. 115
Figure 4.3. Inactivation of Scn8a in excitatory forebrain neurons increases resistance to induced epileptiform hippocampal bursting activity................................................................. 116-117

Figure 4.4. Resistance to flurothyl-induced seizures is influenced by the level of inactivation of Scn8a in excitatory forebrain neurons................................................................. 118

Figure 4.5. Selective inactivation of Scn8a in excitatory forebrain neurons in Scn1a mutant mice improves survival and increases resistance to flurothyl-induced seizures .................. 119-120

Figure 4.6. Inhibitory neuron-specific but not forebrain excitatory neuron-specific inactivation of the Scn8a gene is sufficient to produce SWDs......................................................... 122-123

Figure 4.7. Evaluation of Scn8a expression in interneuronal populations of thalamocortical circuitry ......................................................................................................................... 125

Figure 4.8. nRT neurons of Scn8a-deficient mice have impaired tonic firing....................... 126

Figure 4.9. Developmental increases in SWDs in Scn8a<sup>med/+</sup> mice................................. 128

Figure 5.1. Homozygous Scn8a-R1627H mice exhibit deficits in interneuron firing in response to large depolarization .................................................................................................. 141

Figure 5.2. Loss of inhibition model of Scn1a dysfunction leading to generalized tonic-clonic epilepsy and reversal by loss of Scn8a .................................................................................. 143

Figure 5.3. Thalamocortical circuit models of conditional cell-type specific inactivation of Scn8a leading to SWD generation................................................................. 146-147

Tables

Table 2.1. decreased Scn8a expression reduced the occurrence of bursting in hippocampal slices from Scn1a<sup>R1627H/+</sup> mutant mice................................................................. 34

Table 3.1. Summary of behavioral tasks performed on the R1627H line ........................... 78

Table 4.1. Summary of colocalization of Dlx5/6-Cre and Emx1-Cre expression in the CNS.... 111
CHAPTER 1

INTRODUCTION AND BACKGROUND
1.1. Voltage Gated Sodium Channel Structure and Function

1.1.A. Overview

Voltage gated sodium channels (VGSCs) mediate the voltage-dependent passage of sodium (Na\(^+\)) across cellular membranes. Membrane channels that allow for the voltage-dependant passage of sodium ions were first described in a seminal series of papers by Hodgkin and Huxley on the action potential of the squid giant axon (Hodgkin and Huxley, 1952d, c, a, b). They found that depolarization activates an inward Na\(^+\) current that further depolarizes the cell. This current was found to quickly inactivate, within a few milliseconds, and was followed by an outward K\(^+\) current that repolarizes the cell. The timing and direction of these currents, sodium flowing into the cell followed by potassium flowing out, were found to provide the basis of the action potential. More recently, disruptions in VGSC activity have emerged both as major risk factors in many neurological disorders, and as a targets for the treatment of these disorders.

1.1.B. Molecular Organization of VGSCs

The identification and molecular characterization of VGSCs have been an active subject of research since the discovery of voltage-dependent sodium currents (Hodgkin and Huxley, 1952d). Characteristics of VGSC ion selectivity, gating, and inactivation were intensively studied throughout the 1970s. These experiments established many fundamental principles of VGSC function. Ion selectivity was found to involve Na\(^+\) dehydration through interaction with a selectivity pore followed by rehydration in the luminal space and escape into the larger intracellular environment (Hille, 1971, 1972, 1975). Although Hodgkin and Huxley first proposed the existence of a charged voltage sensing subunit which is coupled to gating of the channel, this principle was established by Armstrong and Bezanilla (Armstrong and Bezanilla, 1973, 1977) using detailed electrophysiological recordings in the squid giant axon in the presence and absence of tetrodotoxin (TTX). Additionally, Armstrong and Bezanilla established basic mechanisms of
VGSC inactivation, including the existence of an intracellular component that moves to block the channel pore and thus ion conduction (inactivation gate) (Armstrong and Bezanilla, 1973, 1977; Bezanilla and Armstrong, 1977) (Figure 1.1).

VGSC proteins were first purified in the laboratory of Dr. William Catterall (Beneski and Catterall, 1980; Tamkun and Catterall, 1981) establishing that these proteins are composed of a large α subunit (260 kDa) associated with smaller β subunits (30-40 kDa) (Figure 1.1). Cloning of the VGSC genes provided important insights into the structure and function of VGSCs. Based on analysis of hydrophobicity and amino-acid sequence, VGSC alpha (α) subunits were predicted to be transmembrane proteins consisting of four homologous domains (DI-IV) arranged around a central ion conduction pore (Noda et al., 1986). Each domain consists of six transmembrane segments (S1-S6) (Noda et al., 1986) (Figure 1.1). The fourth transmembrane segment of each domain serves as a voltage sensor and contains a number of evolutionarily conserved positively charged amino acid residues. Conformational changes of this segment in response to membrane voltage deflections lead to channel transitions from open to closed states (Chanda and Bezanilla, 2002; Goldschen-Ohm et al., 2013) (Figure 1.1). Channel opening triggers a delayed conformational change in the intracellular loop that bridges domain III and IV which inactivates the channel (Catterall, 2000). Recent atomic level resolution, obtained from a crystallized VGSC, revealed previously unidentified interactions with plasma membrane phospholipids, and possible new drug binding targets (Payandeh et al., 2011).

VGSC α subunits complex with one or two beta (β) subunits (Isom et al., 1994; Morgan et al., 2000; Yu et al., 2003). There are five known VGSC β subunits (β1-4 and β1B) (Isom et al., 1992; Isom et al., 1995; Kazen-Gillespie et al., 2000; Morgan et al., 2000; Qin et al., 2003; Yu et al., 2003). The β1B subunit is a secreted protein while the other β subunits are single pass transmembrane glycoproteins (Patino et al., 2011). β1 and β3 subunits bind non-covalently, while β2 and β4 are linked to α subunits via disulfide bonds (Isom et al., 1992; Isom et al., 1995;
Morgan et al., 2000; Yu et al., 2003). β subunits modulate virtually all aspects of VGSC function including voltage dependent gating, kinetics of activation and inactivation, localization to the plasma membrane, and the effects of drugs on the activity of VGSCs (Morgan et al., 2000; Yu et al., 2005; Uebachs et al., 2012; Lacroix et al., 2013; Laedermann et al., 2013).
VGSC alpha subunits are composed of four domains (I-IV) each consisting of six transmembrane segments. The fourth transmembrane segment of each domain forms the voltage sensor (grey) which contains a large number of positively charged amino-acid residues occurring at every third position. A re-entrant loop between segments 5 and 6 of each domain forms the ion-selectivity filter (yellow). The inactivation gate is formed by the intracellular loop joining domains III and IV. The C- and N- termini are oriented intracellularly. Several N-linked glycosylation sites are located in the extracellular loop spanning segments 1 and 2 of the first domain. β subunits (red) are single-pass transmembrane proteins that influence the activity and localization of VGSCs.
1.2. Genetic Organization of VGSCs

VGSCs are part of an ion channel superfamily that includes structurally, functionally, and genetically similar voltage gated calcium and potassium channels, transient receptor potential (TRP) channels, cyclic nucleotide-gated (CNG), and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels (Yu and Catterall, 2004). The VGSC family of genes is thought to have diverged from ancestral four domain calcium channels (Anderson and Greenberg, 2001; Hille, 2001). The differentiation of VGSCs from calcium channels occurred at about the same time that organisms with specialized neurons appeared (Hille, 2001; Yu and Catterall, 2004). Nine VGSC α subunit genes are expressed in the mammalian genome; SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN8A, SCN9A, SCN10A, and SCN11A, which encode the channel proteins, Na\textsubscript{v}1.1, Na\textsubscript{v}1.2, Na\textsubscript{v}1.3, Na\textsubscript{v}1.4, Na\textsubscript{v}1.5, Na\textsubscript{v}1.6, Na\textsubscript{v}1.7, Na\textsubscript{v}1.8, and Na\textsubscript{v}1.9, respectively (Goldin et al., 2000). Throughout this dissertation the VGSCs will primarily be referred to by their gene names. By convention, human genes are written in uppercase and italics, while non-human gene names are also written in italics but only the first letter is uppercase. SCN1A, SCN2A, SCN3A, and SCN9A, are located on chromosome 2 in both humans and rodents. It is likely that SCN1A-SCN3A arose from duplication events as these channels are clustered and share over 95% amino acid homology. SCN4A is located on human chromosome 17 and on rodent chromosome 11. SCN8A is located on human chromosome 12 and on rodent chromosome 15. SCN5A, SCN10A, and SCN11A are found on human chromosome 3 and the mouse orthologs are on chromosome 9 (Goldin et al., 2000).

The human β1 gene is found on chromosome 19, while β2 and β3 and β4 are located on human chromosome 11 (Goldin, 2001).
1.3. Distribution of VGSCs

1.3.A. Overview

Of the nine mammalian VGSCs, *SCN1A, SCN2A, SCN3A*, and *SCN8A* are primarily expressed in the CNS. This section will mainly focus on the expression of the CNS VGSCs, and in particular the rodent *Scn1a* and *Scn8a* genes, as these channels are the major focus of the work presented in this dissertation. However, it is important to appreciate the distinct regional, developmental, cellular, and subcellular expression profiles of the CNS VGSC genes in order to understand the contribution of this gene family to epilepsy.

1.3.B. Distribution of *Scn1a*

In rodents, *Scn1a* is detectable by Western blot analysis and immunocytochemistry after the second postnatal week, reaching adult levels by P24 (Gong et al., 1999). *Scn1a* expression in forebrain interneurons has been extensively demonstrated (Yu et al., 2006; Ogiwara et al., 2007; Dutton et al., 2012; Han et al., 2012b; Papale et al., 2013), with particularly high expression of *Scn1a* in parvalbumin (PV) positive interneurons (Ogiwara et al., 2007). We demonstrated that *Scn1a* colocalizes with inhibitory neuronal markers in the thalamic reticular nucleus, and hypothalamus, as well as serotonergic neurons of the dorsal and median raphe nuclei, cholinergic neurons of the pedunculopontine tegmental nucleus and laterodorsal tegmental nucleus, and orexinergic neurons of the lateral hypothalamus (Papale et al., 2013). *Scn1a* expression has been identified in inhibitory pacemaker neurons of the suprachiasmatic nucleus (Han et al., 2012a). *Scn1a* expression has also been observed in some populations of excitatory hippocampal and cortical neurons (Westenbroek et al., 1989; Yu et al., 2006; Dutton et al., 2012; Ogiwara et al., 2013). We estimate that between 1 and 13% of *Scn1a* positive hippocampal soma colocalize with excitatory cell markers while over 90% of PV cells are *Scn1a* positive (Dutton et al., 2012).
Na\textsubscript{v}1.1 immunoreactivity has been used to determine the subcellular localization of this channel in the rodent brain. Several studies report abundant somatic expression (Yu et al., 2006; Dutton et al., 2012; Papale et al., 2013) (Fig. 1.2.A). Additionally, Scn1a is expressed at the axon initial segment (AIS) of PV positive interneurons (Ogiwara et al., 2007) and is specifically enriched at the proximal AIS (Van Wart et al., 2007; Duflocq et al., 2008; Lorincz and Nusser, 2008), raising the possibility that Scn1a is important for backpropagation. Expression at the nodes of Ranvier has also been reported, implicating Na\textsubscript{v}1.1 in axonal conduction (Duflocq et al., 2008) (Fig. 1.2.A).

1.3.C. Distribution of Scn8a

Scn8a is the most abundant and broadly expressed VGSC gene in the mammalian CNS. Low levels of Na\textsubscript{v}1.6 channel are detectable by P15 but increasing expression is observed from P20 reaching adult levels by P30 (Liao et al., 2010b). Scn8a immunoreactivity has been identified at the soma of hippocampal neurons (Blumenfeld et al., 2009), however, most reports have found enrichment of Scn8a at the AIS (Lorincz and Nusser, 2008; Feng et al., 2013; Sun et al., 2013) and nodes of Ranvier (Caldwell et al., 2000). Dendritic Scn8a expression was also identified, implicating this channel in the propagation of dendritic sodium currents (Lorincz and Nusser, 2010) (Fig. 1.2.B).

Scn8a is expressed in almost 90\% of ankryn-G positive AISs (Osorio et al., 2010) and at most nodes (Caldwell et al., 2000). Scn8a is most highly expressed at the distal AIS, which is in contrast to the enrichment of Scn1a and Scn2a at the proximal AIS. In agreement with previous reports (Rush et al., 2005), it was discovered that proximal AIS VGSCs (putative Scn2a channels) have a higher threshold for activation (~43 mV) than distal VGSCs (~55 mV) (putative Scn8a channels) (Hu et al., 2009). It is speculated that this distribution at the AIS is important for the generation of backpropagating action potentials (Fig. 1.2B). Depolarizing currents at the AIS that
are subthreshold at proximal Scn2a channels but are sufficient to activate distal Scn8a would produce backpropagating potentials as distal Scn8a channel activation will trigger proximal Scn2a channels.

1.3.D. Distribution of Scn2a

Scn2a expression can be found along most unmyelinated and premyelinated neurons during early development. Later in development, Scn2a is primarily found at the proximal axon initial segment (Fig. 1.2.B), in a process that follows the formation of the myelin sheath along the axon and the transition from continual to saltatory axonal conduction (Boiko et al., 2001).

1.3.E. Distribution of Scn3a

Scn3a is most highly expressed embryonically (Beckh et al., 1989) and during early postnatal development in rodents (Siqueira et al., 2009). SCN3A expression decreases during development but is maintained at relatively higher levels during adulthood in humans compared to rodents (Chen et al., 2000). Scn3a is expressed in adult dorsal root ganglion neurons following axotomy in rodents (Waxman et al., 1994) and upregulation of Scn3a in the hippocampus was observed in Scn1a knockout mice, indicating that under certain conditions reemergence of Scn3a expression can occur. (Yu et al., 2006). Electrophysiological analysis of neurons from Scn1a knockout mice indicate that upregulation of Scn3a can restore a small portion of the lost Scn1a sodium currents in hippocampal neurons (Yu et al., 2006).

1.3.F. Glial Expression of VGSCs

VGSC expression has also been identified in non-neuronal cells in the brain and spinal cord of rodents (Korotzer and Cotman, 1992; Schmidtmayer et al., 1994) and humans (Norenberg et al., 1994). Scn1a, Scn5a, and Scn8a are the primary VGSCs expressed in microglia (Black et
Microglia are CNS immune cells that are responsible for removing cellular debris and pathogens (Aloisi, 2001). Reducing sodium channel activity either genetically or pharmacologically inhibits many of the functions of microglia including phagocytosis, migration, activation, and release of proinflammatory cytokines (Craner et al., 2005; Black et al., 2009). Upregulation of Scn1a, Scn5a, and Scn8a expression has been observed in microglia following activation by lipopolysaccharide (LPS) treatment and in an experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis (Craner et al., 2005; Black et al., 2009). Additionally, the Scn1a, Scn2a, Scn3a, Scn5a, and Scn8a have been identified in rodent astrocytes, particularly under proinflammatory pathological conditions (Ritchie, 1987; Black et al., 1993; Black et al., 1994; Black et al., 1995; Black and Waxman, 1996), and Scn5a has been identified in human astrocytes in multiple sclerosis lesions (Black et al., 2010). Upregulation of glial VGSCs in pathological states may help to regulate altered extracellular ion concentration (Black et al., 2010). Additionally, increased glial VGSC expression has been shown to increase proinflammatory cytokine production which may contribute to chronic inflammation in epilepsy.
A. Inhibitory neurons are thought to express high levels of $Scn1a$ at the soma, axon hillock (axon initial segment) and along the axon at the nodes of Ranvier.  

B. $Scn8a$ is thought to be highly expressed at the axon hillock and at the nodes of Ranvier in excitatory projection neurons. A proximodistal gradient exists between $Scn2a$ and $Scn8a$ at the axon hillock (inset) which may be important for back propagation. These models are not meant to represent cells outside of the forebrain and do not include all VGSC subcellular expression.
1.4. Overview of Epilepsy

1.4.A. What is Epilepsy

Epilepsy is defined as a neurological disorder characterized by seizures which are episodes of highly synchronous neuronal activity. Epilepsy is one of the most common neurological conditions, affecting over 50 million people worldwide (Brodie et al., 1997). The prevalence of epilepsy is estimated to be 0.3-1.6% (Begley et al., 2007) and the lifetime risk of diagnosis is estimated to be 2-3% (Browne and Holmes, 2001). Unfortunately, approximately 30% of epileptic patients do not achieve sufficient control of their seizures with currently available treatments (Loscher, 2002) highlighting a continued need to develop novel treatment options.

Epilepsies can be classified by their etiology and presentation. Epilepsies that are thought to be genetic in origin are classified as idiopathic whereas epilepsies in which a precipitating factor is known are classified as symptomatic. Many of the epilepsies are known to have a strong genetic component and heritability can be as high as 70% as has been estimated for partial epilepsy (Kjeldsen et al., 2001). A seizure event is classified as complex if consciousness is lost while simple seizures do not involve loss of consciousness. Seizures involving both hemispheres are classified as generalized while partial seizures only involve one hemisphere. Lastly, absence seizures are non-convulsive events characterized by brief loss of consciousness which are accompanied by three per second spike-and-wave EEG discharges. While seizures can differ substantially in their underlying causes and presentation, a commonality is that they result from aberrant synchronization of neuronal activity.

1.4.B. Idiopathic Epilepsies

Many of the first epilepsy mutations to be identified were found to occur in ion channels and could be considered large effect size variants that often exhibited classic Mendelian
inheritance. Among these channels, the VGSCs and in particular SCN1A emerged as important epilepsy risk genes.

The heritability of epilepsy has been very well documented, however, the majority of the genetic causes remain undetermined. The discrepancy between the lack of identified genetic risk factors and the high degree of heritability of the disorder has been observed in many genetic disorders (Manolio et al., 2009) but appears to be particularly high among the epilepsies. This was thought to be a result of the high degree of heterogeneity and complexity of the epilepsies. Most of the first generation of identified epilepsy risk genes are monogenetic and relatively homogeneous. For example, more than 80% of Dravet syndrome cases are caused by mutations in SCN1A (Claes et al., 2001; Harkin et al., 2007). In contrast, the majority of idiopathic epilepsies involve rare genetic variants and complex interactions of many genetic risk factors. Only recently, with the advent of whole genome and exome sequencing approaches has it been possible to effectively identify de novo disease causing mutations in patients without a family history of the disease (Bamshad et al., 2011; Doherty and Bamshad, 2012; Need et al., 2012; Rauch et al., 2012). Just in the past few years, application of these approaches has revealed a wealth of new epilepsy risk genes (Murdock et al., 2011; Talkowski et al., 2011; Andrade et al., 2012; Cloarec et al., 2012; Elo et al., 2012; Heron et al., 2012; Lemke et al., 2012; Veeramah et al., 2012; Basel-Vanagaite et al., 2013; Jang et al., 2013; Lindgren et al., 2013; Marti-Masso et al., 2013; McDonell et al., 2013; Nakamura et al., 2013; Poulton et al., 2013; Touma et al., 2013; Veeramah et al., 2013). As these approaches continue to reveal new risk genes it will become increasingly possible to understand the complex genetic interactions that lead to many of the epilepsies.
1.5. VGSC Epilepsy Mutations

1.5.A. SCN1A Epilepsy Mutations

Currently more epilepsy mutations have been identified in the SCN1A gene than in any other epilepsy gene (for databases of SCN1A variants see www.molgen.ua.ac.be/SCN1AMutations and www.scn1a.info) (Claes et al., 2009; Lossin, 2009). Missense and in-frame deletions as well as truncation mutations have been identified in virtually every part of the SCN1A channel in epileptic patients, including transmembrane spanning segments, intra and extracellular loops, and the C- and N-terminal domains (Catterall et al., 2008).

SCN1A mutations are the leading cause of the childhood encephalopathy, Dravet Syndrome (DS) (Claes et al., 2001). Approximately 70-80% of DS patients carry mutations in the SCN1A gene (Marini et al., 2007). Seizures in infants with DS are often initially febrile (fever-induced) early in life (4-8 months of age), and often increase in frequency and severity with age. DS is characterized by cognitive impairment, hyperactivity, photosensitivity, developmental arrest, ataxia, and sleep disturbances. Many children with DS are classified as autistic (Li et al., 2011). DS is often refractory to treatment and premature mortality is estimated to be 15-20% (Genton et al., 2011).

SCN1A mutations are also a major cause of genetic epilepsy with febrile seizures plus (GSFS+) (Escayg et al., 2000). It is estimated that 10% of GEFS+ patients carry SCN1A mutations. GEFS+ patients have a heterogeneous epilepsy phenotype but primary characteristics include childhood febrile seizures and afebrile generalized tonic-clonic, absence, atonic, and partial seizures (Scheffer and Berkovic, 1997). SCN1A has also been associated with intractable childhood epilepsy with generalized tonic-clonic seizures (Fujiwara et al., 2003) and severe idiopathic generalized epilepsy (Ebach et al., 2005).
Together, these SCN1A-related epilepsies encompass a spectrum of phenotypes with overlapping clinical presentations and etiologies that range in severity from relatively benign febrile seizures to the catastrophic DS (Harkin et al., 2007). It is interesting that the most severe SCN1A epilepsies often arise from de novo loss-of-function mutations and that less severe SCN1A epilepsies arise from inherited amino acid substitutions (Catterall et al., 2010; Escayg and Goldin, 2010). This suggests that larger perturbations to channel function lead to more severe types of epilepsy.

1.5.B. SCN2A Epilepsy Mutations

Mutations in SCN2A are most frequently observed in benign familial neonatal-infantile seizures (BFNIS). BFNIS is characterized by afebrile generalized seizures that begin in the first 3-6 months of life and typically resolve by the end of the first year of life. SCN2A mutations have also been identified in a small number of cases of infantile spasms, sporadic neonatal epileptic encephalopathy (Ogiwara et al., 2009), migrating focal seizures of infancy (Dhamija et al., 2013), infantile spasms (Sundaram et al., 2013), and DS (Shi et al., 2009).

1.5.C. SCN3A, SCN8A, and SCN9A Epilepsy Mutations

There is comparatively much less information about the role of the other VGSCs in epilepsy. Gain-of-function SCN3A mutations have been identified in five children with partial epilepsy (Holland et al., 2008; Estacion et al., 2010; Vanoye et al., 2013). Very recently, with the application of whole exome and genome sequencing, nine SCN8A mutations have been identified in patients with epilepsy (O'Brien and Meisler, 2013). A gain-of-function SCN8A mutation was recently discovered in a patient with infantile epileptic encephalopathy and sudden death in epilepsy (SUDEP) (Veeramah et al., 2012). Five additional SCN8A mutations linked to epileptic encephalopathies have also been identified (Carvill et al., 2013; Epi et al., 2013), however,
functional analyses of these mutations has not been performed. Three additional unpublished SCN8A mutations, identified in patients with epileptic encephalopathy, have been reviewed (O’Brien and Meisler, 2013). SCN9A has been linked to FS, GEFS+, and DS, and may be a modifier of SCN1A, potentially worsening SCN1A epilepsies (Singh et al., 2009; Mulley et al., 2013).

1.5.D. Epilepsy Mutations in VGSC Beta Subunits

VGSC β subunits modulate the properties of VGSC α subunits and also function as cell adhesion molecules that are important for normal brain development. As such, β subunits provide a means by which VGSC activity and brain development can be altered in ways that can lead to epilepsy.

Several epilepsy mutations have been identified in β subunit genes. Mutations in the SCN1B (β1) gene have been identified in patients with temporal lobe epilepsy and GEFS+ (Wallace et al., 1998; Scheffer et al., 2007) and DS (Patino et al., 2009; Ogiwara et al., 2012). SCN1B knockout mice are ataxic and epileptic (Chen et al., 2004) and exhibit epileptiform burst activity in hippocampal slices and impaired development of the hippocampus (Brackenbury et al., 2013). SCN2B (β2) deficiency is not known to cause human epilepsy but β2 null mice are more susceptible to pilocarpine-induced seizures than wild-type littermate controls and have reduced expression of VGSC α subunits and reduced sodium currents in hippocampal neurons (Chen et al., 2002).

1.6. VGSCs and Epilepsy: Mechanisms

Since reducing sodium conduction would be expected to reduce neuronal excitability, it is not surprising that VGSCs are pharmacological targets for the treatment of epilepsy. However,
what is less intuitive is how mutations in a sodium channel can lead to increased excitability and epilepsy.

1.6.A. Mechanisms of SCN1A Epilepsies

SCN1A channels have been shown to be highly expressed in GABAergic inhibitory neurons of the hippocampus and cortex (see 1.3.B. Scn1a Distribution) and reduced excitability of these neurons has been observed in Scn1a mouse mutants (Yu et al., 2006; Ogiwara et al., 2007; Martin et al., 2010). Cell-type colocalization and electrophysiological analysis of rodent models of Scn1a dysfunction lead to the hypothesis that loss of Scn1a causes reduced neuronal inhibition and thus increased risk of seizure generation (Yu et al., 2006; Ogiwara et al., 2007). Conditional knockout approaches have been used to probe this hypothesis by selectively inactivating the Scn1a gene in different cell types. Work from our lab as well as other investigations have demonstrated that broad loss of Scn1a from interneurons (Cheah et al., 2012), or restricted loss of Scn1a from parvalbumin interneurons (Dutton et al., 2012; Ogiwara et al., 2013) is sufficient to generate spontaneous seizures and reduce lifespan (Fig. 1.3). Interestingly, conditional inactivation of Scn1a in excitatory neurons of the cortex and hippocampal CA1 and dentate granule cell layers was not sufficient to alter latencies to induced seizures (Dutton et al., 2012), but did improve the survival of mice in which Scn1a was broadly deleted from interneurons (Ogiwara et al., 2013). These data are consistent with a model in which Scn1a-mediated reduction in PV interneuron excitability is primarily driving seizure susceptibility and lethality but the severity of these phenotypes can be either worsened by loss of inhibition from other interneuronal subtypes or lessened to some extent by loss of Scn1a from glutamatergic excitatory cells.
Figure 1.3. Loss of inhibition model of Scn1a dysfunction leading to epilepsy

Illustrated are hypothetical cortical parvalbumin positive interneurons (red) synapsing onto two glutamatergic pyramidal neurons (blue) in a normal (left) and epileptic (right) brain. The thickness of the cell body and processes indicates the relative excitability of the cell type. The font size of the VGSC (Scn1a) indicates the relative expression level of this channel. In a normal, non-epileptic brain sufficient Scn1a expression exists to support interneuronal excitability which suppresses network hyperexcitability. Loss of Scn1a expression leads to a reduction in interneuronal function and an overall increase in network activity. This loss of inhibition allows excitatory aspects of the network to enter into hyperexcitable, epileptic states.
1.6.B. Mechanisms of SCN8A Epilepsies

A role for SCN8A in epilepsy was first investigated in Scn8a mouse mutants by determining their susceptibility to induced seizures (Martin et al., 2007; Hawkins et al., 2011). Scn8a mutant mice were also crossed to mice carrying Scn1a mutations to assess the effect of reduced Scn8a activity in DS and GEFS+ epilepsy models (Martin et al., 2007; Hawkins et al., 2011). In contrast to other VGSCs, we found that mutations that reduce the activity of Scn8a increase seizure resistance and extend the survival of mouse models of DS and GEFS+ (Martin et al., 2007; Hawkins et al., 2011). These findings identified Scn8a as a genetic modifier of Scn1a epilepsy phenotypes, and identified SCN8A as a possible target for therapeutic intervention.

Loss of function of the mRNA binding protein Celf4 was found to increase the expression of Scn8a at the AIS and also increase sodium currents (Sun et al., 2013). Interestingly, Celf4 deficient mice have a complex seizure disorder involving both tonic-clonic seizures and absence seizures (Wagnon et al., 2011). While it is possible that seizures are the result of altered expression of any number of the many other targets of Celf4 (Wagnon et al., 2012), it is tempting to speculate that the increased Scn8a expression is responsible for the increased sodium currents and neuronal excitability. Thus alterations that increase Scn8a expression may lead to increased neuronal excitability and epilepsy, while mutations that reduce the activity of Scn8a increase seizure resistance. In support of this hypothesis, increased Scn8a expression was observed in the hippocampus of amygdala-kindled rats (Blumenfeld et al., 2009), and in the entorhinal cortex, a region which provides a major source of excitatory input to the hippocampus, in a hippocampal electrical simulation model of TLE (Hargus et al., 2011). These studies raise the possibility that activity-dependent increases in Scn8a expression can lead to increased neuronal activity, initiating a self-reinforcing feedback cycle that promotes the generation of seizures. Additionally, a gain-of-function SCN8A mutation, N1768D, was identified in a patient with infantile epileptic encephalopathy and sudden unexplained death in epilepsy (SUDEP) (Veeramah et al., 2012).
Functional analysis of the biophysical properties of mutated SCN8A (N1768D) channels revealed a robust increase in persistent sodium current. Given that Scn8a is highly expressed in excitatory neurons of the hippocampus and cortex, it seems possible that increased Scn8a activity/expression could result in a broad increase in the excitability of excitatory cortical and hippocampal projection neurons, thereby promoting seizure states.

In contrast to the increased seizure resistance associated with Scn8a mutations in mice, reduced Scn8a activity has also been shown to cause absence epilepsy (Papale et al., 2009). We demonstrated that absence seizure frequency is influenced by genetic background and is suppressed by ethosuximide, a T-type Ca++ blocker and first-line treatment for absence epilepsy. Interestingly, absence seizures were observed in the patient with the SCN8A N1768D mutation (Veeramah et al., 2012).

1.6.C. Mechanisms of SCN2A and SCN3A Epilepsies

Mutations in SCN2A are most commonly found in children with benign familial neonatal-infantile seizures (BFNIS) (Heron et al., 2002; Herlenius et al., 2007; Liao et al., 2010a). Unlike epilepsies associated with mutations in SCN1A and SCN8A, which often begin in childhood and worsen over time, BFNIS often resolves by one year of age (Berkovic et al., 2004). This is thought to be a consequence of the normal developmental switch of SCN2A with SCN8A α subunits, which occurs throughout early development in concert with myelination of maturing neurons (Liao et al., 2010b). In rare cases, SCN2A alterations have been identified in more severe intractable childhood epilepsies (Ogiwara et al., 2009) and in GEFS+ (Sugawara et al., 2001) and DS (Shi et al., 2009).

Five SCN3A epilepsy mutations have been reported to date; one in a patient with refractory cryptogenic partial epilepsy (Holland et al., 2008) and four in children with focal
epilepsy (Vanoye et al., 2013). Functional analysis of these mutations indicated that they are gain-of-function, leading to increased voltage-dependent sodium currents (Holland et al., 2008).

1.7. VGSC Dysfunction in Cognition and Behavior

1.7.A. SCN1A in Cognition and Behavior

Recently, increased attention has been given to the role of VGSCs in cognition and behavior, with a particular emphasis on the behavioral and cognitive comorbidities that have been reported in VGSC epilepsies. While it is clear that seizure activity itself can disrupt cognition, some VGSC mutations have been identified in patients with cognitive and behavioral abnormalities who do not have epilepsy. This suggests that VGSC dysfunction can lead to epilepsy and cognitive-behavioral deficits by separate and/or convergent mechanisms.

SCN1A mutations are often associated clinically with a host of behavioral and cognitive deficits including hyperactivity, attention deficit disorder, sleep disorders, increased anxiety, and impaired social interactions (Mahoney et al., 2009; Brunklaus et al., 2011; Genton et al., 2011; Li et al., 2011). Scn1a mutant mice exhibit increased anxiety, hyperactivity, impaired spatial learning, and reduced performance on social tasks (Han et al., 2012b; Ito et al., 2012). Additionally, we have identified sleep abnormalities in a mouse model of GEFS+ (Papale et al., 2013), which may lead to deficits in memory consolidation. In the clinic, behavioral and cognitive dysfunction typically follows the onset of seizures and so it is possible these deficits are the consequence of seizure activity. However, siRNA knockdown of Scn1a in the rat basal forebrain was found to interfere with hippocampal oscillations resulting in deficits in spatial memory but not epilepsy (Bender et al., 2013). This finding suggests that at least some SCN1A derived cognitive impairments can occur independently of seizures. In addition, Cre-mediated deletion of Scn1a from interneurons was recently shown to result in autistic-like behaviors in mice (Han et al., 2012a). Surprisingly, acute administration of the gamma-aminobutyric acid
acting benzodiazepine, clonazepam, was capable of transiently abolishing many of these behavioral phenotypes in adult mice (Han et al., 2012b). This finding suggests that 1) many of the behavioral deficits associated with SCN1A arise from reduced GABAergic neurotransmission and, 2) that correcting these deficits, even in adulthood, might lead to cognitive and behavioral improvements.

Additionally, disrupted SCN1A function has been implicated in the etiology of impaired cognition and the increased incidence of epilepsy that occurs in Alzheimer's disease (AD). The enzyme β-site APP-cleaving enzyme 1 (BACE1), also known as β-secretase 1, is responsible for cleaving amyloid precursor protein (APP) and also the VGSC β2 subunit which is responsible, in part, for inserting SCN1A in the plasma membrane (Kim et al., 2011). Thus, elevated BACE1 expression, which often occurs in AD, may lead to cognitive impairment both by increasing Aβ and by reducing SCN1A expression in the brain.

1.7.B. SCN8A in Cognition and Behavior

SCN8A has been associated with psychiatric disease and cognitive impairment in humans. Human genetic studies have identified an association between SCN8A polymorphisms and increased suicidal behavior (Wasserman et al., 2005; Wang et al., 2010), as well as increased risk of bipolar disorder (Wang et al., 2008). An SCN8A truncation mutation was also identified in a patient exhibiting cerebellar atrophy, ataxia, and mental retardation, but not epilepsy (Trudeau et al., 2006). In mice, Cre-driven inactivation of Scn8a in cerebellar Purkinje cells reduces performance in the Morris water maze (Woodruff-Pak et al., 2006). In contrast, no deficits in Morris water maze performance or in a conditioned taste avoidance paradigm were observed in mice carrying a null Scn8a mutation; however, increased emotional behaviors were observed (McKinney et al., 2008). We have found that the Scn8a-medjo mutation leads to modestly increased spatial memory in a novel object recognition task and alterations to sleep architecture.
but not to differences in anxiety or depressive-like phenotypes (Papale et al., 2010). Together, these studies point to a possible role of SCN8A in some aspects of cognitive function and behavior.

1.7.C. SCN2A and SCN3A in Cognition and Behavior

Comparatively little information exists about the possible role of SCN2A and SCN3A in cognitive processes and behavior. Whole genome sequencing approaches have identified SCN2A as a risk gene for autism (Jiang et al., 2013). Furthermore, microdeletions that encompass SCN2A and SCN3A were identified in a patient with autistic-like features, psychomotor delay, microcephaly, but not epilepsy (Celle et al., 2013) and in an unrelated patient with cognitive and psychiatric impairment (Bartnik et al., 2011). Testing of available rodent models of Scn2a and Scn3a dysfunction for behavioral abnormalities could potentially be very beneficial to the field.

1.8. VGSCs as Antiepileptic Drug Targets

Pharmacologic targeting of VGSCs has produced some of the most effective and widely used anti-epileptic drugs (AEDs). These drugs include, phenytoin (Kuo and Bean, 1994), lamotrigine, carbamazepine, oxcarbazepine (Schmutz et al., 1994), and zonisamide (Schauf, 1987). Evidence also exists for VGSC targeting by several additional drugs including felbamate (Tagliatela et al., 1996), topiramate (Taverna et al., 1999), and valproate (Van den Berg et al., 1993; Taverna et al., 1998; Xie et al., 2001). Importantly, phenytoin, carbamazepine, and lamotrigine weakly block VGSCs under conditions of normal neuronal activity but increase their potency in a use-dependent fashion in response to sustained depolarization (Rogawski and Loscher, 2004). Therefore, these drugs become maximally effective when they are most required, under conditions of sustained channel activity, which occurs during seizure.
Despite efforts to find compounds that are selective for different VGSC isoforms, few exist. Tetrodotoxin (TTX) and VGSC-acting AEDs non-selectively target these channels, but conceivably targeting specific isoforms could lead to improved seizure suppression with fewer side effects. Moreover, non-selective targeting of VGSCs with lamotrigine can actually worsen some epilepsies that involve an underlying VGSC deficiency such as DS (Guerrini et al., 1998). However, reduced Scn8a activity has been shown to normalize seizure thresholds and lifespan in mice with Scn1a mutations (Martin et al., 2007; Hawkins et al., 2011), providing proof of concept of the benefits of targeting select VGSC isoforms in epilepsy.

The TTX derivative, 4.9-anhydro-TTX, has been reported to be selective for Scn8a (Rosker et al., 2007). IC$_{50}$ values for this compound were evaluated on a combination of human and rodent VGSCs and range from 341±36 nmol/L (Scn3a) to 785000±11600 nmol/L (SCN5A) compared to 7.8±2.3 nmol/L (Scn8a). Unfortunately, Scn1a was not evaluated for technical reasons. Without knowing the IC$_{50}$ of this compound for Scn1a it is not clear how useful it would be as an experimental tool or a base for developing SCN8A selective drugs. Recently, a selective SCN9A compound was described with over 32-fold selectivity for SCN9A over other VGSC isoforms (Yang et al., 2013). This compound will be useful for the study and treatment of pain but it might also have implications for epilepsy (see the SCN3A, SCN8A, and SCN9A Epilepsy Mutations section). SCN9A variants are enriched in DS, however it is not yet clear if these mutations are gain-, reduction- or loss-of-function. If gain-of-function SCN9A mutations do contribute to DS, then providing an SCN9A selective inhibitor might be beneficial in these patients.
CHAPTER 2

Partial Knockdown of Na,1.6 (Scn8a) Sodium Channels in the Hippocampus Confers Seizure Protection

Chapter 2 contains material from the manuscript in preparation: Partial Knockdown of Na,1.6 (Scn8a) Sodium Channels in the Hippocampus Confers Seizure Protection, Makinson C.D., Tanaka B., Lamar T., Goldin A. L., Escayg A.
2.1. Summary

SCN1A mutations are the main cause of the epilepsy disorders Dravet syndrome (DS) and genetic epilepsy with febrile seizures plus (GEFS+). Mutations that reduce the activity of the mouse Scn8a gene, in contrast, are found to confer seizure resistance and extend the lifespan of mouse models of DS and GEFS+. To investigate the mechanism by which reduced Scn8a expression confers seizure resistance, we induced interictal-like burst discharges in hippocampal slices of heterozygous Scn8a null mice (Scn8a<sup>med/+</sup>) with elevated extracellular potassium. Scn8a<sup>med/+</sup> mutants exhibited reduced epileptiform burst discharge activity after P20, indicating an age-dependent increased threshold for induction of epileptiform discharges. Scn8a deficiency also reduced the occurrence of burst discharges in a GEFS+ mouse model (Scn1a<sup>R1648H/+</sup>). There was no detectable change in the expression levels of Scn1a (Na<sub>1.1</sub>) or Scn2a (Na<sub>1.2</sub>) in the hippocampus of adult Scn8a<sup>med/+</sup> mutants. To determine whether the increased seizure resistance associated with reduced Scn8a expression was due to alterations that occurred during development, we examined the effect of deleting Scn8a in adult mice. Global Cre-mediated deletion of a heterozygous floxed Scn8a allele in adult mice was found to increase thresholds to chemically and electrically induced seizures. Knockdown of Scn8a gene expression in the adult hippocampus via lentiviral Cre injection resulted in a reduction in the number of EEG-confirmed seizures following the administration of picrotoxin. Additionally, knockdown of Scn8a expression in the hippocampus of Scn1a<sup>+/−</sup> and WT mice using an adeno-associated viral shRNA was found to increase thresholds to flurothyl-induced seizures. Our results identify the hippocampus as an important structure in the mediation of Scn8a-dependent seizure protection and suggest that selective targeting of Scn8a activity might be efficacious in patients with epilepsy.
2.2. Introduction

Epilepsy is characterized by unprovoked, recurrent seizures that are manifestations of abnormal neuronal synchrony and excitability. Several genes that are known to cause monogenic forms of epilepsy encode neuronal ion channels, including voltage-gated sodium channels (VGSCs) (Noebels, 2003; Steinlein, 2004). VGSCs are important integrators of synaptic input and are responsible for the initiation and propagation of action potentials in neurons (Gong et al., 1999; Whitaker et al., 2001; Lorincz and Nusser, 2010). Three pore-forming VGSC α-subunit genes are primarily expressed in the adult mammalian central nervous system (CNS): SCN1A, SCN2A, and SCN8A, which encode the Na$_{v}$1.1, Na$_{v}$1.2, and Na$_{v}$1.6 channels, respectively. SCN1A has emerged as an important epilepsy gene and is responsible for a number of different epilepsy disorders, including the catastrophic, treatment-resistant childhood encephalopathy Dravet syndrome (DS) and genetic epilepsy with febrile seizures plus (GEFS+) (Escayg et al., 2000; Claes et al., 2001).

Approximately 30% of epileptic patients do not achieve adequate seizure control with currently available anti-epilepsy drugs (AEDs). Moreover, while new AEDs are generally better tolerated, the percentage of patients with treatment-resistant seizures has not changed significantly in the last 40 years, indicating a critical need to identify new treatment options for patients with refractory epilepsy. VGSCs are known targets for several AEDs; however, these drugs are not isoform specific and affect all VGSCs, likely contributing to unwanted side effects. Alternatively, selective targeting of a specific VGSC isoform, may provide improved seizure control with fewer unintended consequences.

We previously demonstrated that thresholds for flurothyl- and kainic acid-induced seizures are elevated in Scn8a$^{med/+}$ and Scn8a$^{medios/+}$ mutant mice when compared to wild-type (WT) littermates (Martin et al., 2007). Furthermore, the seizure phenotypes of Scn1a mutant mice that model DS and GEFS+ were dramatically improved by the co-expression of an Scn8a
mutation (Martin et al., 2007; Hawkins et al., 2011). In addition, Scn8a-deficient mice are resistant to amygdala kindling, while there is increased Scn8a expression in the CA3 region of the hippocampus of amygdala-kindled rats (Blumenfeld et al., 2009). Together, these studies raise the possibility that reduced hippocampal Scn8a expression may contribute to the seizure protection observed in Scn8a<sup>med/+</sup> mutants and that the selective targeting of Scn8a may be efficacious in some forms of epilepsy. However, a caveat of these earlier experiments is that the relationship between Scn8a and seizure resistance was based on the use of Scn8a mutant mice, in which the activity of Scn8a was reduced throughout brain development. Therefore, whether reduced Scn8a activity would confer seizure protection in the adult brain was unknown.

In this study, we examined the effect on seizure susceptibility of reducing Scn8a expression in adult mice. In addition to exploring the mechanism of seizure protection associated with altered Scn8a function, we used electrophysiological analysis to monitor developmental changes in hippocampal excitability in heterozygous Scn8a<sup>med/+</sup> mutants. Finally, using lentiviral-Cre and adeno-associated viral shRNA strategies, we assessed the effect on seizure phenotypes of reducing Scn8a expression in the hippocampus.

### 2.3. Results

**Epileptiform burst discharge activity is reduced in Scn8a<sup>med/+</sup> mutant mice**

Since the hippocampus is known to play an important role in seizure generation, we examined temporal changes in the excitability of hippocampal slices from heterozygous Scn8a null mutant mice (Scn8a<sup>med/+</sup>). Epileptiform burst discharges were induced in the CA3 pyramidal cell layer of the hippocampus by elevating the extracellular potassium concentration (Fig. 1Aa-c). Burst discharges were not observed during the initial 5 minutes at physiological potassium concentration (2.5 mM [K<sup>+</sup>]<sub>e</sub>) in hippocampal slices from either WT (Fig. 1Aa) or Scn8a<sup>med/+</sup> mutant mice (Fig. 1B). However, elevating the extracellular K<sup>+</sup> concentration to 8.5 mM induced
synchronous burst discharge activity in hippocampal slices from most WT mice at all ages (P13-P84) (Fig. 1A,D). Individual burst discharges were composed of a positive extracellular potential with multiple population spikes (Fig. 1Ac). Burst activity continued until the extracellular K⁺ was returned to physiological concentration (2.5 mM). Similarly, hippocampal slices from young P13-P20 Scn8a<sup>med/+</sup> mutant mice displayed burst discharges when exposed to elevated potassium (Fig. 1D). In contrast, burst discharges were not observed in the majority of slices from Scn8a<sup>med/+</sup> mutant mice older than P20 (Fig. 1B,D). The lack of activity was not due to poor health of the cells because synaptic connections and neuronal firing remained intact, as determined by stable population spike amplitudes in the CA3 pyramidal layer before and after exposure to elevated potassium (Fig. 1C). The frequency of observed epileptiform burst discharges was lower in more mature WT mice (P26 and P70-84), but was still comparably much higher than that observed in slices from Scn8a<sup>med/+</sup> mutant mice (Fig. 1D). For example, burst discharges were observed in 86% of slices from adult WT mice, but in only 12% of slices from adult Scn8a<sup>med/+</sup> mice (P70-84).

**Latency to burst discharges is increased in Scn8a<sup>med/+</sup> mutant mice**

Because Na<sub>1.6</sub> channels are well suited for repetitive firing of action potentials and hence hyperactivity of the neuronal network, we compared the latency to the initiation of burst discharges in slices from Scn8a<sup>med/+</sup> mutants and WT littermates. Latency to the initial burst discharge was measured from the time that elevated potassium ACSF entered the recording chamber. Scn8a<sup>med/+</sup> mutant mice in all 3 age groups tested displayed a significant increase in the latency to the initiation of epileptiform burst activity (Fig. 2.2A). However, once burst discharge activity was induced, there were no qualitative differences in the pattern of synchronous activity. To determine whether there were any quantitative differences in burst activity, we analyzed the inter-burst frequency and single burst duration. Because the majority of hippocampal recordings
from $Scn8a^{med/+}$ mutant mice did not exhibit burst activity (Fig. 2.1D), only hippocampal slices from the few $Scn8a^{med/+}$ mutant mice that produced burst discharges were used for this analysis. Inter-burst frequency was measured as the number of burst discharges during a 4-min period, and burst duration was determined from an average of 50 individual bursts (Fig. 2.1Ac). There were no significant differences in either the inter-burst frequency or single burst duration between $Scn8a^{med/+}$ mutant and WT mice in all 3 age groups examined (Fig. 2.2B-C).

**Reduced $Scn8a$ expression decreases the occurrence of burst discharges in $Scn1a^{R1648H/+}$ mice**

To investigate whether reduced $Scn8a$ expression could alter the occurrence of epileptiform burst discharges in a mouse model of GEFS+ ($Scn1a^{R1648H/+}$ mice), we generated double heterozygous mutants ($Scn1a^{R1648H/+}/Scn8a^{med/+}$) and quantitatively examined burst activity in hippocampal slices exposed to elevated potassium. Burst occurrence, defined as the number of slices that exhibited bursting, was significantly lower in slices from $Scn8a^{med/+}$ and double heterozygous mice compared to WT (Table 1). Burst occurrence was also significantly reduced in double heterozygous mice compared to $Scn1a^{R1648H/+}$ mice (Table 1). While burst occurrence was comparable in slices from $Scn1a^{R1648H/+}$ mutants and WT littermates, burst latency was significantly shorter in $Scn1a^{R1648H/+}$ mice. An increase in inter-burst frequency was also observed in slices from $Scn1a^{R1648H/+}$ mutants compared to WT; however, this difference was not statistically significant. It was not possible to statistically evaluate burst latency or frequency in slices from $Scn8a^{med/+}$ mice (with or without the $Scn1a^{R1648H/+}$ mutation) because of the low percentage of hippocampal slices that demonstrated burst activity. However, increased latencies to bursting and decreased inter-burst frequencies were observed in $Scn8a^{med/+}$ slices (with or without the $Scn1a^{R1648H/+}$ mutation) compared to $Scn1a^{R1648H/+}$ slices in the few instances in which bursting occurred.
Figure 2.1. Spontaneous seizure-like burst discharges in CA3 pyramidal cell layer induced by elevated potassium in hippocampal slices from Scn8a<sup>med/+</sup> mutant and WT mice

**Aa.** CA3 pyramidal cells did not show spontaneous burst activity in physiological 2.5 mM [K<sup>+</sup>]<sub>o</sub>; however, burst activity was induced when extracellular K<sup>+</sup> concentration was elevated to 8.5 mM [K<sup>+</sup>]<sub>o</sub>. **Ab.** Expansion of a segment of spontaneous activity showed synchronous firing of burst activity. **Ac.** Expansion of a single ictal-like burst discharge. Arrow indicates start of a burst discharge and star shows the end of a single burst. **B.** Extracellular recording from CA3 pyramidal cell layer of a Scn8a<sup>med/+</sup> mutant mouse (P24). **C.** Population spike amplitude before and after exposing hippocampal slice to 8.5 mM [K<sup>+</sup>]<sub>o</sub>. Solid gray – before perfusing 8.5 mM [K<sup>+</sup>]<sub>o</sub> into the bath. Black dash – after exposing slice to 8.5 mM [K<sup>+</sup>]<sub>o</sub> and washout with standard

<table>
<thead>
<tr>
<th>Age (days)</th>
<th>P13/P15</th>
<th>P19</th>
<th>P21</th>
<th>P22</th>
<th>P23</th>
<th>P24</th>
<th>P25</th>
<th>P26</th>
<th>P70/P71</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>100% (5.2)</td>
<td>89% (9.3)</td>
<td>100% (3.5)</td>
<td>100% (15.5)</td>
<td>100% (11.4)</td>
<td>100% (8.3)</td>
<td>100% (8.3)</td>
<td>92% (12.4)</td>
<td>86% (7.4)</td>
</tr>
<tr>
<td>med/+</td>
<td>100% (4.2)</td>
<td>100% (5.2)</td>
<td>100% (4.2)</td>
<td>0% (8.3)</td>
<td>23% (8.7)</td>
<td>15% (11.4)</td>
<td>21% (14.5)</td>
<td>13% (16.5)</td>
<td>27% (15.4)</td>
</tr>
</tbody>
</table>

(# of slices, # of mice)
2.5 mM $[K^+]_o$ ACSF. Population spikes were evoked with 50 μA stimulation for 100 μs. $D$, hippocampal slices from $Scn8a^{med/+}$ mutant and WT mice from P13-P20 demonstrated comparable levels of spontaneous burst discharge activity in elevated extracellular potassium. Beginning at P21, the propensity for burst activity dramatically decreased in hippocampal slices from $Scn8a^{med/+}$ mutant mice. Number of slices = 4-17, number of mice = 2-7. *$p < 0.001$ when compared to WT; Fisher's exact test with Bonferroni correction. These experiments were performed by Brian Tanaka in the laboratory of Alan Goldin at the University of California, Irvine.
Figure 2.2. Analysis of burst characteristics between Scn8a<sup>med/+</sup> and WT mice

A. Hippocampal slices from Scn8a<sup>med/+</sup> mutants demonstrate longer latencies to the onset of burst activity compared to slices from WT mice for all age groups (WT vs mutant at P13-P15: 2.7 ± 0.2 min vs 3.8 ± 0.2 min, *p < 0.05; WT vs mutant at P24-P26: 6.1 ± 0.8 min vs 11.1 ± 1.2 min, **p < 0.01; WT vs mutant at P70-P84: 6.9 ± 0.9 min vs 9.2 ± 1.2 min, *p < 0.05). Comparison of burst activity showed similar inter-burst frequency <strong>B</strong>, and burst duration <strong>C</strong>, between slices from Scn8a<sup>med/+</sup> mutants and WT mice. P13-P15, n = 4-5; P24-P26, n = 6-9; P70-P84, n = 3-5; Student’s two-tailed t test, *p < 0.05; **p < 0.001; error bars indicate SEM. These experiments were performed by Brian Tanaka in the laboratory of Alan Goldin at the University of California, Irvine.
<table>
<thead>
<tr>
<th>Genotype</th>
<th>Burst Occurrence</th>
<th>Burst Latency (min)</th>
<th>Inter-burst Frequency (Hz)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>9/9</td>
<td>7.3 ± 0.4 (9)</td>
<td>31.8 ± 2.9 (9)</td>
</tr>
<tr>
<td>$Scn1a^{RH/+}$</td>
<td>7/9</td>
<td>4.5 ± 0.3 (7)$^\dagger$</td>
<td>41.9 ± 6.2 (7)</td>
</tr>
<tr>
<td>$Scn8a^{med/+}$</td>
<td>2/14$^*$</td>
<td>9.4, 12.7 (2)</td>
<td>20.2, 17.0 (2)</td>
</tr>
<tr>
<td>$Scn1a^{RH/+}; Scn8a^{med/+}$</td>
<td>1/13$^*#$</td>
<td>6.3 (1)</td>
<td>14.3 (1)</td>
</tr>
</tbody>
</table>

Table 2.1. Decreased $Scn8a$ expression reduced the occurrence of bursting in hippocampal slices from $Scn1a^{RH/+}$ mutant mice

Burst activity was recorded in slices exposed to elevated potassium from P24-P26 mice. The data are presented as means ± SEM, with the number of slices in the burst occurrence column and in parentheses. Values for burst latency and frequency are listed for $Scn8a^{med/+}$ mice. $^*$ $p < 0.006$ when compared to WT; Fisher’s exact test with Bonferroni correction. $^*$ $p < 0.006$ when compared to $Scn1a^{RH/+}$ mice; Fisher’s exact test with Bonferroni correction. $^\dagger$ $p < 0.001$ when compared to WT; Student’s t-test. These experiments were performed by Brian Tanaka in the laboratory of Alan Goldin at the University of California, Irvine.
**Developmental expression profile of Na\textsubscript{1.6} channels in the hippocampus**

Because decreased burst activity was seen only in slices from \textit{Scn8a}\textsuperscript{med/+} mice older than P20, we investigated whether this decrease was correlated with changes in developmental expression of Na\textsubscript{1.6} channels by performing Western blot analysis. Na\textsubscript{1.6} was first detectable in the hippocampus at P10 and progressively increased until adult levels were reached between 3-4 weeks after birth (Fig. 3A). Expression levels of Na\textsubscript{1.6} in \textit{Scn8a}\textsuperscript{med/+} mutant mice were qualitatively lower, as would be expected (Fig. 3A). To determine whether reduced \textit{Scn8a} expression in \textit{med} mutants is associated with altered levels of other VGSC alpha subunits, we compared \textit{Scn1a} and \textit{Scn2a} mRNA and protein levels from hippocampi of 3-month-old \textit{Scn8a}\textsuperscript{med/+} and WT littermates. Consistent with previous observations (Kearney et al., 2002), we found no significant differences in expression levels (Fig. 3 B-C).
Figure 2.3. Developmental expression of VGSCs in the hippocampus of Scn8a<sup>med/+</sup> mutant and WT mice

A. Western blot analysis of hippocampal membrane fractions from WT and Scn8a<sup>med/+</sup> mutants (P6-P30) using rabbit anti-Na<sub>v</sub>1.6 polyclonal antibody. Pan-cadherin (135 kDa) was used as a loading control. Hippocampal tissues from WT and Scn8a<sup>med/+</sup> mice were analyzed by Western blotting (WB) and qPCR for alterations in the expression of B, Scn1a and C, Scn2a. Alpha tubulin (50 kDa) was used a loading control. No significant differences in protein or RNA levels were observed. The standard sample consists of a mixture of WT P10, P22 and P30, as well as
$Scn8a^{med/+}$ mutant P10, P22 and P30 to achieve an average protein concentration to compare protein levels across different immunoblots. WB and qPCR data were analyzed by the Student’s two-tailed t test, $p > 0.05$. WB, n = 7 per group; qPCR n = 4-5 per group. Error bars indicate SEM. Part A was performed by Brian Tanaka in the laboratory of Alan Goldin at the University of California, Irvine.
Cre recombinase induction leads to deletion of the floxed allele and reduced Na,1.6 levels

To examine the effect of reducing Scn8a expression on seizure thresholds in adult mice, we crossed a tamoxifen (TAM)-inducible Cre line (ER-Cre) with Scn8a floxed mice to generate progeny in which inactivation of the Scn8a gene could be achieved by TAM injection. PCR analysis performed on hippocampal tissue from flox/+, ER-Cre mice 15 d after the last TAM injection detected a 300-bp PCR band, indicating deletion of exon 1 of the Scn8a gene (Fig. 4A). This PCR product was not observed in mice that were not administered TAM, or in mice that either lacked the floxed Scn8a allele or the Cre transgene (Fig. 4A). Reduced optical density (78% reduction) of the Scn8a band by Western blot analysis demonstrated reduced expression of the Na,1.6 protein in flox/flox, ER-Cre mice that were administered TAM compared to flox/flox, ER-Cre mice that were administered vehicle (Fig. 4B-C).
Figure 2.4. Tamoxifen-induced global deletion of the Scn8a gene

A. PCR product amplified from dissected neocortical tissue from flox/+, ER-Cre, TAM mice as well as control littermates (flox/+, ER-Cre, Veh) demonstrated that deletion is only detectable following TAM injection in mice that express the ER-Cre transgene and the floxed Scn8a allele (third lane). Additionally, the Scn8a floxed allele was only marginally detectable following TAM-initiated deletion, providing further evidence of efficient deletion. B. Western blotting demonstrated significant (79%) knockdown of Na,1.6 protein in homozygous floxed mice carrying the ER-Cre transgene following TAM injection (flox/flox, ER-Cre, TAM) compared to flox/flox, ER-Cre mice administered vehicle. n = 3 per group; Student’s two-tailed t test, *p < 0.05; Error bars indicate SEM. C. Representative Western blot from vehicle and TAM treated...
flox/flox, ER-Cre mice demonstrates reduced band intensity in the TAM treated group. Error bars indicate SEM.
Inactivation of *Scn8a* leads to increased resistance to chemically and electrically induced seizures

Latencies to flurothyl-induced seizures following TAM-induced inactivation of the *Scn8a* allele were compared between *Scn8a*-deficient animals (*flox/+*,*ER-Cre*,TAM) (white bar, Fig. 5A) and control littermates with normal levels of *Scn8a* (+/+,no *Cre*,TAM; +/-,*ER-Cre*,TAM; *flox/+*,no *Cre*,TAM; and *flox/+*,*ER-Cre*,Veh) (black bars, Fig. 5A). Myoclonic jerk latency was reduced in +/-,*ER-Cre*,TAM; *flox/+*,no *Cre*,TAM; and *flox/+*,*ER-Cre*,Veh animals but not +/-,no *Cre*,TAM mice compared to *flox/+*,*ER-Cre*,TAM animals. Significantly increased latencies to the GTCS were observed between *Scn8a*-deficient mice when compared to all control groups (Fig. 5A).

Latencies to KA-induced seizures were also compared between *Scn8a*-deficient (*flox/+*,*ER-Cre*,TAM) mice and control (*flox/+*,*ER-Cre*,Veh) mice. Latency to the first occurrence of each seizure stage on a modified Racine scale was recorded. Significantly increased latencies to stage 5 and stage 6 were observed in the *flox/+*,*ER-Cre*,TAM mice when compared to control littermates (Fig. 5B).

The 6-Hz model of psychomotor seizures was used to determine the effect of reducing *Scn8a* expression on electrically induced seizures. The severity of evoked seizures in *Scn8a* \(^{flox/+},*ER-Cre\) mice before and after TAM or vehicle administration was recorded using a modified Racine scale. A significant reduction in seizure severity was observed after TAM injection but not after vehicle injection (Fig. 5C). A trend toward a reduction in the percentage of mice exhibiting seizure activity was also observed following TAM administration, with 43% (3/7) of mice exhibiting seizures after TAM administration, compared to 89% (8/9) of mice exhibiting seizures after vehicle administration (Fig. 5D).
Figure 2.5. Inducible deletion of the Scn8a gene in the adult mouse is sufficient to increase the latency to flurothyl- and KA-induced seizures and to protect against electrically induced 6-Hz psychomotor seizures.

A, Latencies to flurothyl-induced myoclonic jerk (MJ) and generalized tonic-clonic seizures (GTCS) were increased following TAM-induced inactivation of the Scn8a gene (floxed/+,$ER^{-}-Cre$,TAM) (white bar) compared to control littermates (+/+,no Cre,TAM; +/+,$ER^{-}-Cre$,TAM; floxed/+,no Cre,TAM; and floxed/+,ER-Cre,Veh) (black bars). n = 10-12 per group. MJ and GTCS, one-way ANOVA, $p < 0.001$; Dunnett’s post hoc, $p < 0.05$.

B, Latencies to KA-induced seizure events were increased following Scn8a deletion (floxed/+,$ER^{-}-Cre$,TAM) (solid line) when
compared to vehicle-injected controls (floxed/+,ER-Cre,Veh) (dashed line). Seizure activity was scored using a modified Racine scale: 1 = freezing, 2 = head nodding, 3 = tail clonus, 4 = forelimb clonus, 5 = rearing and falling, 6 = GTCS. n = 12-13 per group. Two-way ANOVA, p < 0.01; Bonferroni post hoc, p < 0.05. n = 12-13. C, 6-Hz psychomotor seizure severity was decreased after TAM-initiated inactivation of Scn8a (floxed/+,ER-Cre,TAM) (solid line) when compared to vehicle-injected controls (floxed/+,ER-Cre,Veh) (dashed line). n = 7-9 per group. Mann-Whitney-U test, p < 0.05. Seizure activity was scored using the following modified Racine scale: 1 = freezing, 2 = head nodding 3 = rearing and falling. Average Racine scores: floxed/+,ER-Cre,Veh. pre = 2.1, post = 2.0; floxed/+,ER-Cre,TAM pre = 2.0, post = 0.4. D, There was a trend toward reduced 6-Hz psychomotor seizure activity following inactivation of Scn8a (floxed/+,ER-Cre,TAM) when compared to vehicle-injected controls (floxed/+,ER-Cre,Veh). n = 7-9 per group; Fisher’s exact test, n.s. p = 0.07. *p < 0.05; **p < 0.01; error bars indicate SEM
Lentiviral Cre-induced inactivation of the Scn8a gene in the hippocampus reduces seizure generation in vivo

To determine whether restricting Scn8a inactivation to the hippocampus would be sufficient to increase seizure resistance in vivo, LV-Cre or LV-GFP were injected into the hippocampus of flox/flox mice. GFP-positive cells were observed in the CA1, CA3, and DG layers of the hippocampus with highest expression in the DG and CA3 (Fig. 6A). Responses to picrotoxin (PT) were measured 15 days after injection of the lentiviral constructs. We observed a statistically significant reduction in the number of seizures in LV-Cre-injected mice compared to LV-GFP-injected controls (Fig. 6B); however, the average latency to the first seizure and the average seizure length were not significantly altered (Fig. 6C-D). Representative EEG recordings of baseline and seizure activity are shown for LV-GFP-injected controls and LV-Cre-injected mice (Fig. 6E).

Efficient shRNA-mediated knockdown of Scn8a in the hippocampus

An adeno-associated viral vector (AAV) expressing a small hairpin RNA (shRNA) against Scn8a (AAV-Scn8a-shRNA) or a control vector expressing a scrambled sequence (AAV-GFP) were injected into the hippocampus of WT and Scn1a+/− mice. Two weeks following injection, GFP positive cells were broadly observed in the CA1, CA3, and DG (Figure 2.7A). Hippocampi were dissected from WT and Scn1a+/− mice and Na,1.6 (Scn8a), Na,1.1 (Scn1a), and Na,1.2 (Scn2a) protein levels were quantified by Western blot analysis. α-tubulin was detected on each blot and used to normalize protein loading (Figure 2.7B). Efficient knockdown (63.5%) of Na,1.6 by the shRNA was observed in the hippocampus (Figure 2.7C). As expected, Na,1.1 expression was reduced in Scn1a+/− animals. No significant change in Na,1.1 or Na,1.2 levels resulted from shRNA delivery.
Flurothyl thresholds are increased in WT and Scn1a°/° mice following shRNA-mediated knockdown of Scn8a expression in the hippocampus.

Latencies to flurothyl-induced seizures were measured in WT and Scn1a°/° mice two weeks following injection with either AAV-GFP or AAV-Scn8a-shRNA. The latency to the generalized tonic-clonic seizure was increased by 48% in WT animals injected with AAV-shRNA compared to WT animals injected with AAV-GFP (Mean GTCS latency, WT-shRNA = 461 ± 58 sec; WT-GFP = 238 ± 26 sec; one-way ANOVA, p < 0.001; Figure 2.8). Seizure latencies were increased by 46% in Scn1a°/° mice injected with AAV-shRNA compared to Scn1a°/° mice injected with AAV-GFP (Mean GTCS latency, Scn1a°/°-shRNA = 255 ± 18 sec, Scn1a°/°-GFP = 137 ± 23 sec; one-way ANOVA, p < 0.05; Figure 8). Seizure thresholds were not significantly different between WT mice injected with AAV-GFP and Scn1a°/° mice injected with AAV-shRNA (one-way ANOVA, p > 0.05; Figure 2.8), indicating that selective knockdown of Scn8a in Scn1a mutant mice was capable of restoring seizure latencies to WT levels.
Figure 2.6. Lentiviral Cre-mediated knockdown of Scn8a in the hippocampus reduces seizure activity following PT administration

Scn8aflox/flox mice were injected with either LV-GFP or LV-Cre to achieve knockdown of Scn8a in the hippocampus. A, GFP-positive cells were observed in the CA1, CA3, and DG layers of the hippocampus with highest expression in the DG and CA3. Images were captured at 4X and 40X magnification (inset), scale bar = 100 μm. B, Fewer seizures were recorded in LV-Cre- compared to LV-GFP-treated mice following PT administration. No significant difference in the latency to the first seizure C, or the average duration of each seizure event D, was observed in LV-Cre- compared to LV-GFP-injected mice. E, Representative examples of baseline EEG and seizure activity indicating normal baseline EEG activity in both GFP and Cre groups and seizure activity
in Cre and GFP groups following PT administration. n = 6-7 per group. Mann-Whitney-U test,

*p < 0.05. Error bars indicate SEM.
Figure 2.7. Efficient adeno-assiociated viral shRNA-mediated knockdown of the Scn8a gene in the hippocampus of Scn1a+/- and WT mice

A. GFP positive cells were observed in the CA1, CA3, and DG regions of the hippocampus following hippocampal injection of AAV-GFP and AAV-3 (Scn8a-shRNA) constructs. B. Representative immuno blots of dissected hippocampi taken from WT and Scn8a+/- mice two weeks following injection with either AAV-GFP (GFP) or AAV-shRNA (shRNA). Na,1.6 (Scn8a), Na,1.1 (Scn1a), and Na,1.2 (Scn2a) were probed using the same hippocampal samples. α-tubulin was detected on each blot and used to normalize protein loading. C. Quantitative analysis of Western blots demonstrates efficient knockdown (63.5%) of Na,1.6 by the shRNA in the hippocampus. As expected, Na,1.1 expression is reduced in Scn1a+/- animals. The shRNA did not
significantly alter Na\textsubscript{v}1.1 or Na\textsubscript{v}1.2 levels. One-way ANOVA, Tukey post-hoc; **p < 0.01, ***p < 0.001, n.s. p > 0.05; error bars represent SEM; n = 4 per group.
Figure 2.8. Adeno-associated viral shRNA-mediated knockdown of the Scn8a gene in the hippocampus increases furothyl-induced seizure thresholds in Scn1a<sup>+/−</sup> and WT mice

GFP and shRNA AAV constructs were injected into the hippocampus of WT and Scn1a<sup>+/−</sup> mice. Seizure latencies in WT mice administered the shRNA were elevated when compared to GFP-injected WT littermates. Likewise, shRNA-knockdown increased seizure thresholds in Scn1a<sup>+/−</sup> mice when compared to GFP-injected Scn1a<sup>+/−</sup> littermates. No difference in seizure thresholds was detected between GFP-injected WT mice and shRNA-injected Scn1a<sup>+/−</sup> littermates. One-way ANOVA, Tukey post-hoc; *<i>p</i> < 0.05, **<i>p</i> < 0.001, n.s. <i>p</i> > 0.05; n = 7-11 per group; error bars represent SEM.
2.4. Discussion

Previous studies examining the relationship between *Scn8a* and seizure resistance relied on the use of mice that expressed *Scn8a* mutations throughout development. To determine whether seizure protection would also be observed if *Scn8a* expression was reduced only in the adult brain, we used a TAM-inducible Cre transgenic line to initiate the inactivation of a floxed *Scn8a* allele in adult mice. We found that global reduction of *Scn8a* expression in the adult brain was capable of raising latencies to flurothyl- and KA-induced seizures. In addition, we found that reduced *Scn8a* expression in adult mice increased resistance to 6-Hz psychomotor seizures, a paradigm used to screen for novel anti-epileptic drugs (Brown, 1953; Barton et al., 2001). These results show that seizure protection can be achieved by reducing *Scn8a* expression in the adult brain, which is a critical requirement for an anticonvulsant therapy.

To test the hypothesis that reduced *Scn8a* expression leads to reduced hippocampal excitability and seizure suppression, we studied hippocampal slices from *Scn8a*med/+ and WT littermates in a high-potassium model of epileptiform activity throughout postnatal development. We found that *Scn8a*med/+ hippocampal slices were resistant to interictal-like burst discharges beginning at P20. There was an increase in the latency to epileptiform burst discharges in *Scn8a*med/+ slices, suggesting that reduced *Scn8a* expression inhibits the initiation of bursting activity; however, there were no changes in inter-burst frequency or single burst duration relative to slices from WT mice. Our data indicate that there is a deficiency in epileptiform burst discharge initiation but not burst discharge propagation since epileptiform activity progresses comparably between WT and *Scn8a*-deficient slices following initiation.

*Na*$_1$1.6 channels have characteristic biophysical properties, including persistent current, resurgent current, and resistance to inactivation, which makes this isoform well suited for the sustained high-frequency firing that occurs at the axon initial segment and nodes of Ranvier, but
may also allow this channel to facilitate the propagation of high-frequency ictal activity (Raman et al., 1997; Zhou and Goldin, 2004). Despite these unique characteristics, \( Scn8a^{med/+} \) mutant mice showed no significant changes in inter-burst frequency or single burst duration. It is possible that there are changes in action potential firing that we could not detect because they are below the sensitivity of our assay; or, it may be that the decreased seizure activity is a property of the overall network and therefore does not reflect simple changes in bursting in any one region. Prior studies have shown that mice with altered \( Scn8a \) expression have reduced persistent current and depolarized action potential spike thresholds in hippocampal pyramidal neurons that may impede the firing of repetitive action potentials (Royer et al., 2008; Blumenfeld et al., 2009). These biophysical changes are consistent with the longer latency to the initial burst discharge and higher seizure threshold in \( Scn8a^{med/+} \) mutants. These results suggest that reduced \( Scn8a \) expression leads to reduced hippocampal network excitability and consequently reduced susceptibility to epileptiform activity. We also demonstrated that reduced \( Scn8a \) expression suppresses the occurrence of burst discharges in the hippocampus of \( Scn1a^{R1648H/+} \) mice thereby providing a mechanistic basis for our previous observations of ameliorated seizure phenotypes in \( Scn1a \) mutant mice that co-express \( Scn8a \) mutations (Martin et al., 2007; Hawkins et al., 2011). Parallel to our measurement of hippocampal bursting activity throughout early postnatal development, we also examined developmental changes in the expression levels of \( Na_v1.6 \) in the hippocampus. Consistent with previous observations, Western blot analysis revealed that \( Na_v1.6 \) is detectable by P10 and reaches adult levels by the third postnatal week (Plummer et al., 1997; Liao et al., 2010b). The emergence of reduced epileptiform burst discharges in \( Scn8a^{med/+} \) mice coincided with the beginning of the developmental period in which \( Scn8a \) is highly expressed, and therefore likely to significantly influence neuronal excitability. This suggests that the reduced epileptiform bursting in \( Scn8a^{med/+} \) mice is, in part, a consequence of lower \( Scn8a \) expression levels during this period. The expression levels of \( Scn1a (Na_v1.1) \) and \( Scn2a (Na_v1.2) \) were
unaltered in the hippocampi of adult Scn8a\textsuperscript{med/+} mutants, which is consistent with previously reported observations on Scn8a\textsuperscript{med/med} mice which have a 90% reduction in Na,1.6 expression (Kearney et al., 2002).

Previous studies examining Scn8a-mediated seizure resistance raised the possibility of a self-reinforcing relationship between Scn8a expression and neuronal activity in which increases in neuronal activity lead to increased Scn8a expression, which in turn further increases neuronal excitability in the CA3 region of the hippocampus and contributes to epilepsy (Blumenfeld et al., 2009). Genetically reducing Scn8a expression might block this positive feedback cycle. An additional possibility is that Scn8a localization at the proximal axon initial segment of hippocampal DG neurons places these channels in a prime location to regulate the low-pass filtering capability of these neurons, which is thought to help protect the hippocampus from seizure activity (Hsu, 2007; Kress et al., 2010). Furthermore, DG neurons express comparatively lower levels of Scn8a when compared to CA3 (Kress et al., 2010), perhaps making their intrinsic excitability more sensitive to changes in Scn8a expression. These results, together with our findings, indicate that the hippocampus is a key region for Scn8a-mediated seizure resistance.

To directly test the hypothesis that targeting Scn8a in the hippocampus is sufficient to increase seizure resistance, we performed lentiviral-Cre and GFP injections into the hippocampus of conditional Scn8a mice (floxflo) and measured response to PT administration. This approach resulted in a significant reduction in the number of electrographic seizures resulting from PT administration. However, the latency to the first electrographic seizure and the average duration of all seizure events were comparable between LV-GFP and LV-Cre groups.

Hippocampal hyperexcitability has previously been demonstrated in Scn1a\textsuperscript{+/} mice (Liautard et al., 2013). Moreover, hyperthermia-induced seizures were first detected in the hippocampus before spreading to the cortex (Liautard et al., 2013). These findings support the possibility that targeting the hippocampus may provide seizure protection in Dravet syndrome.
test this hypothesis, we injected an AAV construct containing an shRNA that targets Scn8a into the hippocampus of WT and Scn1a+/− mice, which model Dravet syndrome. The shRNA produced efficient knockdown (63.5%) of the Scn8a protein (Na,1.6) in the hippocampus. It is potentially interesting that a small but not statistically significant increase in Scn1a expression was observed in the hippocampus of WT mice injected with AAV-shRNA compared to AAV-GFP injected controls and also in Scn1a+/− mice injected with AAV-shRNA compared to Scn1a+/− mice injected with AAV-GFP (Figure 2.7). This may indicate that there is a compensatory increase in Scn1a expression in the hippocampus in response to loss of Scn8a. No change in Scn2a expression levels was observed in any group. Latencies to flurothyl-induced GTCS were found to be increased in both WT and Scn1a+/− mice compared to their genotype-matched AAV-GFP injected controls. Furthermore, no significant difference in average latency was observed between WT AAV-GFP and Scn1a+/− AAV-shRNA groups. Together, the LV-Cre and AAV-shRNA findings indicate that the hippocampus is an important regulator of Scn8a-dependent CNS excitability and supports the possibility that targeting of Scn8a may provide an efficacious treatment for some forms of epilepsy such as Dravet syndrome.

Although heterozygous Scn8a null mice ($Scn8a^{med/}$) are visibly normal, they exhibit anxiety-like behavior and have spike-wave discharges that are characteristic of absence seizures (Burgess et al., 1995; McKinney et al., 2008; Papale et al., 2009). In one human family, SCN8A haploinsufficiency was associated with cognitive deficits (Trudeau et al., 2006). Additional studies will therefore be required to evaluate the effects on behavior and cognition of targeting Scn8a in epileptic animals. It is possible that normalizing the excitability of an epileptic region by targeting Scn8a will not result in the behavioral deficits that may occur when Scn8a is reduced in an otherwise normal animal. In addition, restricted targeting of Scn8a may reduce the likelihood of unwanted consequences. In support of this hypothesis, mice with hippocampal knockdown of Scn8a displayed normal visible behavior and no absence seizures during video/EEG recordings.
The SCN8A mutation N1786D was recently identified in a patient with severe epilepsy, cognitive deficits, and sudden unexpected death in epilepsy (SUDEP) (Veeramah et al., 2012). In addition, loss of the RNA-binding protein Celf4 has been shown to lead to an increase in Scn8a expression and to spontaneous seizure generation in mice (Sun et al., 2013). These findings seem to contradict observed improvements in seizure protection in Scn8a mutant mice. However, the available mouse models of Scn8a dysfunction have reduced sodium currents, whereas the N1786D is a gain-of-function mutation with increased persistent current (Veeramah et al., 2012), and Celf4 deficiency is believed to result in increased Na,1.6 expression at the axon initial segment and increased persistent current (Sun et al., 2013). Thus, reduced Na,1.6 currents likely lead to reduced neuronal excitability and seizure protection, whereas alterations that increase Na,1.6 currents, in particular those that increase persistent current, lead to greater neuronal excitability and seizure susceptibility.

**Conclusions**

We have determined that hippocampal Na,1.6 is an important regulator of neuronal excitability and seizure susceptibility. These results raise the possibility that targeting Scn8a, either genetically or with Na,1.6 specific compounds, may be an efficacious treatment strategy for some forms of epilepsy.

2.5. Materials and Methods

*Animals*

C3HeB/FeJ-Scn8a<sup>med</sup>/J mice (Scn8a<sup>med/+</sup>, Jackson Laboratory, Bar Harbor, stock number 003798) were maintained on the C3HeB/FeJ background. The med mutation is the result of a spontaneous LINE element insertion in the second exon of the Scn8a gene leading to truncation and loss-of-
function of the channel (Kohrman et al., 1996a). \( Scn8a^{med+/} \) male mice were crossed to C3HeB/FeJ females to generate \( Scn8a^{med+/} \) and wild-type (WT) \( Scn8a^{+/} \) littermate controls. Mice expressing the UBC-Cre-\( ER^{T2} \) transgene (\( ER-Cre \)) were obtained from the Jackson Laboratory (stock number, 008085). \( Scn8a \)-floxed mice, in which exon 1 of the \( Scn8a \) gene is flanked by \( loxP \) sites (floxed allele), were a gift from Dr. Miriam Meisler at the University of Michigan, Ann Arbor (Levin and Meisler, 2004). The \( ER-Cre \) and \( Scn8a \)-floxed lines were maintained on the C57BL6/J background. Male \( ER-Cre \) mice were crossed to female \( Scn8a \)-floxed mice, producing progeny that express the floxed allele and the \( ER-Cre \) transgene (\( flox+/+,ER-Cre \)). Controls consisted of offspring that express the floxed allele but lack the \( ER-Cre \) transgene (\( flox+/+,no\ Cre \)), progeny that lack the floxed allele but carry the \( Cre \) transgene (\( +/+,ER-Cre \)), and progeny that lack the floxed allele and the \( ER-Cre \) transgene (\( +/-,no\ Cre \)). Vehicle-injected mice that carry both the floxed allele and the \( ER-Cre \) transgene were also used as controls (\( flox/+,ER-Cre,\ Veh. \)). Homozygous \( Scn8a \)-floxed mice that expressed the \( ER-Cre \) transgene (\( flox/flox,ER-Cre \)) were used to evaluate recombination efficiency. Homozygous floxed mice (\( flox/flox \)) were used for all experiments involving intrahippocampal viral \( Cre \) and \( GFP \) injections. AAV injections were performed on \( Scn1a^{+/} \) mice. These mice were a kind gift by William Catterall at the University of Washington. \( Scn1a^{R1648H+/} \) mice were generated as previously described (Martin et al., 2010). Double heterozygous mutants (\( Scn1a^{R1648H+/},Scn8a^{med+/} \)) were generated by crossing \( Scn1a^{R1648H+/} \) with \( Scn8a^{med+/} \) mutant mice. All crosses yielded genotypes in expected Mendelian ratios. Littermates were used for all experiments to minimize confounds associated with differences in rearing conditions and genetic background. Experimenters were blinded to subject groups during data collection and analysis. Mice were maintained on a 12 h light/dark cycle. Food and water were available \( ad\ libitum \). All experimental procedures were performed in accordance with the guidelines of Emory University and the University of California, Irvine Institutional Animal Care and Use Committees.
Genotyping

The presence of the Cre transgene and the Scn8a floxed allele was determined by PCR analysis using the primer pairs CreF/CreR (TGA CCC GGC AAA ACA GGT AGT TA / TTC CCG CAG AAC CTG AAG ATG TT) and FloxF/FloxB (GTG TGT GAT TCT CAA CAG TGG GTT / GTC TGT AAG AAG GCC TGA AAG TGA), respectively (Levin and Meisler, 2004). The Scn8a-med mutation was identified as previously described (Martin et al., 2007) using the primer pair medF/medR (TCC AAT GCT TAT ACC AAA AGT CCC / GGA CGT GCA CAC TCA TTC CC). Scn1aR1648H/+ mice were genotyped as previously described (Martin et al., 2010).

Tamoxifen-induced inactivation of Scn8a

Individually housed 2-month-old mice were intraperitoneally (i.p.) administered tamoxifen (TAM, 100 mg/kg, Sigma-Aldrich) or vehicle (corn oil, Sigma-Aldrich) for 5 consecutive days. TAM was prepared by dissolving in 100% ethanol and then mixing with 300 μl of corn oil. Excess ethanol was evaporated by vacuum centrifugation. Mice were left undisturbed for 15 days after the last injection.

Preparation and incubation of slices

Mice were anesthetized with halothane, decapitated, and their brains were placed in ice-cold sucrose artificial cerebrospinal fluid (ACSF) containing (in mM): 85 NaCl, 65 sucrose, 2.5 KCl, 25 glucose, 1.25 NaH2PO4, 4 MgSO4, 0.5 CaCl2, and 24 NaHCO3. Transverse hippocampal slices (350 μm) were cut using a Leica VT1000S vibrating blade microtome (Leica, Germany). Slices were incubated at 33°C for at least 1 h before electrophysiological recordings in oxygenated
(95% O₂, 5% CO₂) standard ACSF containing (in mM): 126 NaCl, 2.5 KCl, 1.25 NaHPO₄, 1.2 MgSO₄, 10 glucose, 1.2 CaCl₂, and 24 NaHCO₃.

**Electrophysiological recordings**

Slices were submerged in a recording chamber and continuously perfused at 2 mL/min with oxygenated ACSF at 33°C during electrophysiological experiments. Cells were visualized with an upright microscope (Zeiss Axioskop Plus) equipped with infrared differential interference contrast optics. Recording pipettes (2-5 MΩ) were pulled from borosilicate glass (Sutter Instruments, Novato, CA) with a P-87 Flaming-Brown puller (Sutter Instruments).

Electrophysiological recordings were obtained in current clamp mode using MultiClamp 700B amplifier at 100X AC (Molecular Devices, Union City, CA) and digitized with a Digidata 1322A digitizer (Molecular Devices). Continuous extracellular recordings were acquired at 10 kHz and population spikes were recorded at 50 kHz. All recordings were low-pass filtered at 1 kHz for offline analysis with pClamp 10.2 software (Molecular Devices).

For extracellular recordings, pipettes were filled with 150 mM NaCl and positioned in the CA3 stratum pyramidal layer. ACSF with elevated potassium was prepared by supplementing standard ACSF with 3 M KCl to raise the potassium concentration to 8.5 mM [K⁺]₀. The experimental paradigm consisted of a control recording for 2-5 min in standard ACSF, followed by 20-25 min with 8.5 mM [K⁺]₀, in which burst activity was recorded. To evoke population spikes, constant-current stimuli (100 msec) were applied via stimulus isolator (A365D; WPI, Sarasota, FL) using a bipolar tungsten electrode (50 μm in diameter; A-M Systems, Carlsborg, WA) positioned in the mossy fiber tract. Population spikes were evoked in physiological 2.5 mM [K⁺]₀ before and after exposing the slice to 8.5 mM [K⁺]₀. Slices in which population spike amplitudes did not change more than 20% after exposing the slice to 8.5 mM [K⁺]₀ were used for analysis.
**Protein extraction**

Hippocampi were dissected and frozen at -80°C. To determine developmental changes in Scn8a expression, individual hippocampi were pooled from 10-15 mice at each age. Hippocampi from adult, 2-3-month-old, mice were not pooled. Hippocampi were homogenized on ice using a Dounce homogenizer in homogenization buffer (320 mM sucrose, 5 mM Na phosphate, pH 7.4, 100 mM Na fluoride and protease inhibitor (Pierce, Rockford, IL) or 50 mM Tris, pH = 7.5; 10 mM EGTA, and one complete EDTA-free protein inhibitor tablet (Roche, Germany) per 50 mL solution. Homogenates were centrifuged at 750 x g for 10 min at 4°C, and the supernatant was centrifuged at 39,000 x g for 30 or 60 min at 4°C. The pellet was suspended in protease inhibitor buffer and stored at -80°C. BCA (Thermo Fisher Scientific, Waltham, MA) or Bradford (Bio-Rad, Hercules, CA) protein assays were used to normalize protein concentrations across samples.

**Western blot analysis**

Membrane-enriched whole-brain or hippocampal tissue homogenates (15-30 ug) were subjected to SDS-PAGE electrophoresis. After blocking in 5% milk, blots were incubated overnight at 4°C in either polyclonal rabbit anti-Na,v1.6 primary antibody (1:200, Millipore, Billerica, MA), polyclonal rabbit anti-Na,v1.6 (1:225, Alomone, Israel), polyclonal rabbit anti-Na,v1.1 (1:200, Millipore), or monoclonal mouse anti-Na,v1.2 (1:1000, Neuromab, Davis, CA). Blots were then incubated in either HRP-conjugated donkey anti-rabbit secondary (1:10,000, GE Healthcare, United Kingdom), HRP-conjugated goat anti-mouse secondary (1:10,000, Jackson ImmunoResearch, West Grove, PA), or HRP-conjugated goat anti-rabbit secondary (Sigma, St. Louis, MO, 1:16,000) for 1 h followed by washing in SuperSignal West Pico Chemiluminescent substrate (Pierce) and imaging. Blots were also probed using a monoclonal mouse anti-α-tubulin...
followed by HRP-conjugated goat anti-mouse secondary (1:10,000, Jackson ImmunoResearch) or HRP-conjugated goat anti-mouse secondary (Pierce, 1:26,000) for normalization of sample loading. Image quantification was performed using ImageJ software (NIH).

Quantitative real-time PCR

Total RNA was extracted from the hippocampus of WT and Scn8a<sup>med/+</sup> adult mice using the RNeasy Lipid Tissue Mini Kit (Qiagen, Germany). All RNA samples were quantified using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific), and RNA quality was determined by agarose gel electrophoresis. RNA was reverse-transcribed into cDNA using random hexamer primers and SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA). Scn1a (F: TCA GGA AGG GGT TTC GCT TC, R: CCC CAC ATC CTT GGC TCG CCC TC) and Scn2a (F: CTG CAA CGG TGT GGT CTC CCT AG, R: ATG TAG GGT CTT CCA ACA AGT CC) primers were designed to span introns to avoid amplification of genomic DNA. Each primer pair generated standard curves with efficiencies of 90-100%. Real-time PCR (qPCR) data were generated from cDNA samples in technical triplicate using the BioRad CFX96 Real-Time PCR Detection System and SYBR Green fluorescent dye (BioRad). Expression levels were normalized to beta-actin (F: CAG CTT CTT TGC AGC TCC TT, R: ACG ATG GAG GGG AAT ACA GC). Expression analysis and statistics were performed using the GenEx 5 software (MultiD).

Lentiviral and adeno-associated viral constructs

Previously described viral vectors expressing green fluorescent protein (LV-GFP) or Cre-recombinase (LV-Cre) were obtained from the Emory University Viral Core (Heldt et al., 2007). Briefly, LV-GFP viral vectors were derived from the pLV-CMV-GFP-U3Nhe backbone. LV-Cre viral vectors were created by replacing the GFP coding sequence with Cre-recombinase coding.
sequence using the BamH1/Sal1 restriction sites in the pLV-CMV-GFP-U3he backbone. Viral production procedures have been described previously (Miyoshi et al., 1998; Pfeifer et al., 2001). Viral titer of the LV-\textit{GFP} and LV-\textit{Cre} was assessed in HEK-293T cells and ranged from $1 \times 10^8$ to $1 \times 10^9$ infectious particles per ml.

Adeno-associated viral (AAV) constructs were produced by the University of Pennsylvania Vector Core. Scrambled sequence was placed downstream of the U6 promoter in addition to GFP. This virus is referred to as AAV-GFP. The shRNA construct was also placed downstream of the U6 promoter along with a GFP sequence. This construct is referred to as AAV-\textit{Scn8a-shRNA}. Viral titer of the AAV-GFP and AAV-\textit{Scn8a-shRNA} ranged from $1 \times 10^8$ to $1 \times 10^9$ infectious particles per ml.

\textit{Surgical procedures}

Surgical implantation of EEG electrodes was performed as previously described (Martin et al., 2007; Dutton et al., 2012; Papale et al., 2013). Mice were anesthetized by isoflurane inhalation, and then fixed in a stereotaxic apparatus (Kopf, Tujunga, CA). Four holes were drilled in the skull above each injection site. Injections were performed using a Hamilton 0.5-μl microsyringe (model #75) and 30-gauge needle. Four injection sites were chosen to target the hippocampus at the following coordinates, from bregma: anteroposterior (AP), -1.9 mm; mediolateral (ML), ±1.1 mm, ±2.1 mm; dorsoventral (DV), -1.9 mm. The syringe was lowered to -2.0 mm, and then retracted to -1.9 mm and left in place for 4 min. Virus solution (1.0 μl) was injected into each site at a rate of 0.12 μl/min. After each injection, the syringe was left in place for 4 minutes before being retracted. Following viral injections, 4 sterile cortical screw electrodes (Vintage Machine Supplies, OH) were implanted subdurally in the skull for EEG recordings at the following
coordinates, from bregma: 1.5 mm (AP) and +2.1 mm ML; -1.9 mm AP and ±2.1 mm ML; 0.5 mm AP and -2.1 mm ML. Fine-wire electrodes were implanted into the neck muscle for EMG acquisition. Incisions were closed with tissue adhesive (Vetbond, 3M; St. Paul, NM), and the animal was allowed to recover on a heating pad. Postoperative analgesic (ibuprofen, 0.1 mg/kg) was provided for 3 days in the drinking water.

**Histological procedures**

Mice were anesthetized using isoflurane and transcardially perfused with 4% paraformaldehyde (PFA) 15-20 d following LV-GFP injection. Brains were post-fixed for 2 h in ice-cold 4% PFA, and then transferred to 30% sucrose for 3 d at 4°C. Coronal sections (45 μm) were sliced using a cryostat (Leica) between bregma -1.0 mm and -4.0 mm. Sections were washed in TBS/Triton-X and mounted. Images were collected using a Leica DM6000 B upright fluorescence microscope and Simple PCI software.

**Seizure induction paradigms**

**Flurothyl seizure induction.** Flurothyl seizure induction was performed as previously described (Martin et al., 2007; Martin et al., 2010). Briefly, 3-month-old mice were placed in a clear Plexiglas chamber. Flurothyl (2,2,2-trifluoroethyl ether, Sigma-Aldrich) was introduced at a rate of 20 μl/min. The latencies to the first myoclonic jerk (MJ) and generalized tonic-clonic seizure (GTCS) were recorded. The MJ was defined as a jerking movement of the neck and shoulders sometimes associated with tail clonus. The GTCS was defined as complete loss of postural control associated with forelimb and hindlimb tonic-clonic movement lasting longer than 3 s.
**Kainic acid (KA) seizure induction**

Three-month-old mice were administered KA (i.p., 25 mg/kg, Sigma-Aldrich) and observed for 2 h. The latency to the first occurrence of each event on a modified Racine scale was recorded: 1 = freezing, 2 = head nodding, 3 = tail clonus, 4 = forelimb clonus, 5 = rearing and falling, 6 = GTCS. The GTCS was defined as complete loss of postural control associated with forelimb and hindlimb tonic-clonic movement lasting longer than 3 s.

**6-Hz psychomotor seizure induction**

A brief electric current (6-Hz, 26 mA, 3-ms pulse width, 3-s duration) was applied to the cornea of 3-month-old mice (Ugo Basile S.R.L, Germany). Seizure severity was recorded using the following modified Racine scale: 1 = staring, 2 = forelimb clonus, 3 = rearing and falling. Mice that did not exhibit seizure activity in response to the first exposure were excluded from the study and did not proceed to receive TAM or vehicle. Those mice that exhibited seizure activity were placed into two groups for TAM or vehicle administration. These groups were balanced based on seizure severity to ensure that seizure susceptibility was comparable between groups before administration of TAM or vehicle. TAM or vehicle injections were initiated one day after the first current exposure. Two weeks after the last TAM injection, the mice underwent 6-Hz seizure induction a second time.

**Picrotoxin (PT) seizure induction**

Fifteen days following either LV-Cre or LV-GFP hippocampal injection and surgical EEG implantation, PT seizure induction was performed as previously described (Distler et al., 2013). Video/EEG recordings were collected and amplified using the Stellate Harmony System and software (Natus Medical, Inc., San Carlos, CA). Signals were filtered (EEG 0.3-35 Hz bandpass, EMG 10-70 Hz bandpass) and digitized at a sampling rate of 200 Hz. Twenty min of baseline video/EEG recording was collected before administering PT. Following PT administration (i.p.,
10 mg/kg, Sigma-Aldrich), the latency to the first seizure, duration of each seizure, and number of seizures were recorded. Seizures were defined behaviorally by the presence of generalized convulsions and confirmed by the presence of highly synchronous EEG activity that reached at least twice the baseline amplitude in all cortical EEG channels and persisted for at least 3 s. Video/EEG monitoring was performed for at least 2 h following PT administration.

Statistics

All bar graphs indicate the mean and all error bars represent ± standard error of the mean (SEM). Statistical analyses were performed using SigmaPlot 11.0 software (Systat Software Inc., Chicago, IL), Prism 6 (GraphPad Software Inc, La Jolla, CA), and GenEx 5 software (Multi D). The Levene’s test was used to assess for differences in the variance between groups, and the Shapiro-Wilk test was used to determine normality of continuous data sets. One-way analysis of variance (ANOVA) was used to evaluate seizure thresholds between ER-Cre groups treated with flurothyl. Two-way analysis of variance (ANOVA) was used to evaluate KA seizure thresholds. Post-hoc comparisons were performed using either the Dunnett’s or Bonferroni test. The Student’s two-tailed t test was used to analyze the percentage knockdown of Scn8a protein levels by the ER-Cre transgene and by LV-Cre injection, as well as to compare qPCR results between genotypes for each sodium channel. qPCR expression analysis and statistics were performed using the GenEx 5 software. Student’s two-tailed t test was also used to determine the significance of burst discharge latency, duration, and frequency, and Fisher’s exact test with Bonferroni correction was used to compare the occurrence of burst discharges. Fisher’s exact test was used to assess categorical seizure outcomes following 6-Hz seizure induction. The Mann-Whitney-U test was used to assess PT seizure outcomes.
2.6. Acknowledgements

Research in this publication was supported by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) under award numbers R01NS072221 (A.E.), R01NS048336 (A.L.G.), R01NS065187 (A.E. and A.L.G.), and F31NS074717 (C.D.M). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. We would like to thank the Emory University Viral Core for assistance with reagents and Dr. Miriam Meisler for providing the Scn8a floxed line. We would also like to thank Karoni Dutt and Eric Velazquez for helpful discussions during the course of this work and Cheryl Strauss for editorial assistance.
CHAPTER 3

Effects of an Epilepsy Mutation in the Voltage Sensor of \textit{Scn8a} on Seizure Susceptibility and Behavior

Chapter 3 contains material from the manuscript in preparation: Effects of an epilepsy mutation in the voltage sensor of \textit{Scn8a} gene on seizure susceptibility and behavior, Makinson C.D., Dutt K., Papale A. L., Shankar A., Lin F., Liu R., Goldin A. L., Escayg A.
3.1. Summary

Voltage gated sodium channels are involved in the pathophysiology of epilepsy as they regulate neuronal excitability, facilitate synaptic integration, and contribute to the initiation and propagation of action potentials. Mutations in \(SCN1A\), \(SCN2A\) and \(SCN3A\) have been identified in patients with various subtypes of epilepsy. In contrast, we demonstrated that \(Scn8a^{med}\) and \(Scn8a^{medjo}\) mice that carry mutations in the \(Scn8a\) gene display elevated thresholds to flurothyl and kainic acid-induced seizures. However, these mutants also display spontaneous absence epilepsy. To further investigate the relationship between altered \(Scn8a\) function and epilepsy, we introduced the R1648H-\(SCN1A\) mutation, identified in a family with generalized epilepsy with febrile seizures plus (GEFS+), into the corresponding position in \(Scn8a\) (R1627H). Mice homozygous for the \(Scn8a\) R1627H mutation (\(Scn8a^{R1627H/R1627H}\)) display a normal lifespan; however, they exhibit an unstable gait, impaired performance in the rotarod test and reduced locomotor activity. Heterozygous (\(Scn8a^{R1627H/+}\)) mice are more resistant to chemically and electrically-induced seizures when compared to wildtype littermates and the \(Scn8a^{R1627H}\) mutation was found to increase the lifespan and seizure thresholds of mice carrying the \(Scn1a^{R1648H}\) mutation.

Interestingly, \(Scn8a^{R1627H/R1627H}\) mice have comparable seizure thresholds to WT littermates and appear to be susceptible to audiogenic seizures. In addition, unlike previously reported \(Scn8a\) mutant mice, spontaneous absence seizures were not been observed in R1627H mutants. Together these results 1) support previous findings that altered \(Scn8a\) function provides resistance to seizures and leads to improvements in \(Scn1a\) epilepsy models; 2) demonstrate that some alterations of \(Scn8a\) function may provide resistance to generalized tonic clonic seizures without leading to absence epilepsy; 3) expands the known epilepsy phenotypes associated with altered \(Scn8a\).
3.2. Introduction

Voltage-gated sodium channels (VGSCs) are important regulators of neuronal excitability and are responsible for the initiation and propagation of action potentials in neurons. Given their fundamental role in neuronal communication, disruptions in VGSC function can lead to a host of pathophysiological conditions (George, 2005; Mantegazza and Catterall, 2012). Most notably, mutations in the four VGSCs that are primarily localized to the CNS, SCN1A, SCN2A, SCN3A, and SCN8A, are responsible for several types of idiopathic epilepsy. Specifically, SCN1A mutations lead to genetic epilepsy with febrile seizures Plus (GEFS+) and Dravet syndrome (DS) (Escayg et al., 2000; Claes et al., 2001). SCN2A mutations cause benign familial neonatal-infantile seizures (Heron et al., 2002), mutations in SCN3A have been identified in patients with partial epilepsy (Holland et al., 2008; Estacion et al., 2010; Vanoye et al., 2013), and mutations in SCN8A were recently found in patients with epileptic encephalopathies (Veeramah et al., 2012; Carvill et al., 2013).

Based on the VGSC mutations that have been identified to date, it is clear that distinct seizure and behavioral outcomes can result from different mutations in the same VGSC gene, with the magnitude and direction of the observed phenotypes potentially reflecting specific biophysical changes caused by the mutation. For example, in the spectrum of SCN1A epilepsies, the most severe condition, DS, often results from null mutations in the SCN1A gene, while amino acid substitutions can give rise to less severe forms of epilepsy such as GEFS+ (reviewed in Claes et al., 2009; Lossin, 2009; Escayg and Goldin, 2010). Furthermore, a gain-of-function substitution SCN8A mutation (N1768D), that was found to increase sodium currents, was identified in a patient with epileptic encephalopathy (Veeramah et al., 2012), whereas cognitive and motor deficits but not epilepsy has been described in a family with a loss-of-function truncation mutation in the SCN8A gene (Trudeau et al., 2006).
The introduction of clinically relevant VGSC mutations into mouse models have proven critical to our understanding of the functional consequences of distinct VGSC mutations on seizure and behavioral phenotypes. The expression of loss-of-function Scn1a mutations in mice recapitulates many of the clinical features of DS and GEFS+ (Yu et al., 2006; Martin et al., 2010). Similarly, mice with loss-of-function Scn8a mutations exhibit behavioral alterations that are consistent with psychiatric findings in patients (McKinney et al., 2008; Papale et al., 2010). Interestingly, we demonstrated that mutations that reduce the activity of Scn8a in the mouse confer resistance to induced seizures (Martin et al., 2007; Hawkins et al., 2011), and result in the generation of absence epilepsy (Papale et al., 2009).

To better understand the phenotypic consequences of altered Scn8a function, we generated a novel mouse mutant in which the well-characterized SCN1A mutation R1648H, first identified in a family with GEFS+ (Escayg et al. 2000), was knocked into the corresponding location in the mouse Scn8a gene. The mutant line (Scn8a-R1627H) was evaluated for seizure susceptibility, spontaneous seizure generation, behavioral deficits, and neuronal excitability.

3.3. Results

The R1627H mutation alters voltage dependent activation, recovery from inactivation and persistent current

In order to identify possible alterations in the biophysical properties of Na,1.6 channels that result from the R1627H mutation, recordings of Xenopus oocytes expressing WT and mutant channels were first performed. We found that the R1627H mutation causes a depolarizing shift in the voltage dependence of activation (Figure 3.1A) and leads to accelerated recovery from inactivation (Figure 3.1B). Increased persistent current was observed in oocytes expressing R1627H channels (Figure 3.1C). No change in use dependence was observed (Figure 3.1D).
Figure 3.1. Characterization of the biophysical properties of *Scn8a-R1627H* channels

A. Xenopus oocyte recordings demonstrate that the R1627H mutation leads to a depolarizing shift in voltage-dependent activation. B. R1627H channels have accelerated recovery from inactivation. C. At holding potentials from -30 to +40 mV, R1627H channels exhibit increased persistent current. D. The R1627H mutation did not influence use dependence. These experiments were performed by A.J. Barela in the laboratory of Alan Goldin at the University of California, Irvine.
**Targeted insertion of the R1627H into the mouse Scn8a gene**

To further examine the effect of the R1627H mutation, we generated a mouse model of Scn8a dysfunction by knocking in the human SCN1A R1648H GEFS+ mutation into the corresponding position in the mouse Scn8a gene (R1627H) (Figure 3.2). Neomycin-resistant ES cell clones were screened for correct targeting by PCR amplification of the 3' and 5' arms of homology. Correct targeting was further verified by Southern blot analysis of the ES clones (Figure 3.2A). Selected ES cell clones were injected into blastocysts to generate chimeric mice. The targeted allele was confirmed in the knock-in mice by Southern blot analysis (Figure 3.2B). Western blotting was performed on whole brain membrane enriched tissue from three Scn8a<sup>RH/RH</sup>, Scn8a<sup>RH/+</sup>, and WT littermates. Protein levels of Na<sub>1.1</sub>, Na<sub>1.2</sub>, Na<sub>1.3</sub>, and Na<sub>1.6</sub> were compared. No changes in VGSC expression was observed between WT, Scn8a<sup>RH/+</sup> or Scn8a<sup>RH/RH</sup> mice, indicating that knock-in of the R1627H mutation did not lead to altered protein levels (Figure 3.2C).
Figure 3.2. Generation of the R1627H mutant mouse line

A. Diagram of the strategy for introducing the R1627H mutation into the mouse Scn8a gene. The targeting construct was designed to introduce the R1627H mutation into exon 26 of the Scn8a gene and a PGKpuro transgene flanked by FRT sites for selecting embryonic stem cells that incorporated the construct. Targeted mice were crossed to FLP mice to remove the PGKpuro
transgene. B. Southern blotting was used to verify proper targeting of the construct. Arrows indicate expected fragment sizes on Southern blots following digestion with KpnI and PacI. KpnI cuts upstream of the 5’ arm and downstream of the 3’ arm while PGKpuro contains the PacI site. Three probes were used for hybridization, 2 internal probes (A and B) for the 5’ and 3’ arms of homology and an external probe C downstream of the 3’ arm of homology. Each blot contains DNA from a targeted heterozygous ES cell (lane 1) and a wild-type mouse (lane 2). Bands of the expected sizes corresponding to the targeted and wild-type alleles can be seen in lane 1 with all probe/enzyme combinations. A single band corresponding to the wild-type allele is seen in lane 2. 

C. Western blot analysis was used to confirm that R1627H knock-in mice have normal levels of expression of the major CNS VGSCs. No change in Na\textsubscript{1.6}, Na\textsubscript{1.1}, Na\textsubscript{1.2}, or Na\textsubscript{1.3} was detected. α-tubulin was used to control for differences in loading (n = 3-4 per group). Experiments \textit{A-B} were performed by Anupama Shankar in the laboratory of Andrew Escayg.
Survival, weight, and video monitoring of the R1627H line

Mice were monitored, weighed, and videotaped weekly from P10 to P120 in order to examine locomotor function and to make general assessments of health and survival. R1627H mice were born in the expected Mendelian ratio (1:2:1) (WT = 24, Scn8a^{RH/+} = 36, Scn8a^{RH/RH} = 28) and have a normal lifespan. However, Scn8a^{RH/RH} mutants gain weight more slowly so that by 14 weeks of age the average weights of male and female Scn8a^{RH/RH} mice were 5.6% (males) and 9.5% (females) less than WT and Scn8a^{RH/+} sex-matched littermates, respectively (Figure 3.3). While WT and Scn8a^{RH/+} mice appeared visibly normal, body tremors and uncoordinated gait were observed in Scn8a^{RH/RH} mutants by the third postnatal week and persisted throughout the life of the animal. The hind legs of Scn8a^{RH/RH} mice are rotated outward, possibly in order to provide a wide base for postural support. Repetitive "high stepping" movements often precede locomotion. These findings are consistent with recessive motor abnormalities that have been reported in other Scn8a mutant mouse lines (Kohrman et al., 1996b; Sprunger et al., 1999).

Scn8a^{RH/RH} mutant mice have reduced motor function

Because recessive motor dysfunction has been described in previous Scn8a mutant mice, we assessed motor function in the R1627H mice by measuring 24hr locomotor activity, rotating rod performance, and stride length. Significantly reduced locomotor activity was observed in Scn8a^{RH/RH} mice compared to Scn8a^{RH/+} and WT littermates in the first 5 hours of recording and at the beginning of the dark cycle, when mice are most active (two-way ANOVA, genotype X time, \( p < 0.05 \); Figure 3.4A). Scn8a^{RH/RH} mice had significantly reduced latencies to fall from a rotating rod (one-way ANOVA, \( p < 0.05 \); Figure 3.4B). Average latency to fall was not significantly different between WT and Scn8a^{RH/+} (\( p > 0.05 \); Figure 3.4B). Decreased stride lengths were observed in Scn8a^{RH/RH}, but not Scn8a^{RH/+} mice compared to WT controls (one-way ANOVA, \( p < 0.001 \); Dunnett's post hoc, \( p < 0.05 \), Figure 3.4C-D).
Figure 3.3. Homozygous Scn8a-R1627H mutants have reduced weight

Male and female WT, Scn8a^{RH+}, and Scn8a^{RH/RH} mice were weighed weekly from the 2\textsuperscript{nd} to the 14\textsuperscript{th} postnatal week. No differences were detected between WT and Scn8a^{RH+} mice at any time point. Scn8a^{RH/RH} mice had significantly lower average weights compared to WT littermates (two-way ANOVA, genotype X week, \(p < 0.05\)). The maximum difference between WT and Scn8a^{RH/RH} weights was 28\% (males) and 30\% (females) at 4 weeks after birth. At 14 weeks after birth, the average weight of Scn8a^{RH/RH} mice was lower by 5.6\% (males) and 9.5\% (females) when compared to WT littermates (Error bars represent SEM, \(n = 11-18\)).
Figure 3.4. Recessive motor impairment in R1627H mice

A. Locomotor activity of Scn8a-R1627H mice in a new home cage was measured over a 24-hour period. A significant deficit in locomotor activity was detected between Scn8a^{RH/RH} mice (red) and WT (black) littermates (two-way ANOVA, genotype X time, $p < 0.05$). No significant differences were detected between Scn8a^{RH/+} (blue) and WT littermates ($p > 0.05$). Inset graph demonstrates that Scn8a^{RH/RH} mice have reduced locomotor activity in a novel environment ($p < 0.05$). White and black bars under the X-axis represent the light-dark cycle. n = 9-12. 

B. Rotating rod performance was reduced in Scn8a^{RH/RH} (red) but not WT (black) or Scn8a^{RH/+} (blue) mice (one-way ANOVA, $p < 0.001$; Dunnett's post hoc, $p < 0.05$; n = 7-18). 

C. Representative example of stride length paw prints reveals reduced stride length in Scn8a^{RH/RH} mice. Black lines show relative stride length. 

D. Stride lengths were found to be significantly reduced in Scn8a^{RH/RH} but not Scn8a^{RH/+} mice compared to WT littermates (one-way ANOVA, $p < 0.001$; Dunnett's post hoc, $p < 0.05$, Error bars represent SEM, n = 6-10).
The R1627H mutation is not associated with deficits in performance on anxiety, depression-like, or learning and memory tasks

*Scn8a* mutations have been reported to cause altered performance on anxiety and learning behavioral tasks in mice (McKinney et al., 2008; Sawyer et al., 2013) and psychiatric and cognitive deficits in humans (Wasserman et al., 2005; Trudeau et al., 2006; Wang et al., 2008). However, R1627H mutants did not show significant differences in the percentage of time spent in the open arm or the number of entries into the open arm of an elevated plus maze (Table 3.1). Likewise, no significant changes were observed in the time spent in the center zone or the number of entries into the center of the open field (Table 3.1). Significantly increased struggling time and decreased immobile time was observed in the tail suspension task in *Scn8a*<sup>RH/RH</sup> mice compared to *Scn8a*<sup>RH/+</sup> and WT littermates (one-way ANOVA, *p* < 0.05) (Table 3.1). However, no alterations in time struggling or time floating were observed in the forced swim task (Table 3.1). Likewise, preference for sucrose was comparable between *Scn8a*<sup>RH/RH</sup> mice and *Scn8a*<sup>RH/+</sup> and WT littermates (Table 3.1).

We previously reported modest increases in spatial memory in mice with the *Scn8a*<sup>medjo</sup> mutation (Papale et al., 2010). In contrast, comparable performance was observed between WT, *Scn8a*<sup>RH/+</sup>, and *Scn8a*<sup>RH/RH</sup> littermates in the novel object recognition task. However, *Scn8a*<sup>RH/RH</sup> mice had modestly increased performance in spatial learning as measured by the Y-maze (one-way ANOVA, *p* < 0.05) (Table 3.1). However, this increase failed to reach statistical significance by Dunnett's *post hoc* test.
<table>
<thead>
<tr>
<th>Category</th>
<th>Test</th>
<th># of Animals</th>
<th>Measurement</th>
<th>Genotype</th>
<th>Average</th>
<th>s.e.m.</th>
<th>p</th>
<th>Post hoc Test</th>
<th>Comparison</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survival</td>
<td>Survival</td>
<td>WT = 24</td>
<td>4 mo % mortality</td>
<td>WT</td>
<td>0.0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/+ = 39</td>
<td></td>
<td>RH/+</td>
<td>0.0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/RH = 28</td>
<td></td>
<td>RH/RH</td>
<td>0.0%</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Elevated Plus Maze</td>
<td>WT = 10</td>
<td>% time in open arm</td>
<td>WT</td>
<td>25.14</td>
<td>3.78</td>
<td>0.84</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/+ = 12</td>
<td></td>
<td>RH/+</td>
<td>26.65</td>
<td>2.61</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/RH = 10</td>
<td></td>
<td>RH/RH</td>
<td>28.62</td>
<td>5.46</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Open arm entries</td>
<td>WT</td>
<td>13.30</td>
<td>2.50</td>
<td>0.73</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/+</td>
<td>12.08</td>
<td>1.57</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/RH</td>
<td>10.90</td>
<td>2.38</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Distance traveled</td>
<td>WT</td>
<td>109.22</td>
<td>8.14</td>
<td>0.64</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/+</td>
<td>115.90</td>
<td>7.30</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/RH</td>
<td>104.56</td>
<td>12.59</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Time in center (sec)</td>
<td>WT</td>
<td>5.34</td>
<td>5.47</td>
<td>0.05</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/+</td>
<td>7.91</td>
<td>8.46</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/RH</td>
<td>1.08</td>
<td>1.99</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Open Field</td>
<td>WT = 8</td>
<td>Number of entries</td>
<td>WT</td>
<td>2.75</td>
<td>2.05</td>
<td>&lt; 0.01</td>
<td>Dunnett's Test</td>
<td>WT vs. RH/+</td>
<td>p &lt; 0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/+ = 12</td>
<td>into the center</td>
<td>RH/+</td>
<td>3.85</td>
<td>2.54</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/RH = 10</td>
<td></td>
<td>RH/RH</td>
<td>0.8</td>
<td>0.70</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Latency to first</td>
<td>WT</td>
<td>67.3</td>
<td>85.52</td>
<td>0.23</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>center entry (sec)</td>
<td>RH/+</td>
<td>131.99</td>
<td>93.82</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/RH</td>
<td>65.6</td>
<td>108.64</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Forced Swim</td>
<td>WT = 10</td>
<td>Time swimming (sec)</td>
<td>WT</td>
<td>90.12</td>
<td>10.30</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/+ = 10</td>
<td></td>
<td>RH/+</td>
<td>83.58</td>
<td>11.21</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/RH = 10</td>
<td></td>
<td>RH/RH</td>
<td>99.47</td>
<td>8.61</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Time floating (sec)</td>
<td>WT</td>
<td>122.21</td>
<td>22.29</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/+</td>
<td>121.48</td>
<td>24.50</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/RH</td>
<td>71.18</td>
<td>15.78</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Depression-like</td>
<td>WT = 10</td>
<td>Time struggling</td>
<td>WT</td>
<td>170.73</td>
<td>8.41</td>
<td>0.01</td>
<td>Dunnett's Test</td>
<td>WT vs. RH/+</td>
<td>p &lt; 0.05</td>
</tr>
<tr>
<td></td>
<td>Tail</td>
<td>RH/+ = 10</td>
<td>(sec)</td>
<td>RH/+</td>
<td>117.84</td>
<td>10.61</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Suspension</td>
<td>RH/RH = 10</td>
<td></td>
<td>RH/RH</td>
<td>247.66</td>
<td>7.22</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Time immobile (sec)</td>
<td>WT</td>
<td>229.48</td>
<td>4.96</td>
<td>&lt; 0.05</td>
<td>Dunnett's Test</td>
<td>WT vs. RH/+</td>
<td>p &lt; 0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/+</td>
<td>220.69</td>
<td>12.90</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/RH</td>
<td>164.12</td>
<td>8.48</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Succrose Preference</td>
<td>WT = 11</td>
<td>Sucrose preference</td>
<td>WT</td>
<td>99.91</td>
<td>2.94</td>
<td>0.64</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/+ = 10</td>
<td>(sucrose g / total g)</td>
<td>RH/+</td>
<td>99.97</td>
<td>1.88</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/RH = 11</td>
<td>*100</td>
<td>RH/RH</td>
<td>89.46</td>
<td>10.74</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Novel Object Recognition</td>
<td>WT = 8</td>
<td>Novel object</td>
<td>WT</td>
<td>59.98</td>
<td>4.66</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>(20 min exposure)</td>
<td>RH/+ = 10</td>
<td>preference</td>
<td>RH/+</td>
<td>62.06</td>
<td>6.75</td>
<td>0.77</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/RH = 12</td>
<td></td>
<td>RH/RH</td>
<td>55.11</td>
<td>10.91</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Novel Object Recognition</td>
<td>WT = 8</td>
<td>Novel object</td>
<td>WT</td>
<td>59.24</td>
<td>4.66</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>(5 min exposure)</td>
<td>RH/+ = 10</td>
<td>preference</td>
<td>RH/+</td>
<td>62.58</td>
<td>6.77</td>
<td>0.41</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/RH = 12</td>
<td></td>
<td>RH/RH</td>
<td>64.78</td>
<td>10.91</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Learning/Memory</td>
<td>WT = 8</td>
<td>Novel object</td>
<td>WT</td>
<td>69.93</td>
<td>10.32</td>
<td>0.923</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/+ = 10</td>
<td>preference</td>
<td>RH/+</td>
<td>58.51</td>
<td>8.61</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/RH = 12</td>
<td></td>
<td>RH/RH</td>
<td>66.41</td>
<td>7.76</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Novel position</td>
<td>WT</td>
<td>61.92</td>
<td>10.90</td>
<td>0.136</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>preference</td>
<td>RH/+</td>
<td>60.59</td>
<td>5.68</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/RH</td>
<td>70.93</td>
<td>12.95</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Y-Maze</td>
<td>WT = 10</td>
<td>% correct rotations</td>
<td>WT</td>
<td>59.28</td>
<td>2.19</td>
<td>0.031</td>
<td>Dunnett's Test</td>
<td>WT vs. RH/+</td>
<td>p &lt; 0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/+ = 12</td>
<td></td>
<td>RH/+</td>
<td>56.82</td>
<td>1.40</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RH/RH = 10</td>
<td></td>
<td>RH/RH</td>
<td>64.22</td>
<td>6.42</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Distance traveled</td>
<td>WT</td>
<td>331.39</td>
<td>19.32</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(cm)</td>
<td>RH/+</td>
<td>352.29</td>
<td>18.74</td>
<td>0.021</td>
<td>Dunnett's Test</td>
<td>WT vs. RH/+</td>
<td>p &lt; 0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>RH/RH</td>
<td>264.32</td>
<td>27.11</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 3.1. Summary of behavioral tasks performed on the R1627H line
Scn8a<sup>RH/RH</sup> mice do not exhibit spontaneous absence seizures

We previously reported that Scn8a mutants exhibit spontaneous absence seizures (Papale et al., 2009). To determine if the R1627H mutation also leads to absence seizure generation, ten days of continuous video-EEG recordings were collected from WT, Scn8a<sup>RH/+</sup>, and Scn8a<sup>RH/RH</sup> mice. No seizures were detected in any mice (n = 4-6). To exclude the possibility that the observed lack of absence seizures was due to differences in genetic background, Scn8a<sup>RH/+</sup> mice were back-crossed for five generations to C3H/HeJ mice, which are susceptible to absence seizures. No absence seizures were observed over five days of continuous video-EEG recordings collected from Scn8a<sup>RH/+</sup> mutants and WT littermates at this generation.

Scn8a<sup>RH/+</sup> but not Scn8a<sup>RH/RH</sup> mice are resistant to 6Hz- and flurothyl-induced seizures and have reduced hippocampal bursting activity in the presence of high extracellular potassium

Latencies to flurothyl-induced seizures were determined for WT, Scn8a<sup>RH/+</sup>, and Scn8a<sup>RH/RH</sup> mice. The average latencies to the myoclonic jerk (MJ) and the generalized tonic-clonic seizure (GTCS) were significantly increased in Scn8a<sup>RH/+</sup> mice when compared to Scn8a<sup>RH/RH</sup> and WT littermates (one-way ANOVA, p < 0.05; Figure 3.5A). The severity of flurothyl-induced seizures, as assessed by the presence of hindlimb extension and mortality following the GTCS, was reduced in both Scn8a<sup>RH/+</sup> and Scn8a<sup>RH/RH</sup> mice when compared to WT littermates ($X^2$, p < 0.05; Figure 3.5B). Scn8a<sup>RH/+</sup> but not Scn8a<sup>RH/RH</sup> mice were found to be resistant to 6Hz-induced psychomotor seizures when compared to WT littermates (Figure 3.5C). However, reduced 6 Hz-induced seizure severity was observed in both Scn8a<sup>RH/+</sup> and Scn8a<sup>RH/RH</sup> mice at current intensities of 20, 22, and 24 mA (one-way ANOVA, p < 0.0001; Dunnett’s post hoc, p < 0.001; Figure 3.5D).

Extracellular recordings were performed in hippocampal slices in the presence of high extracellular potassium to compare susceptibility to epileptiform burst discharges between WT,
Scn8a<sup>RH/+</sup> and Scn8a<sup>RH/RH</sup> mice. The average latency to the onset of bursting was higher in Scn8a<sup>RH/+</sup> slices (20.0 min) compared to WT (6.1 min) and Scn8a<sup>RH/RH</sup> mice (6.3 min) (Figure 3.5E.a). The intra-burst spiking frequency was reduced in Scn8a<sup>RH/+</sup> mice (32.0 Hz) compared to WT (61.5 Hz), and Scn8a<sup>RH/RH</sup> mice (49.3 Hz) (Figure 3.5E.b). The percentage of slices exhibiting bursting was lower in Scn8a<sup>RH/+</sup> mice (1/8, 12.5%) when compared to WT (5/5, 100%) and Scn8a<sup>RH/RH</sup> 57.1% (4/7, 57.1%) mice (Figure 3.5F).

The Scn8a-R1627H mutation increases the lifespan and seizure thresholds of Scn1a-R1648H GEFS+ mice

We previously demonstrated that the Scn8a<sup>medjo</sup> mutation was capable of increasing the lifespan and seizure thresholds of mice with GEFS+ and DS Scn1a mutations (Martin et al., 2007; Hawkins et al., 2011). To determine the effect on survival and seizure thresholds of the R1627H mutation in a GEFS+ model, we generated mice that carry both the GEFS+ Scn1a-R1648H and the Scn8a-R1627H mutations. Scn1a<sup>RH/+</sup> and Scn1a<sup>RH/RH</sup> mice experienced 18% (2/11) and 100% (11/11) mortality, respectively, by 3 months of age. In contrast, the survival of WT, Scn8a<sup>RH/+</sup>, and Scn1a<sup>RH/+/Scn8a</sup>RH/+/Scn8a<sup>RH/</sup> mice were comparable, and 40% of Scn1a<sup>RH/RH/Scn8a</sup>RH/+/ Scn8a<sup>RH/</sup> mutants survived to at least three months of age (Figure 3.6A). Latencies to flurothyl-induced seizures were also measured in these mice (Figure 3.6B). Consistent with our previous findings in Scn8a mutant mice, average latencies to the MJ and GTCS were increased in mice carrying the Scn8a<sup>RH/</sup> mutation, while mice carrying the Scn1a<sup>RH/</sup> mutation had reduced latencies to the GTCS. Latencies to the GTCS were comparable between Scn1a<sup>RH/+/Scn8a</sup>RH/+/ mutants and WT littermates, indicating that the Scn8a mutation was capable of elevating seizure latencies in Scn1a mice to normal levels. However, significantly lower latencies to the MJ and GTCS were still observed in Scn1a<sup>RH/RH/Scn8a</sup>RH/+/ mutants (one-way ANOVA, Dunnett’s post hoc, *p < 0.05, ***p <0.001, Figure 3.6B).
Figure 3.5. Effects of the R1627H mutation on flurothyl- and 6 Hz-induced seizure susceptibility and hippocampal bursting

A. *Scn8a*<sup>RH/+</sup> but not *Scn8a*<sup>RH/RH</sup> mice have longer latencies to flurothyl-induced seizures (one-way ANOVA, MJ and GTCS, Tukey post hoc, *p* < 0.05; n = 11-12). B. Seizure severity, as measured
by hindlimb extension (HE) and death, were reduced in $Scn8a^{RH/+}$ and $Scn8a^{RH/RH}$ mice ($X^2, *p < 0.05$). **C-D.** $Scn8a^{RH/+}$ mice have increased thresholds to 6 Hz seizures compared to $Scn8a^{RH/RH}$ and WT littermates. **D.** Both $Scn8a^{RH/+}$ and $Scn8a^{RH/RH}$ mice experience less severe seizures in response to stimulus intensities of 20, 22, and 24 mA compared to WT littermates (one-way ANOVA, $p < 0.0001$; Dunnett's post hoc, $p < 0.001$; n = 8-10). **E.a.** The latency to the occurrence of bursting activity in the presence of high potassium (K+) in hippocampal slices was increased in slices from $Scn8a^{RH/+}$ but not WT or $Scn8a^{RH/RH}$ littermates (n = 1-5). **E.b.** The frequency of intraburst high amplitude spiking activity was reduced in $Scn8a^{RH/+}$ compared to WT and $Scn8a^{RH/RH}$ littermates. **F.** The percentage of slices that exhibited bursting in the presence of high K+ was WT (5/5, 100%), $Scn8a^{RH/+}$ (1/8, 12.5%), and $Scn8a^{RH/RH}$ (4/7, 57.1%). Experiments **E-F** were performed by Karoni Dutt in the laboratory of Alan Goldin at the University of California, Irvine.
Figure 3.6. The $Scn8a$-R1627H mutation increases lifespan and seizure resistance in a mouse model of GEFS+ ($Scn1a$-R1648H)

A. Normal survival was observed over the first three months of postnatal development in WT, $Scn8a^{ RH/+ }$, and $Scn1a^{ RH/+ }/Scn8a^{ RH/+ }$ mice. In contrast, $Scn1a^{ RH/RH }$ and $Scn1a^{ RH/RH }$ mice experienced 18% (2/11) and 100% (11/11) mortality respectively. $Scn1a^{ RH/RH }/Scn8a^{ RH/+ }$ mice experienced 60% (6/10) mortality. B. The R1627H mutation is capable of increasing seizure thresholds and restoring seizure thresholds in $Scn1a^{ RH/+ }$ mice. $Scn1a^{ RH/+ }$ mutants (green) have lower latencies to flurothyl-induced GTCS latency, while $Scn8a^{ RH/+ }$ mutants (orange) exhibit elevated latencies when compared to WT littermates. Normal latencies were restored in $Scn1a^{ RH/+ }/Scn8a^{ RH/+ }$ mice (blue). $Scn1a^{ RH/RH }/Scn8a^{ RH/+ }$ mice (grey) have reduced latencies to the MJ and GTCS. One-way ANOVA, Dunnett’s post hoc, *$p < 0.05$, ***$p < 0.001$; Error bars represent SEM; n = 5-17).
**Scn8a\(^{RH/RH}\) mice exhibit sound-induced wild running behavior**

To evaluate responses to high intensity auditory stimuli, WT, Scn8a\(^{RH/+}\), and Scn8a\(^{RH/RH}\) mice were exposed to tones (12 kHz, 80 dB) or broad-spectrum (13-85 kHz, 50-80 dB) acoustic stimulus (Figure 3.7). Approximately 36% (11/31) of Scn8a\(^{RH/RH}\) mice exhibited wild running behavior followed by loss of postural control and forelimb and hindlimb clonus in response to broad-spectrum stimuli (\(X^2, *p < 0.05\); Figure 3.8A). In contrast, only one WT littermate (1/15) exhibited wild running behavior in response to sound stimuli. The WT mouse progressed to tonic hindlimb extension, which was not a feature of the response observed in the Scn8a\(^{RH/RH}\) mutants. No Scn8a\(^{RH/+}\) (0/10) mice exhibited audiogenic responses. High amplitude EEG signals were recorded in the inferior colliculus, a major audiogenic seizure region, during acoustic stimulus in Scn8a\(^{RH/RH}\) mice (Figure 3.7B). C-Fos expression in the cortex, hippocampus, superior colliculus (SC) and IC was qualitatively evaluated (Figure 3.7C-D). Low levels of c-Fos expression was observed in the cortex and hippocampus of all animals (Figure 3.7D). High levels of c-Fos were observed in the SC and IC of responding Scn8a\(^{RH/RH}\) mice but not, non-responding Scn8a\(^{RH/RH}\), WT, or Scn8a\(^{RH/+}\) mice (Figure 3.7D).

**Scn8a\(^{RH/RH}\) mice have reduced auditory brainstem nuclei responses (ABRs)**

In order to test the possibility that the auditory-induced wild running behavior in Scn8a\(^{RH/RH}\) mice is a result of increased sensitivity to acoustic stimulus, auditory brainstem nuclei responses (ABR) to sound stimuli were recorded (Figure 3.8). 5-24 kHz tones from 110-20 dB were played to WT, Scn8a\(^{RH/+}\) and Scn8a\(^{RH/RH}\) mice while measuring ABR responses. Scn8a\(^{RH/RH}\) mice were found to have reduced auditory responses between 12-15 kHz (two-way ANOVA, genotype X frequency, Dunnett’s post hoc, *p < 0.05; Figure 3.8A,C). No differences in ABR thresholds at 12 kHz was observed between Scn8a\(^{RH/RH}\) mice that are not susceptible to audiogenic wild-running
behavior (non-responders) compared to $\text{Scn8a}^{R1/RH}$ mice that were found to be susceptible (responders) (Student's t-test, $p > 0.05$; Figure 3.8B).
Figure 3.7. Scn8a<sup>RH/RH</sup> mice are susceptible to audiogenic seizures

A. Scn8a<sup>RH/RH</sup>, Scn8a<sup>RH/+</sup>, and WT mice were exposed to 5 minute duration tones (12 kHz, 80 dB) or broad-spectrum (13-85 kHz, 50-80 dB) acoustic stimulus to induce audiogenic seizures. Aproximately 6.7% (1/15) of WT, 0% (0/10) of Scn8a<sup>RH/+</sup>, and 35.5% (11/31) of Scn8a<sup>RH/RH</sup> mice responded to broad-spectrum stimuli (X<sup>2</sup>, *p < 0.05).

B. Representative example of inferior colliculus (IC) and cortical EEG activity before (baseline) and during (during behavior) audiogenic seizure in a Scn8a<sup>RH/RH</sup> mouse.

C. Representative image of c-Fos expression in the IC of a responding and non-responding Scn8a<sup>RH/RH</sup> mouse 2 h following exposure to sound stimulus.
E. Regional expression of c-Fos 2 h following exposure to sound stimulus. The relative c-Fos expression was qualitatively evaluated: (+) low; (++) light; (+++) moderate; (++++) high. High levels of c-fos expression were observed in the SC and IC of Scn8a<sup>RH/RH</sup> responding animals but not non-responding Scn8a<sup>RH/RH</sup>, Scn8a<sup>RH/+</sup> or WT littermates. Low to light levels of c-Fos was observed in the hippocampus and cortex of all animals.
Figure 3.8. \textit{Scn8a}^{RH/RH} mice have reduced auditory brainstem nuclei responses (ABRs)

A. Auditory brainstem nuclei responses (ABR) were measured in response to 5-24 kHz tones in WT, \textit{Scn8a}^{RH/+} and \textit{Scn8a}^{RH/RH} mice. \textit{Scn8a}^{RH/RH} mice were found to have reduced auditory responses between 12-15 kHz (two-way ANOVA, Dunnett's post hoc, *\( p < 0.05 \); \( n = 8-10 \)). B. No differences in ABR thresholds at 12 kHz were observed between \textit{Scn8a}^{RH/RH} mice that are not susceptible to audiogenic seizure (non-responders) compared to \textit{Scn8a}^{RH/RH} mice that were found to be susceptible to audiogenic seizure (responders) (Student's t test, \( p > 0.05 \); \( n = 4-8 \)). C. Representative examples of ABR responses in WT and R1627H mutant mice. Black dot indicates threshold at which response is no longer detectable. Error bars represent SEM.
Reduced latencies to flurothyl-induced seizures and susceptibility to audiogenic wild-running behavior in mice carrying the Scn8a-medjo mutation

To determine if unaltered seizure thresholds and susceptibility to auditory-induced wild running behavior, observed in Scn8a<sup>RH/RH</sup> animals, are also features of a different Scn8a mutation, we measured latencies to flurothyl-induced seizures and responses to high intensity sound stimuli in Scn8a-medjo mice. We measured latencies to flurothyl-induced seizures and responses to high intensity sound stimuli in Scn8a-medjo mice. Scn8a<sup>medjo/+</sup> mice were found to have increased resistance to flurothyl-induced MJ and GTCS when compared to WT littermates (one-way ANOVA, \( p < 0.001 \); Tukey post hoc, MJ \(*p < 0.05\), GTCS \(**p < 0.001\); Figure 3.9A).

Homozygous Scn8a<sup>medjo/medjo</sup> mice however, were found to have reduced latencies to the MJ and equivalent latencies to the GTCS when compared to WT littermates (one-way ANOVA, \( p < 0.001 \); Tukey post hoc, MJ \(**p < 0.001\), GTCS \(*p < 0.05\); Figure 3.9A). Seizure severity, as measured by hindlimb extension (HE) and death, were reduced in Scn8a<sup>medjo/+</sup> and Scn8a<sup>medjo/medjo</sup> mutants \( (\chi^2, *p < 0.05; \ \text{Figure} \ 3.10B) \). Wild-running responses during 5-minute exposures to an 80 dB, 12 kHz tone were observed in 22% of Scn8a<sup>medjo/medjo</sup> (2/9). No WT (0/10) or Scn8a<sup>medjo/+</sup> (0/10) mice exhibited wild-running behavior in response to acoustic stimulus (Figure 3.9C).
Figure 3.9. Flurothyl seizure thresholds and response to acoustic stimuli in mice carrying the Scn8a-medjo mutation

**A-B.** Flurothyl seizure induction was performed on Scn8a-medjo mutant mice. A. Scn8a<sup>medjo/+</sup> mice were found to have increased latencies to flurothyl-induced seizures compared to WT littermates (one-way ANOVA, p < 0.001; Tukey post hoc, MJ *p < 0.05, GTCS ***p < 0.001). Scn8a<sup>medjo/medjo</sup> mice were found to have reduced latency to the MJ and equivalent latency to the GTCS when compared to WT littermates (one-way ANOVA, p < 0.001; Tukey post hoc, MJ ***p < 0.001, GTCS *p < 0.05; n = 12-16). B. Seizure severity, measured by the presence of hindlimb extension (HE) and death, was reduced in Scn8a<sup>medjo/+</sup> and Scn8a<sup>medjo/medjo</sup> mice (X<sup>2</sup>, *p < 0.05; n = 12-16). C. Responses to high intensity acoustic stimuli were assessed in WT, Scn8a<sup>medjo/+</sup>, and Scn8a<sup>medjo/medjo</sup> mice. Wild-running behavior was observed in 22% of Scn8a<sup>medjo/medjo</sup> mice (2/9). No WT (0/10) or Scn8a<sup>medjo/+</sup> (0/10) mice exhibited wild-running behavior.
3.4. Discussion

We have introduced a GEFS+ epilepsy mutation, *Scn1a*-R1648H, into the corresponding position in the voltage sensor of the *Scn8a* gene, *Scn8a*-R1627H. In *Xenopus* oocytes this mutation was found to reduce voltage-dependent activation, increase recovery from inactivation, and increase persistent sodium current in *Xenopus* oocytes (Fig. 3.1). These alterations are predicted to increase channel activity which is particularly interesting given that a gain-of-function mutation in the SCN8A gene was recently identified in a patient with epilepsy (Veeramah et al., 2012). In further support of a role for *Scn8a* in epilepsy, a mutation in the *Celf4* gene was reported to cause increased *Scn8a* expression, increased neuronal persistent sodium current, and seizures in mice (Sun et al., 2013).

We have found that the *Scn8a*-R1627H mutation leads to recessive motor impairment and reduced locomotor activity, similar to previously described *Scn8a* rodent models (Dickie, 1965; Kearney et al., 2002; Hamann et al., 2003). Interestingly, the *Scn8a*-R1627H mutation confers both seizure protection and seizure susceptibility in a gene-dose dependent manner. In the heterozygous state, the *Scn8a* R1627H mutation reduces susceptibility to chemically and electrically-induced seizures and increases the lifespan of mice with the *Scn1a*-GEFS+ mutation (R1648H), which is consistent with findings in other *Scn8a* rodent mutations (Martin et al., 2007; Hawkins et al., 2011). However, surprisingly, homozygous *Scn8a*-R1627H mice (*Scn8a*RH/RH) are not resistant to chemically- and electrically-induced seizures and likely experience seizures in response to auditory stimuli. We propose that the auditory-induced wild running and forelimb-hindlimb clonic behaviors observed in 36% of homozygous R1627H mice are audiogenic seizures (AGSs) based on three observations. First, the behavioral responses of *Scn8a*RH/RH mutants to high-intensity auditory stimuli are similar to flurothyl-induced brainstem seizure behaviors (Samoriski et al., 1998), consisting of loss of posture and forelimb and hindlimb clonus. Secondly, high levels of c-Fos expression were observed in the brainstem, including inferior
coli(culus (IC), following exposure to auditory stimuli in $Scn8a^{R1627H}$ mice that exhibited seizure-like behavior. c-Fos expression was not increased in the midbrain and brainstem of non-responding $Scn8a^{R1627H}$, $Scn8a^{RH/+}$, or WT littermates and comparatively little c-Fos expression was observed outside of AGS brainstem regions in $Scn8a^{R1627H}$ responders following auditory stimulus. The IC is considered to be the site of initiation of AGS (Kesner, 1966; Willott and Lu, 1980; Browning, 1986) and c-Fos expression in brainstem nuclei following exposure to sound stimuli is a hallmark of AGS (Le Gal La Salle and Naquet, 1990; Snyder-Keller and Pierson, 1992; Kwon and Pierson, 1997; Klein et al., 2004). Thirdly, we observed high amplitude EEG activity in the IC during seizure-like behaviors in $Scn8a^{R1627H}$ mice.

We sought to determine if auditory responses in R1627H mice are a consequence of increased sensory response to sound stimulus by recording auditory brainstem nuclei responses (ABR). We observed reduced ABRs in $Scn8a^{R1627H}$ mice, while responses in $Scn8a^{RH/+}$ mice were comparable to WT (Fig. 3.8). Reduced ABRs were similarly observed in the $Scn8a$ mutant ‘Cloth-ears’, leading to the hypothesis that $Scn8a$ dysfunction may contribute to neural hearing loss (Mackenzie et al., 2009). This finding reduces the possibility that the audiogenic seizures in $Scn8a^{R1627H}$ mice were due to an increased sensitivity to sound.

In contrast to previously described $Scn8a$ mutants, the R1627H mutation was not associated with alterations in measures of anxiety, depression, or learning and memory (McKinney et al., 2008; Papale et al., 2010). Furthermore the R1627H mutation did not result in the generation of absence seizures, which were observed in mice expressing $Scn8a$-8J, $Scn8a$-med, and $Scn8a$-medjo alleles (Papale et al., 2009). This raises the possibility that it may be possible, in a therapeutic setting, to decouple the seizure protection conferred by altered $Scn8a$ function from the generation of absence epilepsy or negative behavioral outcomes. Furthermore, it is possible that rodent $Scn8a$-behavioral abnormalities are, in part, a consequence of disruptions caused by absence seizures, which were not observed in R1627H mice.
In order to determine if the major seizure findings observed over the course of investigating the R1627H mutation extend to other Scn8a mutations, we evaluated responses to auditory stimuli and proconvulsants in mice with the Scn8a-medjo mutation. We found that Scn8a\textsuperscript{medjo/medjo} mice respond similarly to flurothyl and audiogenic stimuli as Scn8a\textsuperscript{R1627H/R1627H} mice, indicating that recessive seizure susceptibility may be a common feature of Scn8a dysfunction.

3.5. Methods

*Generation of construct for expression in Xenopus oocytes*

We introduced the Scn1a-R1648H mutation plus two additional silent substitutions into exon 26 of the Scn8a cDNA plasmid (R1627H), which contains the entire coding region of mouse Na\textsubscript{v}1.6. A targeting construct was produced using the following primers (R1627H arm LF: TAG ATT CCC GAA AGC CGG ACG AGC AGC CTG, R1648H arm LmutR: TGG CGC CCT TGA TGA GGT GCA AGA TGC GCC, 636bp product; R1627H arm RmutF: GGC GCA TCT TGC ACC TCA TCA AGG GCG CCA, R1648H arm RR: CCA GCG GCA TCA GCA CCT TGT CGC CTT GCG, 1862bp product).

To clone the mutation into the plasmid, the targeting construct and the plasmid were digested with *Bst*EII, which cuts just 5’ to exon 26, and *Not*I, which cuts just 3’ to exon 26. The targeting construct and plasmid were then ligated and transfected into chemically competent HB101 cells.

*Expression and Electrophysiology*

The R1627H mutation was cloned into the rat cDNA clone encoding mNa\textsubscript{v}1.6. Electrophysiological properties of the channels were determined in the absence and presence of the β1 subunit by expression in *Xenopus* oocytes.
Wild-type or mutant sodium channel α subunit RNA was transcribed in vitro from NotI linearized DNA templates using the T7 mMESSAGE mMACHINE kit (Ambion, Austin, TX). Stage V oocytes that were removed from adult female *Xenopus laevis* frogs were injected with between 1 and 200 pg of RNA to obtain current amplitudes between 1 μA and 5 μA, as described previously (Goldin, 1991).

Sodium currents were recorded using an OC-725B two-electrode voltage-clamp (Warner Instruments, Hamden, CT) at room temperature with a DigiData 1322A interface (Molecular Devices, Foster City, CA) and pCLAMP 8.0 software (Molecular Devices), as described previously (Patton and Goldin, 1991) and the OpusXpress 6000A workstation consisting of eight parallel two-electrode voltage-clamps (Axon Instruments, Union City, CA) at room temperature with a DigiData 1322A interface (Molecular Devices) and OpusXpress Clampex 1.1 software (Molecular Devices). Recordings were performed in ND96 solution (in mM: 96 NaCl, 2 KCl, 1.8 CaCl$_2$, 1 MgCl$_2$, and 5 HEPES, pH 7.5). Capacitive transients were eliminated by subtraction of currents recorded in the presence of 500 nM tetrodotoxin (TTX) for voltage dependence of activation protocols.

*Generation of mice expressing the Scn8a R1627H mutation*

A targeting construct consisting of a 4.5-kb 5’ arm of homology, the R1627H substitution, a neomycin cassette flanked by *FLP1* recombinase (Fft) sites, and a 4-kb 3’ arm of homology, was electroporated into 129X1/SvJ-derived PAT-5 embryonic stem (ES) cells at the University of Michigan Transgenic Core. PCR analysis and Southern blotting were performed to identify correctly targeted ES cells.
Animal breeding and maintenance

All mice were housed in a temperature and humidity controlled vivarium and provided drinking water and food ad libitum. R1627H targeted mice were crossed to mice carrying FLP recombinase to remove a neomycin cassette included in the targeting vector. Mice were then crossed to C57BL6/J wildtype (WT) for three generations. Heterozygous males and females from this generation (N3) were crossed together to generate WT, heterozygous (Scn8a\textsuperscript{RHH/+}), and homozygous (Scn8a\textsuperscript{RHH/RHH}) mice (N3F1) for experiments. The following strategy was used to generate mice carrying both the Scn8a-R1627H and the Scn1a-R1648H mutations. Scn8a\textsuperscript{RHH/+} (N3) females were crossed to Scn1a\textsuperscript{RHH/+} (N10) males to produce Scn8a\textsuperscript{RHH/+}/Scn1a\textsuperscript{RHH/+} offspring. Scn8a\textsuperscript{RHH/+} males were then crossed to N10 Scn1a\textsuperscript{RHH/+} females to produce WT, Scn8a\textsuperscript{RHH/+}, Scn1a\textsuperscript{RHH/+}, Scn8a\textsuperscript{RHH/+}/Scn1a\textsuperscript{RHH/+}, Scn1a\textsuperscript{RHH/RHH}, and Scn8a\textsuperscript{RHH/+}/Scn1a\textsuperscript{RHH/RHH} offspring. Scn8a\textsuperscript{RHH/+} mice (N3 generation) were also crossed to C3/HeJ for three generations and used for EEG analysis. A cohort of N3F1 mice were monitored, weighed, and videotaped weekly from P10 to P120 in order to assess locomotor function and to make general assessments of health and survival.

Genotyping of mutants

Genotyping of R1627H mutant mice was performed by PCR analysis of DNA extracted from tail biopsies. A 400 bp PCR product spanning the R1627H mutation was amplified using the following primers: (R1627H F, 5’-AAG ACA GGT TAT CTG TGT AAA CTG-3’; R1627H R, 5’-AAT CGG TTT TGT CTG CAA GAC TGG-3’) to produce 600bp (R1627H) and 500bp (WT) products. Genotyping of Scn1a R1648H mutant mice was performed as we previously reported (Martin et al., 2010). The Scn8a medjo mutation was identified by PCR amplification using the primer pair (medjo F 5’-ATG CCA CAG AAG TGT CAT TCC-3; medjo R 5’-GGT ATT TCC
CAG CAA ACA GGT-3') followed by enzymatic digestion by MsII to yield bands of 129, 102, and 75 bp (Kohrman et al., 1996b).

**Protein extraction**

Protein extraction was performed as described in chapter 2. Briefly, three month-old mice were anesthetized with isoflurane. Whole brains were removed and homogenized in protease inhibitor buffer (50mM Tris (pH 7.5), 10mM EGTA, and 1 protease inhibitor tablet (Roche) per 50 ml PI buffer). Homogenates were centrifuged for 10 min at 3500 rpm to remove debris, and the supernatant was further centrifuged at 38,000 rpm for 30 min. The resulting pellet was re-suspended in 400 µl PI buffer. Protein concentration was determined by BCA assay (Thermo). Protein was diluted to a final concentration of 1µg/µl in 1X protein loading dye (Fisher). Isolated protein was stored at -80°C.

**Western blot analysis**

Western blotting was performed as described in Chapter 2. Briefly, protein (10 µg) was subjected to SDS-PAGE electrophoresis and transferred to a PVDF membrane. The following primary antibodies were used: rabbit anti-\textit{Scn8a} (1:75, Millipore), mouse anti-\textit{Scn1a} (1:75, Neuromab), rabbit anti-\textit{Scn2a} (1:75, Millipore), and mouse anti-alpha tubulin (1:10,000, Abcam). The following secondary antibodies were used: peroxidase-conjugated secondary antibody donkey anti-rabbit IgG, (1:10,000; GE Healthcare) and peroxidase-conjugated goat anti-mouse secondary (1:10,000, Jackson Immuno Research)

**Animal behavior**

Video analysis of open field, forced swim, tail suspension, and novel object recognition tasks were performed using Any-Maze video tracking software (Stoelting Co. IL). All behavioral
procedures were conducted between the hours of 10:00AM and 3:00PM to minimize possible circadian rhythm effects.

Locomotor activity was measured by photobeam breaks of individually housed mice (San Diego Instruments, La Jolla, CA, USA) over a 24-hour period. Ambulations were counted as consecutive beam breaks.

Rotating rod performance was assessed by measuring the latency to fall from an accelerating rotating rod (Columbus Instruments, Rotamex-5 1.3). Each mouse was trained to walk on the rod three times per day for three days. Training trials were 5 minute duration at 5 r.p.m., with each training trial separated by 60 minutes. Mice that fell from the rod during the training trial were placed back on the rod a maximum of three times. Following training, rod acceleration was increased in 0.2 r.p.m. increments every second starting at 0 r.p.m. and reaching a maximum of 50 r.p.m. Falls were detected by photobeam break.

Stride length was determined by measuring the distance between paw prints as mice walked across a 5 cm wide 60 cm long corridor. Mice were trained daily for 5 consecutive days to walk down the corridor. On training days, each mouse was placed at the beginning of the corridor and the home cage was placed on its side at the other end of the corridor. Once mice traversed the length of the corridor to their home cage they were allowed to remain for at least 5 minutes before the next training trial. No more than three training trials were conducted on each day. Mouse forepaws were dipped in black ink so that a print would be left on white paper as the mouse traversed the corridor. Strides were measured from the tip of one paw print to the base of the next paw print on the same side. Stride length was measured in instances in which at least 5 consecutive uninterrupted strides occurred. A minimum of 15 strides were collected for each mouse to determine average stride length.

The elevated-plus maze consisted of four 12-inch arms (two open and two enclosed), suspended 30 inches above the floor. Each test began with the mouse oriented toward an open
arm. Each mouse was given 5 minutes to freely explore the apparatus during which time beam breaks were recorded to track movement and location. The percentage of time spent in the open arm was recorded and used as a measure of anxiety as mice naturally prefer the enclosed arms and anxiolytics have been shown to increase the time rodents spend in the open arm (Pellow et al., 1985). The percentage of time spent exploring the open arms was calculated by dividing the time spent in the open arms by the combined time spent in the open and closed arms. Total distance traveled in the apparatus was also recorded.

Open field performance was measured by individually placing each mouse in an opaque Plexiglas box (61 cm X 61 cm) for 5 minutes. The center of the open field was set 15 cm from the each side of the box. The time each mouse was in the center, the number of entries into the center, and the latency to entry into the center of the open field were measured.

Forced swim performance was measured by placing each mouse in a beaker (diameter 30 cm) filled with water 27°C ±1°C. Swimming behavior was scored for the first 6 minutes and defined as forelimb movement in which forelimbs broke the surface of the water. Floating was defined as a lack of active movement except to remain afloat (treading).

Tail suspension performance was assessed by suspending each mouse from its tail at a height of 15 cm above a surface. Struggling was defined as forelimb and hindlimb movement or twisting movements. Mice were considered to be immobile if their forelimb and hindlimbs were not moving. Swinging was not scored as movement. Behavior was scored for the first 6 minutes.

Sucrose preference was assessed by providing two food cups to individually housed mice. One cup contained between 1-2 g of standard rodent diet (Purina, Lab Diet 5001) the second cup contained high sucrose diet (AIN-76A Rodent Tablets, TestDiet). The amounts of the sucrose and standard diets consumed over the course of 1 h was determined by subtracting the post-feeding weight of the food from the pre-feeding weight of the food. This procedure was
repeated on 3 consecutive days. The reported sucrose preference values were collected on the third day.

The novel object recognition task was performed as we previously described (Papale et al., 2010). Briefly, mice were acclimated to an open-field box for five consecutive days for 10 minutes each day. On the sixth day each animal was placed in the open-field box for 5 minutes and then returned to the home cage for 2 minutes. Mice were then returned to the open field box where they were given 5 minutes to explore three objects arranged in three of the four corners of the box, at least 10 inches from the edge. Mice were returned to their home cage for either 5 (short exposure) or 20 (long exposure) minutes. Mice were returned to the open-field box for 5 minutes where one object had changed position (novel position), one object had been exchanged for a different object (novel object), and one object was the same (familiar object). The time each mouse spent exploring each object at the second exposure was recorded.

Y-maze performance was determined by placing each mouse at the end of one arm of the Y-maze and allowing free exploration of the apparatus for 8 minutes. The Y-maze consists of three identical arms and a center zone. Spontaneous alternations were recorded by video camera.

Continuous video-electrocorticogram monitoring

Video-EEG recordings to detect cortical seizure activity were collected and analyzed as we previously described (Martin et al., 2007; Papale et al., 2009; Dutton et al., 2012). EEG recordings from the inferior colliculus were collected as follows. Mice were anesthetized by isoflurane (2-chloro-2-(difluromethoxy)-1,1,1-trifluorothane) inhalation. Two sterile 0-80x3/32 sterile screw electrodes (Vintage Machine Supplies, Medina, OH) were implanted in the skull at the following coordinates from Bregma (anteroposterior (AP) 1.5 mm and mediolateral (ML) 1.2 mm; AP 1.0 mm and ML 1.2 mm). Stainless steel electrodes (diameter 0.25 mm, length 1.5 mm; Plastics one, Roanoke, VA) were implanted at the following coordinates (AP -3.5 mm, ML ±1.5 mm).
mm, depth 1.2 mm from the surface of the skull). Two fine-wire electrodes were implanted in the neck muscle for electromyography (EMG) acquisition. Electrodes were covered with dental acrylic following implantation. After a minimum of five days for recovery from surgery, mice were moved to a recording chamber where they were allowed to freely move and were provided food and water ad libitum during EEG acquisition. EEG recordings were sampled at 200 Hz. Signals were digitized, amplified and processed by Stellate Harmonie EEG system (Natus Medical, Inc.). EEG traces were manually scored.

Seizure induction

Flurothyl seizure induction was performed as we previously described (Martin et al., 2007). Latencies to the first occurrence of the myoclonic jerk (MJ) and generalized tonic-clonic seizure (GTCS) were recorded. MJ presents as a jerk of the upper body sometimes accompanied by tail-limb clonus. The GTCS was defined by complete loss of postural control and clonus of all limbs. Mice were also observed for the presence of hind-limb extension immediately following the GTCS.

Partial psychomotor seizures were evoked as described in Chapter 2. Briefly, mice were administered a corneal analgesic 30 minutes prior to stimulation. Corneal electrical stimulation (6-Hz, 3 sec, 14 mA to 30 mA) was applied. Resulting seizures were scored according to the following modified Racine scale. 1 = staring, 2 = forelimb clonus, 3 = rearing and falling.

Audiogenic seizures were induced using a key ringing method and by the use of a high-intensity tone. For the key ringing method, each mouse was placed in a clear Plexiglas box and keys were shaken for 5 minutes approximately 25 cm above the mouse. Shaking a key bundle was found to produce a broad-spectrum acoustic stimulus (13-85 kHz) at an intensity ranging from 50-80 dB, as determined by a 1/4" Brüel & Kjaer microphone (Brüel & Kjaer, Denmark). For the high-intensity tone method, a wide range speaker (Model RT1.3, HiVi Inc., Arcadia, CA)
was used to produce a 12 kHz, 80 dB tone. Each mouse was exposed to this tone for 5 min and audiogenic seizures were defined by wild-running behavior progressing to loss of posture and forelimb and hindlimb clonus, sometimes followed by tonic hindlimb extension.

**Preparation and incubation of slices**

Mice (p26-p28) were anesthetized with halothane before removing their brains. Transverse hippocampal slices (350 μm) were cut using a Leica VT1200S microtome in oxygenated (95% O₂, 5% CO₂) ice cold sucrose ACSF (sACSF) containing (in mM): 85 NaCl, 65 sucrose, 2.5 KCl, 25 glucose, 1.25 NaH₂PO₄, 4 MgSO₄, 0.5 CaCl₂, and 24 NaHCO₃. Slices were incubated at 33°C for at least 1 h before electrophysiological recordings in oxygenated standard ACSF containing (in mM): 126 NaCl, 2.5 KCl, 1.25 NaHPO₄, 1.2 MgSO₄, 10 glucose, 1.2 CaCl₂, and 24 NaHCO₃.

**Electrophysiological slice recordings**

Slices were held at 33°C and perused with oxygenated standard ACSF at 2 mL/min during electrophysiological experiments. Cells were visualized with an upright microscope (Zeiss) equipped with infrared differential interference contrast optics. Recording pipettes (2-3 MΩ) were pulled from borosilicate glass with a P-87 Flaming-Brown puller (Sutter Instruments, Novato, CA). Electrophysiological experiments were obtained using MultiClamp 700B amplifier (Molecular Devices, Union City, CA) and digitized with a Digidata 1322A digitizer (Molecular Devices). Data were acquired and analyzed with pClamp 10.2 software (Molecular Devices). Pipettes were filled with 150 mM NaCl and positioned in the CA3 stratum pyramidal layer. ACSF with elevated potassium was prepared by supplementing standard ACSF with 3 M KCl to raise the potassium concentration to 8.5 mM [K⁺]ₒ. The experimental paradigm consisted of a control recording for 2 min in standard ACSF, followed by 15-25 min with 8.5 mM K+ ACSF perfusion,
in which burst activity was recorded. This was followed by a 7 minute washout with standard ACSF. Population spikes were elicited in the CA3 pyramidal layer by stimulation of the mossy fiber tract with a tungsten wire. Population spikes were evoked in physiological 2.5 mM $[K^+]_o$ before and after exposing the slice to 8.5 mM $[K^+]_o$. Slices in which population spike amplitudes did not change more than 20% after exposing the slice to 8.5 mM $[K^+]_o$ were used for analysis.

*Auditory Brainstem Nuclei Response*

Mice were anesthetized with ketamine and xylazine (i.p., 100 and 10 mg/kg respectively) and placed in a heated (25°C) sound attenuating booth (Industrial Acoustics Company, Bronx, NY). ABRs were recorded using Tucker Davis Technologies BioSigRP© software running on a System 3 platform equipped with an RX5 Pentusa Base Station connected to subdermal electrodes via an RA4LI low impedance headstage (TDT, Alachua, FL, USA). Sets of tone pips at different frequencies were presented in a random order to each animal to avoid possible ordering effects.

A subdermal needle electrode was placed over the skull vertex as the active lead. The ground was placed ventral lateral to the left external pinna and the reference was placed ventral lateral to the right external pinna. The bioelectric signals were sampled at 25 kS/s, bandpass filtered between 100 Hz - 3000 Hz, amplified 200,000 times and averaged over 500 consecutive responses, following a previously established ABR screening protocol in mice (Zheng et al., 1999). To determine the ABR threshold, we reduced the stimulus intensity in 10 dB steps and then 5 dB steps until the lowest intensity at which the dominant ABR wave was visible. Thresholds were then finally determined offline with the observer blinded to an animal’s group identity.
**Auditory stimuli**

Calibrated stimuli were generated using TDT SigGenRP© software and presented through BioSigRP© software via a TDT RX6 digital signal processor at a sample rate of 195 kS/s. Sounds were attenuated by a TDT PA5 programmable attenuator and played from an Infinity EMIT tweeter placed 90° to the right side of the animal. Absolute sound pressure levels (SPL) of sound stimuli were measured prior to ABR recording experiments using a calibrated ¼” Brüel and Kjaer (B&K, Denmark) Type 4139 microphone with a Type 2669 preamplifier. Pure tone pips of 3 ms duration with 1.5 ms cos2 rise/fall times were presented for 5, 8, 10, 12, 15, and 24 kHz at a rate of 21 per second.

**Immunohistochemistry**

Following auditory stimuli exposure, mice were transcardially perfused with ice-cold 4% paraformaldehyde (PFA). Brains were extracted and stored in 30% sucrose for 5 days before slicing. Coronal slices (45 μm) were cut using a cryostat (Leica, Germany). Every fifth slice was washed in phosphate buffered saline (PBS) and incubated overnight in primary rabbit anti-c-Fos antibody (Abcam, 1:5,000). Slices were washed in PBS and incubated in secondary antibody horseradish peroxidase conjugated goat anti-rabbit (GE, 1:5,000) for 30 minutes. Staining was performed using the Vectastain Elite ABC System (Vector). Images were collected using the Microbrightfield stereology system (MBF Bioscience, Williston, VT).

**Statistics**

All behavioral tests and flurothyl latencies were analyzed using a one-way analysis of variance (ANOVA) followed by Dunnett's or Tukey's *post hoc* tests. Binary seizure outcomes were analyzed using the $X^2$ test. Weight data was analyzed using a two-way analysis of variance, genotype X time. ABRs were analyzed by two-way ANOVA or by the Student's t-test.
3.6. Acknowledgments

We would like to thank the Emory University Rodent Behavioral Core for assistance with assessing locomotor activity. In particular we would like to thank David Weinshenker and Jason Schroeder of the Rodent Behavior Core for their assistance.
Chapter 4

Contrasting Effects on Seizure Susceptibility of Conditional Cell-Type Specific Inactivation of the Scn8a Gene

Chapter 4 contains material from the manuscript in preparation: Contrasting effects on seizure susceptibility of conditional cell-type specific inactivation of the Scn8a gene, Makinson C.D., Tanaka, B., Papale A. L., Christian C., Huguenard, J.R., Goldin A. L., Escayg A.
4.1. Summary

Voltage gated sodium channels (VGSCs) are critical regulators of neuronal excitability and synchrony and play important roles in the pathophysiology of many disorders including epilepsy. Mutations in the VGSC gene Scn8a lead paradoxically to protection against induced seizures and the generation of spontaneous absence seizures in mice. To determine the relative contribution of excitatory and inhibitory cells to these seizure phenotypes, we generated mice in which Scn8a was selectively deleted from these cell types and evaluated seizure susceptibility and spontaneous seizure activity. Reduced Scn8a expression in excitatory cells of the hippocampus and cortex was found to elevate seizure thresholds, reduce hippocampal epileptiform bursting in the presence of high extracellular potassium, and normalize the survival of mice carrying a human Scn1a epilepsy mutation. In contrast, broad, inhibitory cell-specific deletion of the Scn8a gene had no effect on seizure thresholds or hippocampal bursting, but resulted in the generation of spontaneous spike-wave discharges (SWD). Scn8a immunoreactivity was assessed in major inhibitory neuronal populations of the thalamocortical circuit which is important for generating SWDs. Inhibitory thalamic reticular neurons but not inhibitory cortical neurons were found to express high levels of Scn8a. Intracellular recordings from thalamic reticular neurons revealed robust deficits in tonic but not bursting outputs. These findings demonstrate that the two major seizure phenotypes associated with loss of Scn8a, resistance to tonic-clonic seizures and susceptibility to absence epilepsy, can be decoupled and attributed to loss of channel activity in forebrain excitatory cells and inhibitory interneurons, respectively. Loss of Scn8a leads to profound deficits in nRT output, which likely contributes to the generation of SWD.
4.2. Introduction

High levels of *Scn8a* expression have been observed at the axon initial segments of excitatory neurons of the hippocampus and cortex (Boiko et al., 2003; Van Wart et al., 2007; Lorincz and Nusser, 2008; Kress et al., 2010; Liao et al., 2010b) where it sets the thresholds for action potential generation (Hu et al., 2009) and contributes to subthreshold sodium currents (Cooper et al., 2005; Hargus et al., 2013). As revealed by electrophysiological examination of *Scn8a* deficient mice, loss of this channel reduces the excitability of hippocampal and cortical excitatory neurons (Royeck et al., 2008). Additionally, in Chapter 2 we demonstrated that hippocampal slice preparations from *Scn8a*-med mice exhibit less bursting activity, and that selective *in vivo* reduction of *Scn8a* in the hippocampus increases resistance to picrotoxin- and flurothyl-induced seizures and ameliorates the seizure phenotype of *Scn1a* mutants.

Paradoxically, we also identified spike-and-wave discharges (SWD), a hallmark of absence epilepsy, in three separate mouse models of *Scn8a* dysfunction, indicating that *Scn8a* mutations can also cause absence epilepsy in mice (Papale et al., 2009). This finding was unexpected given that loss of VGSC function is expected to reduce neuronal excitability but absence seizures are thought to be a consequence of hyperexcitability of thalamocortical circuitry.

A better understanding of the mechanistic basis underlying the relationship between *Scn8a*-associated seizure protective and absence seizure generation is necessary in order to accurately access the feasibility of selectively targeting *SCN8A* as a treatment for refractory seizure disorders such as Dravet Syndrome.

Here we propose a mechanism to describe each of the major seizure phenotypes that result from loss of *Scn8a* activity. We demonstrate that loss of *Scn8a* expression in forebrain excitatory circuits leads to resistance to induced tonic-clonic seizures, and increased survival and seizure resistance in an *Scn1a*-GEFS+ epilepsy model. Additionally, we demonstrate that loss of *Scn8a* from CNS interneurons does not influence seizure thresholds but is sufficient to generate
spontaneous SWDs. We further propose that loss of Scn8a expression leads to deficits in nRT output that may contribute to SWDs.

4.3. Results

The floxed Scn8a allele does not alter Na,1.6 (Scn8a) protein levels or flurothyl-induced seizure thresholds.

To determine if the floxed Scn8a allele alters Na,1.6 (Scn8a) expression levels in the absence of Cre recombinase, we quantified and compared Na,1.6 levels by Western blot analysis of whole brain homogenates between WT and homozygous Scn8a-floxed (Scn8a^{f/f}) littermates. Normalized optical densities (OD) were not statistically different (mean normalized OD, WT = 5.7 ± 0.9, Scn8a^{f/f} = 5.0 ± 0.6; Student's t test p > 0.05; Fig. 4.1, A). To determine if the floxed Scn8a allele alters seizure susceptibility in the absence of Cre, we measured latencies to flurothyl-induced seizures in WT and Scn8a^{f/f} littermates. No significant differences in the average latencies to the myoclonic jerk (MJ) or the generalized tonic clonic seizure (GTCS) were observed (Mann-Whitney U test MJ p > 0.05, GTCS p > 0.05; Fig. 4.1B).

The floxed Scn8a allele is efficiently recombined by the Emx1- and Dlx5/6-Cre transgenes.

To determine if the Emx1- (Gorski et al., 2002) and Dlx5/6-Cre (Monory et al., 2006) lines are capable of driving recombination of the Scn8a floxed allele in the expected brain regions, PCR detection of DNA isolated from the cortex, hippocampus, and thalamus of Emx1-Cre/Scn8a^{f/+}, Dlx5/6-Cre/Scn8a^{f/+}, and Cre negative littermates (no-Cre/Scn8a^{f/+}) was performed. A 325 bp PCR band indicating deletion of the floxed allele was detected in samples from the cortex, hippocampus, and thalamus of Dlx5/6-Cre/Scn8a^{f/+} mice but not from tail-derived DNA or in samples from no-Cre/Scn8a^{flox/+} littermates (Fig. 4.1C). A 325 bp PCR product indicating deletion of the floxed allele was detected in samples from the cortex and hippocampus of Emx1-
Cre/Scn8a\textsuperscript{f/+} mice but not in the thalamus, tail-derived DNA or samples from no-Cre/Scn8a\textsuperscript{fox/+} littermates (Fig. 4.1C). The intensity of the deleted bands isolated from the cortex and hippocampus of Emx1-Cre/Scn8a\textsuperscript{f/+} mice were qualitatively more intense than the bands from the same regions of Dlx5/6-Cre/Scn8a\textsuperscript{f/+} mice.

**Verification of cell-type and region specificity of Cre lines**

To verify the brain region and cell-type specificity of Emx1- and Dlx5/6-Cre-driven recombination, these lines were crossed to a ROSA reporter. Anti-GluR2 immunoreactivity was used to detect excitatory neurons and GAD67 was used as a marker of inhibitory neurons. The percentage of reporter positive cells that colocalized with each cell type marker was recorded. High levels of reporter expression were observed in the majority of hippocampal and cortical regions in Emx1-ROSA mice: dentate gyrus (DG) 98\% (333/340), CA1 99\% (92/93); layer 2-3 85\% (55/65), layer 4 91\% (50/55), layer 5-6 59\% (36/63) (Table 4.1). Emx1-Cre positive neurons were not observed in the CA3 region of the hippocampus. Very few Emx1-Cre positive cells were detected outside of the forebrain including the caudate putamen 50\% (2/4) and thalamic reticular nucleus (nRT) 0\%. High levels of co-localization was observed between Dlx5/6-reporter and GAD67 expression in most brain regions that were evaluated including: hippocampal subfields, DG 83\% (10/12), CA3 100\% (3/3), CA1 90\% (9/10); cortex, layer 2-3 93\% (14/15), layer 4 100\% (3/3), layer 5-6 100\% (7/7) (Table 4.1). GAD67 colocalization with reporter expression was also observed in other regions including the caudate putamen 8\% (16/198), amygdala 54\% (14/26), and the thalamic reticular nucleus 100\% (64/64) (Table 4.1).
Figure 4.1. The floxed Scn8a allele does not alter Na,1.6 (Scn8a) protein levels or flurothyl-induced seizure thresholds in the absence of Cre but is efficiently recombined in expected brain regions by the Emx1- and Dlx5/6-Cre drivers

A. No change in Na,1.6 levels was detected by Western blot analysis of membrane-enriched whole brain samples isolated from WT and Scn8a<sup>f/f</sup> mice (Student's t test, p > 0.05; n = 4 per group). B. Likewise, the latency to the myoclonic jerk (MJ) and the generalized tonic-clonic seizure were not significantly different between WT and Scn8a<sup>f/f</sup> mice (Mann-Whitney U test, MJ n.s. p > 0.05, GTCS n.s. p > 0.05; n = 9 per group). C. PCR detection of DNA isolated from the cortex, hippocampus, and thalamus and tail of Scn8a<sup>f/+</sup>/Emx1-Cre, Scn8a<sup>f/+</sup>/Dlx5/6-Cre, and Cre negative littermates (Scn8a<sup>f/+</sup>/no-Cre) was performed. Deleted product was detected in samples from the cortex, hippocampus, and thalamus of Scn8a<sup>f/+</sup>/Dlx5/6-Cre mice but not from the tail or in samples from Scn8a<sup>f/+</sup>/no-Cre littermates. Deleted product (325 bp) was detected in samples from the cortex and hippocampus of Scn8a<sup>f/+</sup>/Emx1-Cre mice but not in the thalamus or tail or in samples from Scn8a<sup>f/+</sup>/no-Cre littermates.
Table 4.1. Summary of colocalization of Dlx5/6-Cre and Emx1-Cre expression in the CNS

<table>
<thead>
<tr>
<th>Brain Region</th>
<th>Emx1 GluR2 &amp; Cre+ Cells Counted</th>
<th>Dlx5/6 GAD67 &amp; Cre+ Cells Counted</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hippocampus</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dentate Gyrus</td>
<td>98% 340</td>
<td>83% 12</td>
</tr>
<tr>
<td>CA3</td>
<td>- 0</td>
<td>100% 3</td>
</tr>
<tr>
<td>CA1</td>
<td>99% 93</td>
<td>90% 10</td>
</tr>
<tr>
<td><strong>Cerebral Cortex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Layer 1</td>
<td>0% 0</td>
<td>97% 16</td>
</tr>
<tr>
<td>Layer 2-3</td>
<td>85% 65</td>
<td>93% 15</td>
</tr>
<tr>
<td>Layer 4</td>
<td>91% 55</td>
<td>100% 3</td>
</tr>
<tr>
<td>Layer 5-6</td>
<td>59% 63</td>
<td>100% 7</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannate Putamen</td>
<td>50% 4</td>
<td>8% 198</td>
</tr>
<tr>
<td>Amygdala</td>
<td>0% 15</td>
<td>54% 26</td>
</tr>
<tr>
<td>Reticular Nucleus</td>
<td>- -</td>
<td>100% 64</td>
</tr>
</tbody>
</table>

Immunofluorescence detection of cell-type markers was performed in brain slices of Dlx5/6-Cre-ROSA and Emx1-Cre-ROSA animals. The percentage of reporter positive cells that also express the cell-type marker are indicated. High levels of colocalization between Emx1-Cre and Glur2 immunoreactivity was detected in most regions of the forebrain. High levels of colocalization were observed between Dlx5/6-Cre and GAD67 immunoreactivity in the forebrain and nRT. These experiments were performed by Brian Tanaka in the laboratory of Alan Goldin at the University of California, Irvine.
Conditional inactivation of Scn8a in excitatory neurons confers resistance to flurothyl-induced seizures.

Cell-type specific Cre-mediated deletion of the floxed Scn8a allele was used to determine the contribution of relevant cell types to Scn8a-associated seizure resistance. Four Cre transgenic lines were chosen based on cell-type and region specificity. The Emx1- and Camk2a-Cre lines were used to achieve selective reduction of Scn8a expression in excitatory neurons. The Dlx5/6-Cre line was used to achieve broad interneuron deletion of the floxed Scn8a allele and the Ppp1r2-Cre line was used to primarily reduce Scn8a expression in parvalbumin interneurons of the forebrain. Latencies to flurothyl-induced seizures were increased following Scn8a deletion by both Cre lines that target excitatory neurons (Mann-Whitney U test, Emx1, MJ n.s. $p = 0.055$, GTCS $p < 0.01$; Camk2a: $p < 0.05$; Fig. 4.2A-B). Susceptibility to flurothyl-induced seizures was not altered in mice expressing the floxed allele and Cre transgenes from either the Dlx5/6 or the Ppp1r2-Cre lines (Mann-Whitney U test $p > 0.05$, Fig. 4.2C-D).

Conditional inactivation of Scn8a in excitatory neurons confers resistance to hippocampal epileptiform burst discharges in slice preparations.

To establish that excitatory cell-specific deletion of Scn8a is protective in a separate seizure model, we measured epileptiform burst discharges, elicited by high extracellular potassium, in hippocampal slices of Scn8a<sup>+/−</sup>/Emx1-Cre and Scn8a<sup>+/−</sup>/Dlx5/6-Cre mice (Fig. 4.3). Consistent with our seizure susceptibility data, we observed reductions in the latency and frequency of burst discharges in Emx1-Cre but not in Dlx5/6-Cre animals when compared to Cre negative controls (Student's t-test, Emx1-Cre $p < 0.05$; Dlx5/6-Cre $p > 0.05$; Fig. 4.3).
Resistance to flurothyl-induced seizures increase with increasing levels of Scn8a inactivation in excitatory forebrain neurons

In Chapter 2 we showed that the Scn8a mutations, R1627H and medjo, increase resistance to flurothyl-induced seizures in heterozygous mutants but not in homozygous mutants. To determine if a similar gene-dosage relationship exists following excitatory cell-specific deletion of Scn8a, we crossed Scn8a<sup>f/+</sup>/Emx1-Cre mice to Scn8a<sup>f/f</sup> mice and compared susceptibility to flurothyl-induced seizures between homozygous (Scn8a<sup>f/f</sup>/Emx1-Cre) and heterozygous (Scn8a<sup>f+</sup>/Emx1-Cre) deletion of Scn8a. Littermates in which Scn8a was not deleted (Scn8a<sup>f+</sup>/no-Cre) served as controls (Fig. 4.4). In contrast to mice globally expressing Scn8a mutations, we found that the order of seizure resistance was; Scn8a<sup>f+</sup>/Emx1-Cre > Scn8a<sup>f+</sup>/Emx1-Cre > Scn8a<sup>f+/no-Cre</sup> (one-way ANOVA <i>p</i> < 0.05; Tukey post hoc MJ, Scn8a<sup>f+/no-Cre</sup> vs. Scn8a<sup>f+</sup>/Emx1-Cre <i>p</i> < 0.01; GTCS, Scn8a<sup>f+/no-Cre</sup> vs. Scn8a<sup>f+/Emx1-Cre</sup> <i>p</i> < 0.01, Scn8a<sup>f+/no-Cre</sup> vs. Scn8a<sup>f+</sup>/Emx1-Cre <i>p</i> < 0.0001, Scn8a<sup>f+</sup>/Emx1-Cre vs. Scn8a<sup>f+</sup>/Emx1-Cre <i>p</i> < 0.05; Fig. 4.4).

Forebrain excitatory cell-specific deletion of Scn8a increases seizure resistance and survival of Scn1a-R1648H GEFS+ mutants

Increased survival and seizure thresholds have been observed in Scn1a GEFS+ (Hawkins et al., 2011) and DS (Martin et al., 2007) mutants that also express Scn8a mutations. Also, we showed that reduced Scn8a activity can reduce induced epileptiform bursting in hippocampal slices from Scn1a-R1648H mutants (Chapter 2). To determine if selectively reducing Scn8a expression in forebrain excitatory neurons would similarly lead to increased seizure resistance and prolong survival, we crossed mice carrying the Scn8a-floxed allele to mice carrying the Scn1a-R1648H GEFS+ mutation and the Emx1-Cre gene and evaluated survival and susceptibility to flurothyl-induced seizures in the offspring (Fig. 4.5). Survival was reduced by 20% in Scn8a<sup>f+</sup>/no-
Cre/Scn1a<sup>RH/+</sup> mice, but normal in Scn8a<sup>+/+</sup>/Emx1-Cre/Scn1a<sup>+/+</sup> and Scn8a<sup>+/+</sup>/Emx1-Cre/Scn1a<sup>RH/+</sup> mice (Fig. 4.5A). No significant changes in average latencies to the MJ were observed between any of the genotypes (Fig 4.5B). However, average latencies to GTCS were increased in Scn8a<sup>+/+</sup>/Emx1-Cre/Scn1a<sup>+/+</sup> and Scn8a<sup>+/+</sup>/Emx1-Cre/Scn1a<sup>RH/+</sup> mice, and reduced in Scn8a<sup>+/+</sup>/no-Cre/Scn1a<sup>RH/+</sup> mice when compared to WT littermates (Fig. 4.5B).
Figure 4.2. Seizure thresholds are increased by loss of Scn8a from excitatory but not inhibitory neurons

A. Inactivation of the Scn8a gene in excitatory forebrain neurons by the Emx1-Cre line increased seizure thresholds to the GTCS but not MJ (Mann-Whitney U test, MJ n.s. $p > 0.05$, GTCS **$p < 0.01$; $n = 13-17$ per group). B. Inactivation of the Scn8a gene in excitatory neurons by the Camk2a-Cre line increased thresholds to flurothyl-induced MJ and GTCS (Mann-Whitney U test, MJ *$p < 0.05$, GTCS ***$p < 0.001$; $n = 15-16$ per group). C. Flurothyl thresholds were not significantly altered by inactivation of Scn8a in inhibitory neurons (Mann-Whitney U test, MJ n.s. $p > 0.05$, GTCS n.s. $p > 0.05$; $n = 6-8$ per group). D. Latencies to the MJ but not the GTCS were decreased in mice with preferential inactivation of Scn8a in forebrain parvalbumin interneurons (Mann-Whitney U test, MJ *$p < 0.05$, GTCS n.s. $p > 0.05$; $n = 11-15$ per group).
Figure 4.3. Inactivation of *Scn8a* in excitatory forebrain neurons increases resistance to induced epileptiform hippocampal bursting activity

**A.** Representative example of hippocampal bursting activity in an animal without *Cre* (top trace) and an animal with *Emx1-Cre*-mediated inactivation of *Scn8a* (bottom trace). **B.** The latency to the initiation of bursting was reduced in animals carrying the *Emx1-Cre* gene compared to littermates without *Cre* (Student’s t test **p** < 0.01; *n* = 7-8 per group). Intra-burst frequency was also reduced in animal carrying *Emx1-Cre* compared to controls without *Cre* (Student’s t test **p** < 0.01; *n* = 7-8 per group). **C.** No significant changes to the burst latency or to the burst frequency
were observed between animals carrying Dlx5/6-Cre and animals without Cre (Student's t test, burst latency $p > 0.05$, burst frequency $p > 0.05$; $n = 9$ per group). Error bars represent SEM. These experiments were performed by Brian Tanaka in the laboratory of Alan Goldin at the University of California, Irvine.
Figure 4.4. Resistance to flurothyl-induced seizures is influenced by the level of inactivation of *Scn8a* in excitatory forebrain neurons

Latencies to the MJ were not altered in *Scn8a*\(^{+/+}\)/Emx1-Cre mice but were increased in *Scn8a*\(^{−/−}\)/Emx1-Cre mice compared to no-Cre littermates (one-way ANOVA, MJ \(p < 0.01\); Tukey post-hoc, *Scn8a*\(^{−/−}\)/no-Cre vs. *Scn8a*\(^{+/+}\)/Emx1-Cre \(n.s.\) \(p > 0.05\), *Scn8a*\(^{−/−}\)/no-Cre vs. *Scn8a*\(^{+/+}\)/Emx1-Cre **\(p < 0.01\), *Scn8a*\(^{−/+}\)/Emx1-Cre vs. *Scn8a*\(^{−/−}\)/Emx1-Cre n.s. \(p > 0.05\)). Mice with heterozygous inactivation of *Scn8a* in forebrain excitatory neurons (*Scn8a*\(^{−/+}\)/Emx1-Cre) experienced higher latencies to the GTCS that no-Cre controls, and mice with homozygous inactivation of *Scn8a* (*Scn8a*\(^{−/−}\)/Emx1-Cre) experienced increased latencies to over mice with heterozygous inactivation (*Scn8a*\(^{−/+}\)/Emx1-Cre) (one-way ANOVA, GTCS \(p < 0.0001\); Tukey post-hoc, GTCS, *Scn8a*\(^{−/−}\)/no-Cre vs. *Scn8a*\(^{−/+}\)/Emx1-Cre **\(p < 0.05\), *Scn8a*\(^{−/−}\)/no-Cre vs. *Scn8a*\(^{−/−}\)/Emx1-Cre ****\(p < 0.0001\), *Scn8a*\(^{−/+}\)/Emx1-Cre vs. *Scn8a*\(^{−/−}\)/Emx1-Cre *\(p < 0.05\); \(n = 8-16\)). Error bars represent SEM.
Figure 4.5. Selective inactivation of Scn8a in excitatory forebrain neurons in Scn1a mutant mice improves survival and increases resistance to flurothyl-induced seizures

Survival (A) and flurothyl-induced seizure latencies (B) were examined in mice carrying the Scn1a R1648H mutation (Scn1a<sup>R1648H</sup>) the Emx1-Cre transgene and the Scn8a-floxed allele (Scn8a<sup>f<sup>+<sup>+</sup></sup></sup>). A. Survival was reduced by 33% (4/12) in Scn8a<sup>f<sup>/+</sup></sup>/no-Cre/Scn1a<sup>R1648H</sup>/+ mice. No premature mortality was observed in GEFS+ mice with the Emx1-Cre (Scn8a<sup>f<sup>/+</sup></sup>/Emx1-Cre/Scn1a<sup>R1648H</sup>/+, n=8), Emx1-Cre/Scn1a<sup>+<sup>+</sup></sup> (n= 7), and Scn8a<sup>f<sup>/+</sup></sup>/no-Cre/Scn1a<sup>+/+</sup> (n=9). B. No significant alterations in MJ latencies were observed (one-way ANOVA, MJ, n.s. p > 0.01). As expected, latencies to the GTCS were decreased in Scn1a mutant mice (Scn8a<sup>f<sup>+</sup></sup>/no-Cre/Scn1a<sup>R1648H</sup>), but were increased in Scn8a<sup>f<sup>+</sup></sup>/Emx1-Cre/Scn1a<sup>+<sup>+</sup></sup> mice as well as Scn8a<sup>f<sup>+</sup></sup>/Emx1-Cre/Scn1a<sup>R1648H</sup> mice when compared to control littermates without Cre (Scn8a<sup>f<sup>/+</sup></sup>/no-Cre/Scn1a<sup>+<sup>+</sup></sup>). (one-way ANOVA, GTCS, p < 0.0001; Dunnett’s post-hoc, GTCS, Scn8a<sup>f<sup>/+</sup></sup>/no-Cre/Scn1a<sup>+<sup>+</sup></sup> vs. Scn8a<sup>f<sup>+</sup></sup>/no-Cre/Scn1a<sup>R1648H</sup> *p < 0.05, Scn8a<sup>f<sup>/+</sup></sup>/no-Cre/Scn1a<sup>+<sup>+</sup></sup> vs. Scn8a<sup>f<sup>/+</sup></subscript>Emx1-Cre/Scn1a<sup>R1648H</subscript> ***p < 0.001, Scn8a<sup>f<sup>/+</sup></subscript>/no-Cre/Scn1a<sup>+<sup>+</sup></subscript> vs. Scn8a<sup>f<sup>/+</subscript>Emx1-Cre/Scn1a<sup>R1648H</subscript> **p < 0.01; n = 8-14; error bars represent SEM).
Inhibitory inactivation of the Scn8a gene leads to spontaneous SWD generation

Spontaneous absence seizures are observed in mice with mutations in the Scn8a gene (Papale et al., 2009). To evaluate the relative contribution of excitatory forebrain neurons and inhibitory neurons to SWD generation in Scn8a mutants, we performed continuous video/EEG recordings of mice with cell-type specific deletion of Scn8a. At least five continuous days of recordings were obtained from Scn8a\textsuperscript{+/Emx1-Cre} and Scn8a\textsuperscript{+/Dlx-Cre} mice and Cre negative littermates. No tonic-clonic seizure activity was observed in any mouse over the recording period. No SWDs were observed in Scn8a\textsuperscript{+/Emx1-Cre} animals. However, spontaneous SWDs were observed in mice in which Scn8a expression was selectively reduced in interneurons (Scn8a\textsuperscript{+/Dlx5/6-Cre}, average SWD per hr = 4.63, n = 5, Fig 4.6A). Because SWD frequency in Scn8a mutant mice is known to be influenced by genetic background (Papale et al., 2009), the Dlx5/6-Cre and Emx1-Cre lines were crossed together so that comparisons could directly be made between littermates (Fig. 4.6C). SWDs were observed in Scn8a floxed mice with the Dlx5/6-Cre transgene (Scn8a\textsuperscript{+/Dlx5/6-Cre}) and in Scn8a floxed mice expressing both Cre transgenes (Scn8a\textsuperscript{+/Emx1-Cre/Dlx5/6-Cre}), but not in Scn8a\textsuperscript{+/Emx1-Cre} or no-Cre littermates. Fewer SWDs were observed in mice with both Cre genes, Scn8a\textsuperscript{+/Emx1-Cre/Dlx5/6-Cre} when compared to Scn8a floxed mice with only the Dlx-Cre transgene (Fig. 4.6C).
Inhibitory neuron-specific but not forebrain excitatory neuron-specific inactivation of the Scn8a gene is sufficient to produce SWDs

A. Continuous EEG recordings were performed of mice carrying the floxed Scn8a allele and either the Emx1- or Dlx5/6-Cre transgenes to assess for the presence of SWDs. No SWDs were observed in mice lacking Cre expression (Scn8a<sup>f/f</sup>/no-Cre; not shown) or in mice with forebrain excitatory neuron-specific Scn8a inactivation (Scn8a<sup>f/+</sup>/Emx1-Cre). Frequent SWDs were observed in mice with inhibitory neuron-specific inactivation of Scn8a (Scn8a<sup>f/+</sup>/Dlx5/6-Cre) (Mann-Whitney U test *p < 0.05, n = 4-5 per group). B. Representative image of SWDs in
Scn8a<sup>fl/+</sup>/Dlx5/6-Cre mice. C. SWDs were not observed in Scn8a floxed mice without Cre (black bar) or Scn8a floxed mice with the Emx1-Cre transgene (light grey bar). A low frequency of SWDs was observed in mice with both excitatory and inhibitory neuron-specific inactivation of Scn8a (dark grey bar). Highest levels of SWDs were observed in mice with only inhibitory neuron-specific inactivation of Scn8a (white bar) (one-way ANOVA p < 0.05, Tukey post-hoc *p < 0.05; n = 5 per group). Error bars represent SEM.
**Scn8a immunoreactivity in forebrain and thalamic interneurons**

Scn8a immunoreactivity was evaluated in brain slices from WT mice to establish channel expression in cell types and regions that are known to play an important role in the generation of SWDs. Scn8a expression was not observed in neurites or soma of inhibitory interneurons in the forebrain (Fig. 4.7A). However, Scn8a expression was observed in inhibitory neurons of the thalamic reticular nucleus (nRT) (Fig. 4.7B-C). Brain sections from homozygous Scn8a null mutants (Scn8a<sup>med/med</sup>) were used to verify the specificity of the Scn8a antibody. Only a low level of background fluorescence was detected in Scn8a<sup>med/med</sup> tissue probed for Scn8a immunoreactivity (Fig. 4.7D).

**Scn8a deficiency leads to reduced tonic firing in nRT neurons**

Current-clamp recordings were performed to determine the firing properties of nRT neurons in WT and Scn8a<sup>med/+</sup> mice. Reduced ability to maintain repetitive firing in response to prolonged depolarizing current injections was observed in Scn8a<sup>med/+</sup> nRT neurons (Fig. 4.9B) when compared to WT (Fig. 4.9A). However, no deficit in calcium-dependent rebound burst firing was observed (Fig. 4.9A-B).
Figure 4.7. Evaluation of Scn8a expression in interneuronal populations of thalamocortical circuitry

*Scn8a* immunoreactivity with the inhibitory neuron marker GAD65/67 is shown in the cortex and nRT. **A.** Colocalization of *Scn8a* immunoreactivity and GAD65/67 immunoreactivity was not observed in neuronal soma or neurites in the cortex. **B.** Colocalization between *Scn8a* and GAD65/67 was observed in the nRT. **C.** Inset of area designated by dashed lines in B to show colocalization. **D.** Lack of immunoreactivity in *Scn8a*<sup>med/med</sup> (null) negative control tissue. Arrows indicate selected *Scn8a* positive processes that are negative for cell type markers. Open arrowheads indicate cells that are negative for *Scn8a*. Closed arrowheads indicate colocalization. Images were captured at 100X magnification. Scale bars, 10 μm.
Figure 4.8. nRT neurons of Scn8a-deficient mice have impaired tonic firing

Representative electrophysiological recordings in the nRT reveal a robust decrease in AP generation in response to prolonged depolarizing currents (blue traces) in WT (A) vs. Scn8a<sup>med/+</sup> (B) mice. Ca<sup>++</sup>-mediated rebound bursts (arrows) following hyperpolarization (red traces) were not perturbed in Scn8a<sup>med/+</sup> nRT neurons. C. Indicates current injection protocol. Grey trace indicates baseline (no current injection). * indicates tonic firing modes. Arrows indicate burst firing modes. n = 10-11 cells. Recordings were performed by Catherine Christian in the Huguenard lab at Stanford.
Developmental progression of absence seizures in Scn8a-deficient mice

EEG recordings were collected of Scn8a^{med/+} and WT mice from P15 to P52 to establish the onset and progression of absence seizures. Two hours of EEG recordings were obtained daily from each mouse from P15-P32 and on P42 and P52. Seizures were first detected at P17 and reached adult levels by P28. No SWDs were detected in WT littermates (not shown) (Fig. 4.9).
Figure 4.9. Developmental increases in SWDs in Scn8a<sup>med/+</sup> mice

EEG recordings were collected from P15-P52 of mice with global Scn8a deficiency (Scn8a<sup>med/+</sup>) and WT littermates (not shown) to determine the age of onset and the developmental progression of SWDs. SWDs were first observed on P17 and increased in frequency until reaching adult levels in the fifth postnatal week. SWDs were not observed in WT animals.
4.4. Discussion

Using a combination of genetic, immunohistochemical, and electrophysiological approaches, we investigated the mechanism underlying our previous paradoxical findings that mutations in the Scn8a gene lead both to seizure protection and absence seizure generation.

We found that selective Cre-mediated deletion of Scn8a from excitatory neurons in the forebrain was sufficient to confer resistance to induced seizures. In contrast, deletion of Scn8a from inhibitory interneurons had no effect on latencies to flurothyl-induced seizures or bursting activity in hippocampal slice preparations, indicating that the observed seizure resistance (Martin et al., 2007; Hawkins et al., 2011) is forebrain excitatory neuron dependent. Increased Scn8a expression/activity, in contrast, has been hypothesized to promote seizure generation. Scn8a expression and neuronal excitability were found to be increased in layer V neurons of epileptic mice that are deficient for Celf4 (Sun et al., 2013). Furthermore, increased Scn8a expression was observed in the hippocampus of amygdala-kindled rats (Blumenfeld et al., 2009), and in the entorhinal cortex in an electrical simulation model of TLE (Hargus et al., 2011). In humans, a gain-of-function SCN8A mutation was identified in a patient with infantile epileptic encephalopathy and sudden unexplained death in epilepsy (SUDEP) (Veeramah et al., 2012). Our results, together with previous reports support a model of Scn8a in epilepsy in which increased Scn8a expression leads to increased neuronal excitability and seizure susceptibility while loss of Scn8a from excitatory forebrain neurons leads to reduced network excitability and seizure resistance.

In Chapter 3 we demonstrated that mice that are homozygous for the Scn8a amino acid substitutions R1627H and medjo do not exhibit increased resistance to flurothyl- or 6Hz-induced seizures or hippocampal burst discharges evoked by high potassium. Interestingly, this gene-dose relationship was not observed in animals with homozygous Emx1-Cre-mediated deletion of Scn8a (Fig. 4.4). Substitution mutations alter channel activity but not channel expression, while
null mutations or conditional inactivation leads to reduced channel levels at the plasma membrane. This critical difference might underlie the different effect of these mutations on seizure phenotypes. The effect of homozygous recessive null Scn8a mutations on seizure phenotypes have not previously been explored because these mutations lead to progressive paralysis and premature death in the first weeks of life. However, homozygous Emx-Cre animals were visibly normal and did not display tremor or gate abnormalities.

We have previously reported that mutations in Scn8a lead to spontaneous absence seizure generation (Papale et al., 2009). Interestingly, we found that broadly inactivating Scn8a in inhibitory neuronal populations using the Dlx5/6-Cre line results in the generation of SWDs, consistent with mouse models of absence epilepsy. Inactivation of Scn8a in excitatory projection neurons, including corticothalamic neurons, did not produce SWDs.

SWDs are the result of oscillatory activity between the cortex and thalamus, specifically involving interplay between reciprocally connected corticothalamic neurons and thalamocortical neurons as well as GABAergic neurons of the thalamic reticular nucleus (nRT) which send inhibitory projections to thalamocortical cells (TC) and also back onto the nRT itself. Thus, loss of VGSC expression in inhibitory neurons could directly lead to absence seizure generation by affecting the activity of inhibitory nRT neurons or indirectly through inhibitory connections onto layer VI corticothalamic neurons. To distinguish between these possibilities, we performed immunohistochemistry for Scn8a and GAD65/67 in the cortex and nRT of mouse brain slices. We were unable to detect colocalization between Scn8a and GAD65/67 in the cortex; however, we did observe colocalization of Scn8a and GAD65/67 in the nRT.

To determine if Scn8a expression in the nRT is important for the activity of these neurons, current clamp recordings were performed on mice that were heterozygous for a null Scn8a mutation (Scn8a<sup>med/+</sup>) and WT littermates. We found that Scn8a<sup>med/+</sup> mice have a profound reduction in their ability to maintain tonic firing, but have normal burst firing.
During SWDs nRT neurons produce high frequency bursts of activity that are capable of strongly inhibiting TC neurons. The strength of this input is highly related to the generation of thalamocortical oscillations as strong nRT-TC hyperpolarization is capable of deinactivating T-type Ca\(^{2+}\) channels, leading to rebound bursts of TC activity once self-limiting nRT bursts terminate (von Krosigk et al., 1993; Warren et al., 1994; Huguenard, 1996; von Krosigk et al., 1999; Beenhakker and Huguenard, 2009). Reinforcement of nRT bursting either through increased excitatory input or reduced inhibitory input has been shown to promote SWDs (Bal et al., 1995; Paz et al., 2011). Since tonic but not bursting nRT outputs are perturbed in Scn8a\(^{med/+}\) mice, we speculate that the nRT in these animals receive less recurrent tonic inhibition which leads to hyperexcitability of the nRT and increased production of rhythmogenic bursting outputs. In support of this hypothesis, we have found that mice carrying both the Emx1- and the Dlx5/6-Cre transgenes experience fewer SWDs than mice only carrying the Dlx5/6-Cre transgene. The nRT in these mice is likely less excitable due to a loss of excitatory input from corticothalamic neurons, which have reduced Scn8a expression due to Emx1-Cre mediated inactivation.

We have demonstrated that seizure resistance and absence seizure susceptibility phenotypes in Scn8a-mutant animals involve perturbations to separate neuronal populations. This finding indicates that specifically targeting SCN8A activity in glutamatergic forebrain neurons might be beneficial in patients with epilepsy. These results also demonstrate a previously unrealized role for Scn8a in thalamocortical circuitry which implicates this channel in the regulation of critical thalamic processes including sleep, sensation, perception, and consciousness.
4.5. Experimental Procedures

Animals

Mice carrying each Cre transgene were crossed to the fluorescent ROSA reporter line B6;129-Gt(Rosa)26Sortm1Jeo/J. Cre expression induces recombination of an upstream floxed stop sequence leading to induction of fluorescent reporter expression in cells which express Cre recombinase. Scn8a-floxed mice were a kind gift from Miriam Meisler at the University of Michigan, Ann Arbor (Levin and Meisler, 2004). Homozygous female Scn8a-floxed mice (Scn8afloxed) were crossed to 4 different Cre transgenic lines: Emx-1 B6.129.Emx1tm1(cre)Krj/J (Jax stock number 005628) (Gorski et al., 2002), Dlx5/6 (Jax stock number 008199), CamKIIa (Dragatsis and Zeitlin, 2000), and Ppp1r2 (Belforte et al., 2010). The Ppp1r2 and the CamKIIa lines were kind gifts from Kazu Nakazawa at the National Institutes of Health and Ioannis Dragatsis at the University of Tennessee, respectively. We crossed each line to C57BL/6J to establish our colony before crossing to Scn8afloxed mice which are congenic on C57BL/6J (Jax Stock number 000664). The mice were maintained on a 12 h light/dark cycle. Food and water were available ad libitum. All experimental procedures were performed in accordance with the guidelines of Emory University and the University of California, Irvine Institutional Animal Care and Use Committees.

Genotyping of Scn8a conditional knockout mice

PCR identification of the Scn8a floxed allele was performed as previously described (Levin and Meisler, 2004) using the primer pair FloxF (5’-GTG TGT TCT CAA CAG TGG GTT-3’)/FloXR (5’-GTC TGT AAG GCC TGA AAG TGA-3’). All Cre transgenes were identified using a primer pair located within the Cre transgene: CreF (5’-TGA CCC GGC AAA ACA GGT AGT TA-3’)/CreR (5’-TTC-CCG-CAG-AAC-CTG-AAG-ATG-TT-3’).
Flurothyl seizure induction

Flurothyl seizure induction was performed as described in Chapters 2 and 3.

EEG implantation recording and analysis

Continuous real-time video and EEG recordings were performed as described in Chapters 2 and 3 with the following modifications. To measure the progression of absence seizures in Scn8a<sup>med/+</sup> mice, EEG implantation surgery was performed on P14 mice. EEG recordings were performed for 2 hours per day so that pups could remain with the dam between recording periods. All recordings were performed between 11:00AM and 2:00PM in order to minimize possible circadian rhythm effects.

Immunohistochemistry

Immunohistochemistry was performed as previously described (Dutton et al., 2012; Papale et al., 2013) in order to determine the cell-type specificity of the Emx1 and Dlx5/6 Cre lines and to measure Na<sub>1.6</sub> expression in cortical and thalamic interneuronal populations. Mice were deeply anesthetized with isoflurane and transcardially perfused with 4% PFA. Brains were post-fixed in paraformaldehyde (4%), cryopreserved in 30% sucrose, and 45 μm sections were cut on a cryostat (Leica, Germany). Coronal sections, 400 μm apart, from bregma − 0.46 mm to − 3.38 mm, were examined. Free-floating sections were washed in TBS/Triton-X and blocked in 2% avidin and then 2% biotin. Sections were then incubated with polyclonal rabbit anit-GAD67 (1:200, Millipore) or polyclonal rabbit anti-GluR2 (1:200, Millipore) and monoclonal mouse anti-GAD65/67 (1:100, Millipore). Sections were then incubated with polyclonal rabbit anti-Scn8a (1:200, Millipore) and monoclonal mouse anti-GAD65/67 (1:100, Millipore). After washing, sections were incubated in secondary antibodies; biotinylated anti-rabbit IgG (1:300, Vector Laboratories) and Alexa Fluor 555 anti-mouse IgG (1:1000, Invitrogen), followed by washing and
incubation in fluorescein avidin D (1:300, Vector Laboratories). Negative controls included sections that were not incubated with primary antibody, and sections from P2-3 neonatal mouse pups that do not express detectable levels of Na\textsubscript{v}1.6. Sections were mounted and visualized using confocal microscopy (Carl Zeiss LSM 510 META). Cells were counted using Imaris software (Bitplane Scientific solutions) on images captured under 40 × and 10 × magnification. Results from three different animals were combined for the analysis of each sodium channel/cell-type combination.

**Preparation of slices for electrophysiology**

Slice preparation for electrophysiology were performed as described in Chapters 2 and 3.

**Slice electrophysiology**

Male WT or Scn8a\textsuperscript{med/+} mice (P147-150) were anesthetized with pentobarbital sodium (i.p., 55 mg/kg) and the brain was quickly removed and placed in cold (~4°C) oxygenated (95% O\textsubscript{2}/5% CO\textsubscript{2}) sucrose slicing solution containing (in mM): 234 sucrose, 11 glucose, 26 NaHCO\textsubscript{3}, 2.5 KCl, 1.25 NaH\textsubscript{2}PO\textsubscript{4}, 10 MgSO\textsubscript{4}, and 0.5 CaCl\textsubscript{2} (310 mOsm). Horizontal thalamic slices (250 mm thickness) containing nRT and VB were prepared as previously described (Huguenard and Prince, 1994) using a Leica VT1200 microtome (Leica Microsystems, Bannockburn, IL). Slices were incubated and continuously oxygenated in warm (~32°C) artificial cerebrospinal fluid (ACSF) containing (in mM): 10 glucose, 26 NaHCO\textsubscript{3}, 2.5 KCl, 1.25 NaHPO\textsubscript{4}; 1 MgSO\textsubscript{4}, 2 CaCl\textsubscript{2}, and 126 NaCl (298 mOsm) for 1 hour and then transferred to room temperature (~21-23°C) for at least 15 min prior to recording.

For current-clamp recordings, the pipette solution contained (in mM): 120 K-gluconate, 11 KCl, 1 MgCl\textsubscript{2}, 1 CaCl\textsubscript{2}, 10 HEPES, 1 EGTA, and pH was adjusted to 7.4 with KOH (290 mOsm).
Recordings were corrected for an estimated -15 mV liquid junction potential. I-V plots were constructed from a series of current steps in 20 pA increments from -140 to 140 pA from a holding potential of -75 mV.

Statistical analysis
All bar graphs indicate the mean and all error bars represent ± standard error of the mean (SEM). Statistical analyses were performed using Prism 6 (GraphPad Software Inc, La Jolla, CA). The Levene’s test was used to assess for differences in the variance between groups, and the Shapiro-Wilk test was used to determine normality of continuous data sets. One-way analysis of variance (ANOVA) was used to evaluate seizure thresholds between groups of three or more. Post-hoc comparisons were performed using either the Dunnett's or Bonferroni test. The Student's two-tailed t test was used to analyze hippocampal bursting. The Mann-Whitney-U test was used to assess differences in seizure thresholds between two groups.

4.6. Acknowledgements
This research was also supported in part by the NINDS core facilities grant P30N5055077 to the Emory University Microscopy Core. We would like to thank Stacey Dutton for assistance with performing flurothyl seizure induction procedures. We would also like to thank Christian Gonzalez for assistance with immunohistochemistry.
CHAPTER 5

Overall Discussion and Conclusions
5.1. Overview

Voltage-gated sodium channels (VGSCs) are important regulators of neuronal excitability and are responsible for the initiation and propagation of action potentials in neurons. Disruptions in VGSC function can lead to a host of pathophysiological conditions (George, 2005; Mantegazza and Catterall, 2012). Most notably, mutations in the four CNS VGSCs, SCN1A, SCN2A, SCN3A, and SCN8A, are responsible for several types of idiopathic epilepsy. Among these, SCN1A mutations are well established as the major cause of DS and GEFS+, and many clinical features of these disorders are recapitulated in mouse models of Scn1a dysfunction. In contrast, mutations in SCN8A have been only recently discovered in patients with epileptic encephalopathy (Veeramah et al., 2012; Carvill et al., 2013). Moreover, clinical presentation in patients with SCN8A mutations contrasts with existing mouse models of Scn8a dysfunction, which exhibit resistance to induced seizures (Martin et al., 2007; Hawkins et al., 2011) yet paradoxically, exhibit SWDs, a hallmark of absence epilepsy (Papale et al., 2009).

The experiments described in this thesis aim to provide a more complete understanding of the role of Scn8a in epilepsy. In Chapter 2, we described the relationship between the development of seizure protection and Scn8a expression in the CNS as well as the effect on seizure phenotypes of selectively targeting Scn8a in the hippocampus of adult animals. Chapter 3 described the generation and initial characterization of a new mouse model of Scn8a dysfunction, revealing new aspects of Scn8a function on recessive seizure and behavioral phenotypes. In Chapter 4 we presented results from the use of a Cre/loxP strategy to investigate the role of Scn8a in different CNS cell types and we proposed a mechanism to explain the major seizure phenotypes observed in Scn8a mutant mice: seizure protection and absence seizure generation.

Our primary findings are as follows:
1) The progression of Scn8a expression in early postnatal development is coincident with seizure resistance and the emergence of absence seizures.

2) Global or hippocampal-specific reduction of Scn8a expression in adult animals increases seizure resistance in multiple seizure and epilepsy models, highlighting the therapeutic potential for targeting SCN8A.

3) Heterozygous but not homozygous substitution mutations in the Scn8a gene confer seizure protection, while homozygous Scn8a mutant mice are susceptible to audiogenic seizures.

4) Reducing Scn8a expression in forebrain excitatory neurons increases seizure resistance while reducing Scn8a in inhibitory cells does not. In contrast, reduced Scn8a expression in inhibitory neurons, but not forebrain excitatory cells, is sufficient to generate spontaneous SWDs.

5) High levels of Scn8a expression were observed in nRT neurons. Also, deficits in tonic but not bursting outputs were observed in nRT neurons from Scn8a-deficient mice, implicating this nucleus in the generation of SWD.

Taken together, these findings provide additional mechanistic insight into the role of Scn8a in epilepsy, and importantly, provide genetic, developmental, anatomical and physiological rationale for selective targeting of Scn8a as a treatment for epilepsy. In this Discussion, I will provide partially overlapping frameworks to understand these results in the context of the VGSC field.

5.2. Reconciliation of Seizure Outcomes Associated with Scn8a Mutations

Heterozygous Scn8a mutations have been shown to confer seizure protection and are capable of increasing the lifespans of animals with mutations in Scn1a (Martin et al., 2007; Hawkins et al., 2011). In addition, we have found that heterozygous conditional inactivation of
Scn8a in forebrain excitatory neurons leads to increased seizure thresholds and that seizure thresholds are further increased following homozygous inactivation of Scn8a (Fig. 4.4). This result demonstrates that Scn8a-mediated seizure protection is dependent on excitatory neurons and that an inverse gene-dosage-dependent relationship exists between Scn8a expression in excitatory neurons and seizure resistance. In agreement with these results, increased seizure resistance was observed in mice that were heterozygous for the Scn8a mutations R1627H (Scn8a<sup>RH/+</sup>) and medjo (Scn8a<sup>RH/+</sup>); however, lower seizure latencies were seen in homozygous mutants (Fig. 3.5, 3.9). Furthermore, homozygous mutants appear to be susceptible to audiogenic seizures (Fig. 3.8, 3.9).

It remains to be determined why Scn8a-mediated seizure protection is lost at the homozygous level in the case of substitution mutations but not following homozygous deletion of Scn8a from excitatory neurons. We hypothesize that homozygous Scn8a mutations lead to reduced activity of forebrain inhibitory neurons, leading to reduced network inhibition, in addition to reduced excitability of forebrain excitatory neurons. In contrast, mice with homozygous conditional excitatory cell-specific Scn8a deletion, which does not affect interneuronal activity, retain normal inhibitory function thereby having the overall effect of reducing neuronal excitability and increasing seizure resistance. Although we did not detect colocalization between inhibitory cells and Scn8a in the rodent forebrain (Fig. 4.8), it is possible that Scn8a is expressed at a low, but functionally important level, which is below the threshold of detection using this technique. Evidence in support of our hypothesis is derived from preliminary in vivo electrophysiological investigations of Scn8a<sup>RH/RH</sup>, Scn8a<sup>RH/+</sup>, and WT interneuronal firing properties. In response to large depolarizing current injections, interneurons in the hippocampus of Scn8a<sup>RH/RH</sup> mice exhibit fatigue and produce significantly fewer action potentials than interneurons in Scn8a<sup>RH/+</sup> or WT littermates (Fig. 5.1). This loss of inhibitory neuronal output would be predicted to promote seizure activity. We therefore propose that mice carrying
homozygous Scn8a mutations experience a competition of effects on network excitability, decreased excitatory neuronal activity and decreased inhibitory neuronal excitability. This in turn leads to the complex seizure phenotypes observed at the homozygous level, including normal thresholds to pharmacologically and electrically-induced seizures (Fig. 3.5, 3.9), reduced tonic extension in response to proconvulsants (Fig. 3.5, 3.9), but susceptibility to audiogenic seizures (Fig. 3.8, 3.9). In the future, it would be interesting to determine if homozygous inhibitory neuronal-specific inactivation of Scn8a driven by the Dlx5/6-Cre line would lead to reduced seizure thresholds and susceptibility to audiogenic seizure.
Figure 5.1. Homozygous Scn8a-R1627H mice exhibit deficits in interneuron firing in response to large depolarization

Current clamp recordings were performed on inhibitory interneurons in the CA3 region of the hippocampus in Scn8aRH/RH, Scn8aRH/+ and WT littermates. The number of action potentials elicited in response to increasing current injections were analyzed. In response to high depolarization (>275 pA), interneurons in Scn8aRH/RH animals fatigue and produce fewer APs than Scn8aRH/+ or WT littermates (two-way ANOVA, Genotype X Current, Tukey post-hoc *p < 0.05 Scn8aRH/RH vs. Scn8aRH/+ and WT; n = 5-8 per group). Error bars represent SEM. These experiments were performed by Karoni Dutt in the laboratory of Alan Goldin at the University of California, Irvine.
5.3. A Circuit Model of SCN1A-Epilepsy and Genetic Modification by SCN8A Mutations

SCN1A-derived epilepsies encompass a spectrum of phenotypes with overlapping clinical presentations that range in severity from relatively benign febrile seizures to the catastrophic DS (Harkin et al., 2007). Mouse models have been successfully used to demonstrate that Scn1a channels are highly expressed in GABAergic inhibitory neurons of the hippocampus and cortex and that loss of Scn1a activity reduces the excitability of these neurons (Yu et al., 2006; Ogiwara et al., 2007; Martin et al., 2010). These observations led to the hypothesis that loss of Scn1a causes reduced neuronal inhibition and thus increased risk of seizure generation (Yu et al., 2006; Ogiwara et al., 2007).

These findings are in stark contrast to emerging data on other VGSCs in epilepsy, including SCN2A, SCN3A, and SCN8A, which express predominantly gain-of-function substitution mutations (Kearney et al., 2001; Holland et al., 2008; Estacion et al., 2010; Veeramah et al., 2012; Lauxmann et al., 2013; Vanoye et al., 2013). In chapter 4, we demonstrated that loss of Scn8a from excitatory forebrain neurons increases seizure resistance (Fig. 4.2) and reduces hippocampal epileptiform bursting activity in the presence of high extracellular potassium (Fig. 4.3), while loss of Scn8a from interneurons did not lead to increased seizure resistance. These results indicate that reducing Scn8a activity increases seizure protection by decreasing the excitability of excitatory forebrain projection neurons. We speculate that loss of Scn8a leads to improved survival and increased seizure thresholds in models of GEFS+ and DS by normalizing neuronal excitability. Figure 5.2 illustrates our simplified model of loss of Scn1a leading to seizure generation and reversal of this phenotype by loss of Scn8a. It should be noted that this model only illustrates the putative effects of heterozygous loss- or reduction-of-function Scn1a and Scn8a mutations in forebrain networks.
Figure 5.2 Loss of inhibition model of Scn1a dysfunction leading to generalized tonic-clonic epilepsy and reversal by loss of Scn8a

A-D. Illustrated are four hypothetical instances of cortical circuitry in Scn1a and Scn8a-deficient animals. Each example includes a cortical parvalbumin positive interneurons (red) synapsing onto two glutamatergic pyramidal neurons (blue). The thickness of the cell body and processes indicates the relative excitability of the cell type. The font size of the VGSC indicates the relative expression level of this channel. 

A. In a normal, non-epileptic brain sufficient Scn1a expression exists to support interneuronal excitability which suppresses network hyperexcitability. 

B. Loss of Scn1a expression leads to a reduction in interneuronal function and an overall increase in network activity. This loss of inhibition allows excitatory aspects of the network to enter into hyperexcitable epileptic states. 

C. Loss of Scn8a reduces the excitability of glutamatergic projection neurons leading to a general reduction in network excitability that inhibits seize generation. 

D. Loss of both Scn1a and Scn8a produces opposing effects on network excitability that approximates the normative state.
5.4. Persistent Sodium Current: Unifying VGSC Epilepsy Mechanisms?

Cortical neurons exhibit a TTX-sensitive fast transient sodium current ($I_{NaT}$) and a low-voltage-activated, slow inactivating, persistent sodium current ($I_{NaP}$). $I_{NaP}$ is implicated in boosting sub-threshold membrane depolarizations and responses to synaptic input (Deisz et al., 1991; Schwindt and Crill, 1995; Stuart and Sakmann, 1995; Lipowsky et al., 1996), while transient Na$^+$ currents are responsible for mediating the rising phase of the action potential. $I_{NaP}$ has been demonstrated to strongly influence excitability and synaptic integration in many neuronal cell types (Chandler and Meves, 1966; Crill, 1996; Pennartz et al., 1997; Taddese and Bean, 2002; Baker et al., 2003). In heterologous expression systems, Scn1a as well as Scn8a have been found to produce a large $I_{NaP}$ (Smith et al., 1998; Goldin, 1999), while many studies have demonstrated that Scn8a carries most (~70%) $I_{NaP}$ in CNS neurons in vivo (Raman et al., 1997; Vega-Saenz de Miera et al., 1997; Maurice et al., 2001; Enomoto et al., 2007; Royeck et al., 2008; Osorio et al., 2010). The large contribution of Scn8a to $I_{NaP}$ may distinguish this channel from SCN1A in regards to the effect of reduced channel activity on seizure susceptibility.

Gain of function mutations in SCN2A (Kearney et al., 2001; Liao et al., 2010a), SCN3A (Holland et al., 2008; Estacion et al., 2010), and SCN8A (Veeramah et al., 2012), identified in epileptic patients, were all found to increase $I_{NaP}$. While Scn8a is normally the primary VGSC responsible for $I_{NaP}$ in CNS neurons, it seems that gain-of-function mutations in other VGSCs can alter these $\alpha$ subunits such that they aberrantly increase their contribution to subthreshold currents. This in turn leads to increased neuronal excitability and epilepsy.

5.5. A Circuit Model of Scn8a-Absence Epilepsy

Absence epilepsy is characterized by spontaneous generalized spike-and-wave discharges (SWDs) that are the consequence of aberrant oscillatory thalamocortical activity (Panayiotopoulos, 2001). Absence seizures result in temporary loss of awareness and can occur
hundreds of times per day, and in fact, absence seizures account for approximately 10% of all childhood seizures (Posner, 2008). These seizures represent a major health concern and are associated with reduced academic performance and attention, and increased accident risk, as well as affective and behavioral disorders (Vrielynck, 2013). We have previously reported that mice with Scn8a mutations exhibit SWDs (Papale et al., 2009).

In Chapter 4 we showed that inactivation of Scn8a in inhibitory neurons leads to spontaneous SWDs (Fig. 4.6). We also demonstrated that Scn8a is expressed in nRT neurites (Fig. 4.7) and that Scn8a deficient animals exhibit reduced tonic but not bursting outputs from nRT neurons (Fig. 4.8). These findings indicate that Scn8a is important for supporting the activity of the nRT and raise the possibility that loss of Scn8a from the nRT can lead to SWDs. What is less clear is how loss of Scn8a expression could lead to increased oscillations in the thalamocortical circuitry and hence SWD generation.

SWDs are the result of oscillatory activity between the cortex and thalamus which involves the interplay between reciprocally connected corticothalamic neurons (CT) and thalamocortical (TC) neurons, as well as GABAergic neurons of the thalamic reticular nucleus (nRT) which send inhibitory projections to thalamocortical cells and also back onto the nRT itself (Fig. 5.3A). nRT neurons produce high frequency bursts of activity that are capable of strongly inhibiting TC neurons during SWD generation. The strength of this input is highly related to the generation of thalamocortical oscillations as strong nRT-TC hyperpolarization is capable of deinactivating T-type Ca^{++} channels, leading to rebound bursts of TC activity once self-limiting nRT bursts terminate (von Krosigk et al., 1993; Warren et al., 1994; Huguenard, 1996; von Krosigk et al., 1999; Beenhakker and Huguenard, 2009). Excitatory feedback to the nRT then initiates another oscillation in the circuit.
Figure 5.3. Thalamocortical circuit models of conditional cell-type specific inactivation of 
Scn8a leading to SWD generation

A. Schematic representation of thalamocortical circuitry. Red cells are inhibitory, blue cells are 
excitatory. CT represents excitatory corticothalamic neurons, TC represents excitatory 
thalamocortical neurons, nRT represents inhibitory thalamic reticular neurons. The thickness of 
projections indicates relative excitability. The green background indicates the thalamus. The nRT 
receives excitatory input from the CT and TC cells (a) and reentrant inhibition from the nRT itself 
(b). Strong bursts of inhibition from the nRT onto TC cells (c) are thought to drive 
thalamocortical oscillations by eliciting strong rebound bursts in TC neurons. B-E. Inset of A 
demonstrating intra-nRT circuitry following loss of Scn8a from different aspects of the 
thalamocortical loop. nRT-B represents nRT neurons that prefer bursting modes and nRT-T 
represents nRT neurons that prefer tonic modes of output. B. In WT animals, normal excitatory 
CT-nRT input as well as normal nRT-B and nRT-T output does not lead to SWD generation. C. 
Loss of Scn8a in the nRT specifically reduces the activity of nRT-T but not nRT-B neurons 
leading to a loss of inhibition at the nRT-B neurons. The resulting increase in nRT bursting 
outputs drive SWDs. D. Loss of CT Scn8a expression reduces excitatory input to the nRT which 
leads to reduced nRT output which inhibits SWD generation. E. Loss of Scn8a in both CT and 
nRT neurons leads to intermediate levels of nRT-B output which is sufficient to generate SWDs, 
but at a lower level than in C.
Given that nRT bursting activity is a critical driver of thalamocortical oscillations and that *Scn8a*-deficiency leads to preserved nRT bursting but reduced tonic firing, we propose two possible explanations for the role of reduced *Scn8a* activity in SWD generation. First, loss of *Scn8a* from the nRT might result in less tonic-firing which would then reduce inhibition to the nRT via recurrent connections (Fig. 5.3C). The resulting loss of inhibitory tone within the nRT would promote increased burst firing and SWD generation. Second, a related possibility is based on the observation that some nRT cells more readily fire bursts while others prefer tonic output modes (Contreras et al., 1992; Lee et al., 2007; Alberi et al., 2013). It is possible that interfering with tonic modes but not bursting modes of output, as a consequence of loss of *Scn8a* activity, causes tonically firing nRT neurons to enter into burst modes of output which would be predicted to increase SWD generation. Thus *Scn8a*-deficiency may specifically alter tonic but not bursting nRT cells which either pushes tonic bursting cells to enter into burst modes or leads to loss of tonic inhibition in the nRT which increases bursting activity.

Lastly, we observed lower SWD frequency in animals with *Scn8a* inactivation in both inhibitory and excitatory neurons (*Scn8a<sup>+/−</sup>/Dlx5/6-Cre/Emx1-Cre*) when compared to animals with only inhibitory neuron inactivation (*Scn8a<sup>+/−</sup>/Dlx5/6-Cre*). This finding is consistent with our proposed models, as loss of corticothalamic activity would partially disrupt the seizurogenic thalamocortical loop and would reduce excitatory input to the nRT leading to a reduction in nRT output (Fig. 5.3E). Thus in an animal carrying a mutation in *Scn8a*, thalamocortical oscillations may be driven by loss of inhibition at the nRT leading to increased nRT output and inhibited by reduced activity of the corticothalamic pathway. The net effect apparently favors oscillation of the thalamocortical loop as mice carrying *Scn8a* mutations experience spontaneous SWDs.
5.6. Therapies for VGSC-Derived Epilepsies

Most AEDs are only partially effective for the treatment of DS (Chiron and Dulac, 2011). Many studies have evaluated the effectiveness of different treatment options for DS and have found that the most effective drugs, such as stiripentol and clobazam, share enhancement of GABAergic neurotransmission as part of their mechanism of action. In contrast, AEDs that worsen DS, for example phenytoin, lamotrigine, and carbamazepine, often block VGSC activity (Guerrini et al., 1998). Interestingly, drugs that both reduce VGSC activity and enhance GABAergic neurotransmission, such as valproate, have intermediate effectiveness. This finding is consistent with the loss of inhibition model of DS, in which loss of SCN1A activity, predominantly in inhibitory interneurons, leads to reduced GABAergic neurotransmission. Thus, VGSC blockers that further decrease sodium currents will be expected to worsen the disorder, while enhancement of GABAergic neurotransmission will provide partial correction of inhibitory neuronal function.

While VGSC blockers are not effective for DS, they might be effective in other VGSC-derived epilepsies which involve gain-of-function mutations. As epilepsy mutations in the SCN2A, SCN3A, and SCN8A genes are most often gain-of-function (see Mechanisms of VGSCs in Epilepsy section), administration of phenytoin, lamotrigine, or carbamazepine may effectively normalize the activity of overactive VGSCs in these individuals with mutations in these genes.

Selective targeting of a specific VGSC isoform as a therapeutic strategy to compensate for the loss of another isoform has been explored using mouse models of VGSC dysfunction. Proof of principle of this approach was demonstrated by crossing Scn1a mutant mice to Scn8a mutant mice, leading to increased lifespan and seizure resistance (Martin et al., 2007; Hawkins et al., 2011). In a mouse model of temporal lobe epilepsy in which up regulation of Scn8a in entorhinal cortex was observed, partially selective inhibition of Scn8a by 4.9-anhydro-TTX was found to improve seizure outcomes (Hargus et al., 2011). In Chapter 2, we demonstrated that
specifically reducing Scn8a expression in the hippocampus is capable of increasing resistance to picrotoxin-induced seizures in WT mice (Fig. 2.6) and increasing latencies to flurothyl-induced seizures in WT and epileptic Scn1a⁺⁻ mice (Fig. 2.8). The injection of an shRNA to reduce Scn8a expression in a specific brain region in order to achieve seizure control may be effective in focal forms of epilepsy where reducing Scn8a expression at the site of seizure initiation might reduce the ability of this region to drive the spread of seizure activity to other regions.

Gene replacement has also been explored as a strategy to correct for loss of the Scn1a gene in epileptic Scn1a⁺⁻ mice. Proof of concept of gene replacement in a DS model was demonstrated using a transgenic mouse carrying a bacteria artificial chromosome (BAC) containing a full length Scn1a gene. Compensation for reduced Scn1a expression in Scn1a⁺⁻ mice by expression of the Scn1a BAC transgene increased the lifespan of these mice (Tang et al., 2009). Unfortunately, the large size of the SCN1A gene and lack of an appropriate delivery system makes this approach currently impractical as a therapeutic avenue.

It is unlikely that a single effective treatment for all VGSC epilepsies will be found. In the end, individualized approaches coupled with selective genetic and pharmacologic tools may be the most effective strategy. Along these lines, patient-derived neurons, using an induced pluripotent stem cell approach, have been successfully generated from DS patients and used to probe disease mechanisms (see Scn1a Epilepsy Mechanisms section) (Liu et al., 2013). This approach in conjunction with isoform specific pharmacologic or genetic tools that are capable of altering VGSC expression levels or activity might facilitate in vitro, low risk, testing of patient-specific therapeutic strategies.

5.7. Concluding Remarks

Voltage gated sodium channels (VGSCs) are integral to the regulation of neuronal excitability. Alterations in the function of the CNS VGSCs are associated with susceptibility to
epilepsy as well as cognitive and behavioral impairments. Mice with mutations in the VGSC
*Scn8a* exhibit increased resistance to induced seizures; however, paradoxically experience
frequent spontaneous absence seizures. We have more fully characterized the development of
*Scn8a* expression and key *Scn8a*-epilepsy phenotypes. We also provided mechanistic insight into
the role of *Scn8a* in seizure protection, and also provided genetic, developmental, anatomical and
physiological rationale for selectively targeting *Scn8a* as a treatment for epilepsy. We have
generated a new mouse model of *Scn8a* dysfunction which has revealed new recessive
phenotypes including loss of proconvulsant resistance and susceptibility to audiogenic seizure.
Lastly, by specifically reducing *Scn8a* expression in discrete cell types, we have proposed a
mechanism to explain both *Scn8a*-mediated seizure protection and *Scn8a*-absence epilepsy. These
findings provide the foundation for future studies on the contribution of VGSCs to epilepsy and
behavioral outcomes and for the development of improved therapies that target VGSCs.
REFERENCES


Gong B, Rhodes KJ, Bekele-Arcuri Z, Trimmer JS (1999) Type I and type II Na(+) channel alpha-subunit polypeptides exhibit distinct spatial and temporal patterning, and


effects of a modifier gene on deficiency of the sodium channel Scn8a (Na(v)1.6). Human molecular genetics 11:2765-2775.


in blocking high-frequency firing via differential effects on persistent Na+ currents.


Waxman SG, Kocsis JD, Black JA (1994) Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. Journal of neurophysiology 72:466-470.


I was born not knowing

and have only had a little time to change that here and there.

- Richard Feynman